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ABSTRACT OF DISSERTATION

ISOPRENOID ANALOGS AS CHEMICAL GENETIC TOOLS TO PROVIDE INSIGHTS
INTO FARNESYL TRANSFERASE TARGET SELECTION AND CELLULAR ACTIVITY
Protein farnesylation is an essential post-translational modification required for
the function of numerous cellular proteins including the oncoprotein Ras. The farnesyl
transferase (FTase) catalyzed reaction is unique because farnesyl diphosphate (FPP),
the farnesyl group donor for the reaction, forms a significant portion of a target protein
binding site. The major goal of this research was to exploit this unique property of the
FTase reaction and determine if changing the structure of the farnesyl donor group
would affect FTase protein targeting. A small library of structural analogues of FPP was
synthesized. Michelis-Menten steady-state kinetic analyses and competition reactions
were used to determine the effect of these structural modifications on FTase targeting.
We found that the analogues did affect FTase protein selectivity and that this could be
exploited to induce unnatural target selectivity into the enzyme.
The second goal of this research was to determine the effect of FPP analogues
on the function of FTase target proteins. To test the effect of these analogues we
determined whether the unnatural lipid could ablate oncogenic H-Ras biological function
in a Xenopus laevis model system. Several analogues were able to disrupt oncogenic
H-Ras function while others mimicked the activity of FPP. These results indicated that
some of the FPP analogues may act a prenyl group function inhibitors that could lead to
an important new class of anti-cancer therapeutics.
Another major goal of this research was to use the FPP analogues as unnatural
probes for the endogenous cellular activity of FTase target proteins. We developed
antibodies to two of the unnatural FPP analogues to study their activity in cell
cultureUtilizing these antibodies we found that alcohol prodrugs of the FPP analogues
could be incorporated into cellular proteins in an FTase dependent manner. The ability
of cell permeant analogues to be incorporated into live cells enhances the chances that
such a molecule could be used to modify oncogenic cellular proteins with a prenyl group
function inhibitor.
KEYWORDS: Protein Farnesyl Transferase, Enzyme
Transferases, Solid-Phase Organic Synthesis, Hapten Synthesis
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CHAPTER 1 BACKGROUND AND OBJECTIVES
Background
Membranes and Lipid Anchoring in Cell Biology
Biological membranes are uniquely organized arrays of lipids and proteins that
constitute the boundaries of cells and intracellular organelles [1, 2]. They provide a
surface for many important biological processes to take place, and contain proteins that
mediate the transport of metabolites, macromolecules and ions. Important biological
processes ranging from electron transport to muscle contraction all depend on
membranes and membrane proteins. Proteins are the “workhorses” of a cell and often
require membrane localization to exert their cellular function. Proteins can interact with
membranes in a variety of ways. Peripherally bound membrane proteins interact with
polar groups on the membrane surface, through electrostatic interactions; integrally
membrane bound proteins are molecules with large hydrophobic regions embedded into
lipid bilayers; and a third class of proteins associate with membranes via small lipid
groups attached to the protein. Four different types of lipid anchoring motifs have been
identified to date (Figure 1-1): amide linked myristoyl anchors, thioester linked fatty acyl
anchors, thioether linked prenyl anchors, and amide linked glycosyl phosphatidylinositol
(GPI) anchors[3-6].

1

Figure 1-1 Lipid Anchoring Motifs

Note: GPI anchored proteins have variable length hydrophobic chains

2

Prenyl anchors are made up of isoprenoids, which are molecules derived from
the mevalonate biosynthetic pathway (Figure 1-2) [6-9]. Isoprenoids are formed through
a head to tail condensation of isopentyl diphosphate and dimethylallyl diphosphate to
give the precursor molecule geranyl diphosphate 1(GPP) [10-12]. Sequential additions
of the isopentyl diphosphate to geranyl diphosphate leads to elongation of the
isoprenoid chain to 3 and 4 isoprene units to give farnesyl diphosphate 2 (FPP) and
geranylgeranyl diphosphate 3 (GGPP), respectively. FPP can be divided into three
isoprene units the first (α) isoprene which is the isoprene unit closest to the
diphosphate, then the β-isoprene which is the middle isoprene unit, and the third
isoprene which is often referred to as the terminal or ω-isoprene unit. The farnesyl and
geranylgeranyl groups of FPP and GGPP are post-translationally added to proteins in a
reaction catalyzed by protein prenyltransferase enzymes. The mevalonate biosynthetic
pathway is essential for the production of FPP and GGPP as well as other biomolecules
including cholesterol, numerous steroid hormones, ubiquinone and dolichol [6].

3

Figure 1-2 Mevalonate Pathway

Note: FPP isoprene unit designation (α, β and ω).

4

Prenylated proteins have received a great deal of attention in recent years due to
the fact that the protein product of the ras oncogene requires post-translational
attachment of a prenyl group in order to function [13-18]. The ras oncogene is present in
10-30% of all human cancers and has become a major target of anti-cancer
therapeutics [19]. Ras proteins are small molecular weight GTPases (Enzymes that bind
and hydrolyze Guanosine Triphosphate or GTP) that act as molecular “on/off” switches
that control cellular signaling cascades leading to cell proliferation and cell growth [19].
The Ras switching mechanism occurs through the cycling of the protein between a GTP
bound “on” state, to a Guanosine diphosphate (GDP) bound “off” state. Ras proteins
must be localized to membranes to carryout this crucial molecular switching function,
and membrane association requires the attachment of an isoprenoid group. The best
characterized Ras signaling pathway is control of the Mitogen Activated Protein Kinase
(MAPK) signaling cascade (Figure 1-3) [20-23]. The MAPK signaling cascade can be
activated by the binding of an external cellular signal to a Receptor Tyrosine Kinase
(RTK) leading to receptor autophosphorylation. Autophosphorylation of the RTK recruits
Guanine Nucleotide Exchange Factors (GEFs) to the membrane of a cell [19, 24-27].
GEF proteins assist the exchange of GDP for GTP and activate membrane localized
Ras proteins [28-31]. GTP bound Ras then signals the initiation of cell proliferation
through effector proteins such as Raf [32-36]. The signal then progresses through a
series of phosphorylation events that eventually results in the activation of transcription
factors essential for cell division. The Ras proteins are essential to cell survival making
them an excellent model protein for studying prenylated protein function. In addition,
inhibiting the activity of Ras proteins may be a key mechanism for the inhibition of
cancer cell proliferation.

5

Figure 1-3 Ras Signaling
This is a simple Ras signaling network leading to cell proliferation via binding of
epidermal growth factor (EGF) to a receptor tyrosine kinase (RTK). The Figure
highlights the molecular switching function of Ras from a GDP bound on state to a GTP
bound off state. Switching between the two states requires guanine nucleotide
exchange factors (GEF), and GTPase activating proteins (GAP).

6

There are at least four hypothesized roles for the prenyl modification of a protein
(Figure 1-4) [37-40]. The best understood is the direct interaction of the isoprenoid
group with the lipid bilayer of a cell. However, small isoprenoid anchors such as the 15
carbon farnesyl isoprenoid poorly partition into membranes as evidenced by a 5-40 µM
half-maximal binding to liposomes relative to 0.2-0.8 µM binding of a 20 carbon
geranylgeranyl isoprenoid moiety [41]. Another potential role of an isoprenoid protein
modification may be for the lipid moiety to directly interact with hydrophobic regions of
other proteins such as chaperones. One example of this type of activity is the interaction
between the small molecular weight GTPase Rac and the Rho GDP dissociation
inhibitor (RhoGDI) [42]. Rac proteins are important in cytoskeleton formation, and are
prenylated with a 20 carbon geranylgeranyl moiety. The geranylgeranyl moiety inserts
directly into a hydrophobic groove in the RhoGDI protein and mediates the interaction
between the two proteins. RhoGDI is thought to act as a carrier or transport protein that
masks the hydrophobic prenyl group from the cytosolic aqueous environment, and
delivers Rac to specific target membrane locations. The lipid groups attached to
proteins may also interact with membranes through a mixed lipid:lipid and lipid:protein
interaction. Another potential role for prenyl protein modifications may be to induce
conformational changes in the modified protein. Such changes in the structure of a
protein may lead to new protein:protein interactions with binding partners that would not
otherwise interact with the unmodified protein [39]. Other types of protein modifications
including phosphorylation and glycosylation have been shown to affect protein structure
and folding, and it is possible that prenyl group modification may also support changes
in the folding of a modified protein [43, 44]. The different roles of prenyl protein
modification may be important for the function and cellular localization of a variety of
proteins, and the role of the prenyl modification may differ depending on the protein
modified.

7

Figure 1-4 Models for Isoprenoid Function
Four models for prenyl group function on modified protein.

8

Protein Prenylation and Processing
The protein prenyltransferases farnesyltransferase (FTase), geranylgeranyl
transferase type I (GGTaseI) and geranylgeranyl transferase type II (GGTaseII) are
heterodimeric zinc metalloenzymes that catalyze the prenylation of proteins. FTase and
GGTaseI catalyze the transfer of FPP 2 or GGPP 3 to a conserved cysteine residue
four amino acids from the C-terminus of target proteins (Figure 1-5) [45-48]. Protein
substrates of both FTase and GGTaseI contain a Ca1a2X group at their C-terminus,
where C is a conserved cysteine residue, a1 and a2 are often aliphatic amino acids and
X is frequently methionine, glutamine or serine for FTase and leucine or phenylalanine
for GGTaseI [49, 50]. However, there are overlapping Ca1a2X substrate specificities for
the prenyltransferases, where some canonical GGTaseI substrates can be farnesylated
by FTase, and visa versa [49, 51-53]. The Ca1a2X motif alone is all that is required for
FTase and GGTaseI protein recognition and small Ca1a2X peptides often mimic the
reactivity of full length proteins [54, 55]. The sequence of the Ca1a2X motif is also often
unique to a single protein or subsets of proteins, and the reactivity of different Ca1a2X
sequences varies from one sequence to another [56].
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Figure 1-5 Prenyltransferase Reaction and Downstream Processing
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Protein prenylation directs an ordered series of processing events (Figure 1-5) to
further increase hydrophobicity leading to the eventual localization of a modified protein
to cell membranes [57-60]. Through a currently unidentified mode of transport, a target
protein is prenylated then directed to the endoplasmic reticulum (ER). At the ER the
protein undergoes two additional processing events. The first of these events is the
cleavage of the a1a2X residues of the Ca1a2X sequence motif. The endoproteolysis of
the protein is catalyzed by the integrally membrane bound Ras converting enzyme,
RCE1 [58, 61-64]. Following the Ca1a2X cleavage reaction the now prenylated Cterminal cysteine residue remains associated with the ER. The carboxyl terminus is then
methylated by a second ER bound enzyme Isoprenylcysteine carboxymethyl
transferase (ICMT) [59, 60, 65, 66]. The ICMT enzyme donates a methyl group from Sadenosyl methionine (Ado-Met) to the carboxyl terminal residue. The reaction results in
the formation of the hydrophobic methylated carboxyl terminus and adenosyl
homocysteine (AdoHCy). A prenylated Ca1a2X motif is the minimum requirement for
recognition by RCE1, and a prenylated cysteine residue is the minimum requirement for
protein recognition by ICMT. Once the protein has been methylated it is then
transported to cell membranes. Carboxyl group methylation and endoproteolysis of the
protein is thought to increase the hydrophobicity of the C-terminus to enhance direct
lipid:lipid interactions with membranes or hydrophobic interactions with protein
chaperones. Once an isoprenylated protein has reached the target membrane it may
undergo further post-translational lipid modification reactions [67-70]. Acyl transferases
can attach palmitoyl hydrocarbon chains to further increase the protein hydrophobicity,
but this modification is not essential for the membrane localization of all isoprenylated
proteins.
Protein Prenyltransferase Reaction Mechanism
FTase and GGTaseI appear to have similar unexpectedly complex reaction
mechanisms (Figure 1-6) [51, 55, 71-82]. Using steady-state kinetic analyses FTase
was initially identified to follow a random ordered binding of the isoprenoid and Ca1a2X
substrates where both FPP and the Ca1a2X substrate could bind to the free FTase
enzyme [55]. However, the FTase reaction showed significant substrate inhibition by the
Ca1a2X substrate making the standard Michaelis-Menten interpretations of the enzyme
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activity difficult. Later using isotope trapping experiments, the reaction mechanism was
found to progress preferentially with FPP binding first to the free enzyme (EÆE•FPP)
followed by the Ca1a2X substrate (E•FPPÆE•CaaX) [72]. In these experiments an
E•FPP complex was formed by mixing FTase and tritiated FPP at stoichiometric
concentrations. Excess Ca1a2X peptide and a large excess of unlabeled FPP were then
added to the “hot” E•FPP complex. The incorporation of radiolabel into product was then
measured, and nearly the entire reaction product (>90%) was tritiated. To test the ability
of the E•CaaX complex to form product a biotinylated Ca1a2X peptide was mixed
stoichiometricly with FTase. The E•CaaX complex was then treated with tritiated FPP
and a large excess of unbiotinylated Ca1a2X peptide. In these reactions very little of the
tritiated product was biotinylated (<5%). These results suggested that the E•CaaX
complex was unreactive, or at the very least dissociated rapidly allowing FPP to bind to
the free enzyme followed by the excess unbiotinylated peptide. The preferred reaction
pathway was therefore, through FPP binding first to the enzyme followed by the Ca1a2X
substrate.
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Figure 1-6 FTase Mechanism
a) FTase kinetic pathway where E is the FTase enzyme, E•FPP is the FTase•FPP
complex, E•FPP•CaaX is the FTase•FPP•CaaX peptide complex, E•Product is the
FTase bound product complex, E•Product•FPP is the FTase bound to both FPP and
the reaction product, and E•CaaX is the peptide bound FTase inhibitory complex. b)
Crystal structures published by Long et al. [80] of the individual steps along the FTase
reaction pathway. Only substrates are shown other than the free E complex with
individual kinetic constants provided for each step of the pathway. The kinetic constants
are for a CVIM peptide and FPP as the isoprenoid donor.
a)

E

[FPP]

E-FPP

[CaaX]

E-FPP-CaaX

E-Product

[FProduct]
[FPP]

E-Product-FPP
E-CaaX
b)

Note: crystal structure diagram from Long et al. [80]
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FPP was later found to have a much higher affinity for the free FTase enzyme
(Kd=5nM) than a Ca1a2X peptide (Kd=4µM GCVLS) [54]. FTase and GGTaseI are α,β
heterodimers with identical α subunits, but vary in the amino acid composition of the β
subunit. FPP binds along one side of a hydrophobic cavity on the FTase β-subunit
made up of the highly conserved aromatic residues Trp303β, Tyr251β, Trp102β,
Tyr205β and Tyr200α [83-85]. When FPP was replaced with a non-hydrolyzable analog
(Figure 1-7, 4) and mixed with FTase to form a non-reactive E•FPP complex, the analog
bound to the same region of the FTase enzyme [83-85]. Surprisingly, the affinity for the
Ca1a2X peptide to the E•FPP complex was increased up to 70 fold (Kd=58nM) relative
to the free enzyme [76]. These results indicated that the isoprenoid directly interacted
with the peptide target of the FTase reaction, and the isoprenoid increased the peptide
binding affinity. Later, Beese et al. solved the crystal structure of a ternary complex
containing FTase, a non-hydrolyzable FPP analog and a Ca1a2X peptide (E•FPP•CaaX)
[49, 86]. The non-hydrolyzable analog bound to the enzyme with the same configuration
as found in the crystal structure of the E•FPP complex. In the E•FPP•CaaX crystal
structure the isoprenoid formed a significant portion of the binding site for the target
protein Ca1a2X sequence (Figure 1-6). Interestingly, a similar interaction was found for
the GGTaseI enzyme, with a non-hydrolyzable GGPP analog and a canonical GGTaseI
target Ca1a2X sequence [49, 87].
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Figure 1-7 Inhibitors of FTase, RCE1 and ICMT
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FTase and GGTaseI have identical α subunits (48 kDa), but differ in the
composition of the β-subunit (25% identity, 46 and 43 kDa respectively) [88]. To
determine the structural parameters that affect Ca1a2X sequence binding, the crystal
structures of different Ca1a2X sequences bound to an E•4•CaaX complex were solved
(4 was the non-hydrolyzable FPP analog in Figure 1-7 and was extended by one
isoprene unit for GGTaseI) [49]. FTase to GGTaseI Ca1a2X discrimination was highly
dependent on the identity of the Ca1a2X sequence X residue. The X residue binds to
what is referred to as the specificity pocket of the protein prenyltransferase enzymes.
The specificity pocket is made up primarily of the β-subunit residues Ala98β, Ser99β,
Trp102β, His149β, Ala151β, and Pro152β of FTase and Thr49β, His121β, Ala123β,
Phe174β of GGTaseI. Interestingly, the X binding site of the GGTaseI enzyme also
included the 4th isoprene of GGPP. A second X residue binding site was found for
FTase with Ca1a2X sequences that are normally considered substrates for GGTaseI.
The second binding site in FTase was made up of Leu92β, Ser99β, Trp102β, Ala151β,
the third isoprene of FPP, and the Ca1a2X sequence a2 residue. This second binding
site in FTase allowed for some of the overlap in the binding specificity of the two
enzymes. The a2 binding site of both FTase and GGTaseI accept the same Ca1a2X
sequence a2 residues. The a2 residue binding site in FTase was made up of the ωisoprene of FPP and the aromatic residues Trp102β, Trp106β and Tyr361β. The a2
residue binding site of GGTaseI was made up of the 3rd and 4th isoprenes of GGPP,
Thr49β, Phe53β and Leu320β. The peptide binding sites of both prenyltransferase
enzymes were made up of the terminal isoprene units of FPP and GGPP interacting
directly with the terminal Ca1a2X residues of the prenylation target.
The chemical step of the FTase reaction is thought to primarily proceed through
an SN2 addition of the zinc activated thiol to the C1 atom of the isoprenoid donor [89,
90]. However, there is some evidence suggesting dissociative character in the
isoprenoid diphosphate suggesting at least a partial SN1 contribution [91]. Crystal
structures have been solved representing the E•4•CaaX and E•product complexes of
both FTase and GGTaseI (Figure 1-6, FTase) [80, 87]. These structures suggest that
the α-isoprene and β-isoprene unit of FPP and GGPP undergo a significant
repositioning in the active site to place the C1 atom in close proximity to the zinc
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activated thiol of the target Ca1a2X sequence. Interestingly, the ω-isoprene of FPP and
GGPP is in the same position throughout the prenyltransferase reaction.
The overall rate of the prenyltransferase reactions are dependent on the rate of
product release from the enzyme [72]. After the chemical step of the reaction the
resulting product remains bound to the enzyme active site. An unusual feature of the
protein prenyltransferase reaction mechanism is that, in order for product to be released
from the enzyme, a new substrate molecule must bind to displace it [74]. Studies have
shown that both FPP and a Ca1a2X peptide can stimulate product release from FTase.
However, FPP stimulated release is faster than peptide stimulated, and the general
consensus is that FPP stimulated product release is the pathway primarily responsible
for product dissociation from the enzyme. A crystal structure of FTase bound to both a
farnesylated peptide and an FPP molecule (Figure 1-6) has revealed that the prenyl
chain of the product is displaced from the active site onto a hydrophobic groove on the
outer surface of the protein (“exit groove”) [80]. The new FPP binds to the active site in
the same position previously occupied by the farnesyl moiety of the product in the
E•product complex. The hypothesized consequence of FPP stimulated product release
is that the free enzyme does not form after the first turnover of the reaction. Instead, the
E•FPP complex is formed as a direct consequence of product release [74].
Farnesyl Transferase Inhibitors
The importance of oncogenic Ras proteins and other prenylated proteins in
cancer biology has led to the development of numerous farnesyl transferase inhibitors
(FTI) to block prenylated protein membrane localization and activity [13, 14, 92-98].
Several of these inhibitors are currently undergoing phase I, II, and III clinical trials as
anti-neoplastic agents [15, 99]. The FTI Tipifarnib 5 (Figure 1-7) has been evaluated in
phase III clinical trials and shows promise in the treatment of blood and breast
malignancies [15, 94, 100-102]. Crystal structures of Tipifarnib and other FTIs
(Lonafarnib 6) bound to FTase show a similar binding pattern. The molecules bind as a
ternary complex with FPP already bound to the enzyme [102-105]. Extensive Van der
Waals contacts are made between the FTI and the FPP lipid indicating an ordered
binding inhibition mechanism where the inhibitor binds to the E•FPP complex not the
free enzyme. The inhibition mechanism was therefore exactly analogous to the ordered

17

binding mechanism of the FTase enzyme substrates. Six potent FTIs bound to FTase
have been crystallized and are positioned in such a way that the aromatic rings of the
inhibitor interact directly with the a2 binding site of the enzyme. The inhibitors form faceon-face or edge-on-face stacking interactions with one or more of the aromatic a2
binding site residues. These aromatic stacking interactions are thought to provide the
binding energy required for the non-peptidomimetic inhibitors to efficiently bind and
inhibit the FTase enzyme.
FTIs have shown considerable activity in a number of clinical trials. However, the
overall response in patients has been less than hoped for [106-108]. One possible
explanation for the lack of FTI clinical efficacy is the process of alternative prenylation
where some FTase substrates can become alternatively prenylated by GGTaseI [107].
Proteins such as K-Ras can be substrates for either FTase or GGTaseI. K-Ras is the
most prevalent mutated Ras isoform found in human cancers, yet FTIs are ineffective at
blocking the proliferation of cells transformed by oncogenic K-Ras. Alternative K-Ras
geranylgeranylation is thought to be responsible for the proteins ability to evade the
effects of an FTI. FTIs also do not appear to function solely by blocking farnesylation of
Ras proteins. A number of pre-clinical studies have shown that FTI sensitivity does not
correlate with the presence of constitutively active Ras; thus, FTIs must also target
other, unknown FTase substrate(s) [109-111].
Recently the use of FTIs have shown promise for the treatment of numerous
other important disease states including hepatitis δ,[112-114] African sleeping
sickness[115] and malaria [116-118]. Each of these disease states are dependent upon
the farnesylation of a protein essential for the development of the disease. For example,
the hepatitis δ virus (HDV) causes chronic and acute liver disease in patients infected
with both HDV and the hepatitis B virus. HDV viral assembly is dependent on the
farnesylation of the HDV large antigen protein. Preclinical studies have shown that
treatment of HDV infected mice with an FTI is highly effective in clearing HDV viremia
[119-121].
Downstream Processing Inhibition
Recently the farnesylated protein processing enzymes have become increasingly
popular targets for the inhibition of prenylated protein function in transformed cells [60,
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122-124]. Targeting the downstream enzymes rather than FTase may avoid issues
related to alternative prenylation of proteins such as K-Ras by targeting post-prenylation
processing. In cells deletion of RCE1 induces mislocalization of Ras, but the affect on
oncogenic transformation of cells has been less pronounced relative to FTI treatment
[58]. Elimination of RCE1 does however markedly increase the sensitivity of cells to an
FTI [58]. In contrast to the effects induced by elimination of RCE1, elimination of ICMT
has profound affects on cell proliferation. Conditional deletion of ICMT completely
blocks the transformation of cells by oncogenic K-Ras [65].
Few inhibitors of RCE1 and ICMT have been developed, due to the fact that
these enzymes are relatively new targets for anti-proliferation drugs. Inhibitors targeting
the RCE1 enzyme have been limited primarily to substrate analogs. RPI (Figure 1-7, 7)
is one such analog that potently inhibits RCE1 activity in vitro. Oncogenic Ras supports
the growth of cells in soft agar and disruption of Ras cellular signaling cascades inhibits
anchorage independent cell growth. A series of choromethylketone Ca1a2X substrate
analogs (Figure 1-9, 8-9) [125-128] also inactivate RCE1 and appear to reduce
anchorage-independent growth of K-Ras transformed cells.
Inhibitors of the ICMT enzyme fall into two classes which are mimics of either
substrates or products of the enzyme [60, 129]. The first class of inhibitor is the reaction
product adenosyl homocysteine (AdoHCy) and methods to increase cellular
concentrations of this molecule [130-134]. AdoHCy is the product of many
methyltransferase reactions including ICMT; therefore, it is not specific for the postprenylation processing enzyme. The second class of ICMT inhibitors is based on the
minimal substrate, farnesylcysteine [135, 136]. N-acetyl farnesylcysteine (Figure 1-7,
AFC 10) is a substrate for ICMT and can be viewed as a competitive inhibitor of the
enzyme[59, 137, 138]. The AFC molecule is effective at inhibiting Ras post-translational
processing, but has also been reported to affect numerous other unrelated cellular
processes. Recently Gibbs group has focused on altering the structure of the AFC
molecule (Figure 1-7, 11) to create new more potent inhibitors of the ICMT enzyme with
limited success [139, 140]. Recently, through small molecule library screening, WinterVann et al. discovered a potent and specific ICMT inhibitor, cysmethynil (Figure 1-7, 12)
[123]. Cysmethynil blocks anchorage independent cell growth and treatment of cancer
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cells with this molecule results in Ras mislocalization and impaired epidermal growth
factor signaling. Cysmethynil is one of the first inhibitors discovered for one of the
downstream processing enzymes that is not a substrate or product analog.
Prenyl Function Inhibition
Another important alternative to the inhibition of prenylated protein function by
farnesyl transferase inhibition is alternative prenylation of the protein with non-functional
analogs of the farnesyl lipid moiety. The farnesyl lipid group is required for recognition
by both of the downstream processing enzymes. In addition the prenyl group may
participate in direct protein:protein interactions with chaperone and effector proteins.
Numerous analogs of FPP have been designed and synthesized that are inhibitors as
well as substrates for the FTase enzyme (Figures 1-8 13-30). Changing the structure of
the farnesyl moiety has been shown to disrupt the function of cellular Ras proteins. The
analog 3vFPP 13a (Figure 1-8) is a substrate for FTase in vitro and in cell culture [141].
Treatment of cells with 3vFPP 13a blocks anchorage-independent growth of rastransformed cells. Presumably, this effect is due to FTase catalyzed modification of
proteins with the 3-Vinyl-farnesyl group. These observations suggest that alternative
prenylation with farnesyl analogs may be an effective way to inhibit prenylated protein
function.
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Figure 1-8 FPP Analogs
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The affect of the farnesyl group structure on the activity of an oncogenic H-Ras
proteins was directly studied in a Xenopus laevis oocyte model system [142-147]. The
Xenopus laevis oocyte is a convenient in vitro system for studying farnesylation
dependent cellular signal transduction. Oocytes are naturally arrested at the G2-M
boundary of the first meiotic cell division. Microinjection of bacterially expressed,
oncogenic H-Ras (H-Ras Q61L) promotes meiotic maturation in a process accompanied
by activation of MAPK. Since, bacteria lack the enzymes required for protein
isoprenylation and subsequent processing, the ability of bacterially expressed
recombinant H-Ras to induce meiotic maturation is completely dependent on
intracellular farnesylation of the protein or in vitro farnesylation of the protein prior to
injection [142, 143]. FPP analogs stripped of most isoprenoid features such as methyl
groups and unsaturation to more resemble simple fatty acids (16-18) can be transferred
to Ras by FTase and support Ras function in the Xenopus signal transduction system.
However, analogs that were shorter and lower in hydrophobicity than the natural FTase
substrate were transferred to Ras, but unable to support Ras function. These results
suggested an isoprenoid structure dependent activity of the H-Ras protein in this
system.
Analogs of Farnesyl Diphosphate
Numerous analogs of FPP have been developed to probe the structural
relationship of FPP with the activity of FTase and target proteins (Figure 1-8) [141, 148163]. These analogs include molecules with altered diphosphate groups (Figure 1-8,
15a-b) and a plethora of changes in the structure of the α, β and ω isoprene units of
FPP (Figure 1-8, 13a-f, 14a-e, 19-30). Small changes in the structure of FPP apparently
have significant affects on FTase reactivity [154, 161]. Substitutions in the diphosphate
leaving group have been used to study the interaction of the highly polar diphosphate
leaving group with the enzyme active site. One of the most important of this class of
analogs was the non-hydrolyzable analog 4 which allowed crystallographers and
kineticists to study the interaction of the isoprenoid and Ca1a2X substrate [76]. Other
diphosphate analogs have been utilized to show that the diphosphate linkage is simply
a leaving group and energy release from phosphoanhydride hydrolysis is not required
for the FTase reaction to occur (Figure 1-8, 15a-b) [164].
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Alterations in the structure of the α, β and ω isoprene units of FPP have shed
light on the importance of the lipid isoprene structure on FTase reactivity. FTase is
incapable of efficiently binding GGPP as a substrate, but GGTaseI can bind both FPP
and GGPP as a substrate. This gave rise to the “molecular ruler” hypothesis which
ascribes FTase isoprenoid substrate binding discrimination to the length of the
isoprenoid diphosphate [149]. Micali et al. synthesized a series of benzyloxy FPP
analogs in which the ω-terminal isoprene of FPP was replaced with a benzyloxy group
and the β-isoprene was replaced with variable length methylene chains (Figure 1-8, 1924) [160]. Modeling and kinetic studies indicated that even the longer chain analogs
could bind to the FTase enzyme although the reactivity and binding of the analogs was
best where there were only 4 or 5 methylene units between the α and ω isoprenes.
Modeling of the longer chain isoprenoid analogs into the FTase active site indicated that
these analogs bound to the enzyme with a bent conformation in which part of the lipid
chain protruded into the binding site of the target Ca1a2X sequence. This protrusion of
the molecule may lead to Ca1a2X peptide exclusion from the enzyme active site
suggesting that larger isoprenoids reacted poorly due to a second substrate exclusion
rather than inability to bind. Additional support for the second substrate exclusion
hypothesis was later generated in crystallographic studies of GGPP or a benzophenone
analog (Figure 1-8, 25a-b) bound to the FTase enzyme [149]. In the GGPP•FTase
crystal structures the longer prenyl chain did fit into the FTase active site, but the
structure of the molecule was “kinked” where part of it protruded into the region typically
occupied by the target Ca1a2X sequence.
Gibb’s group attempted to exploit the interaction of the isoprenoid and target
peptide with the α-isoprene substituted FPP analog 3-BFPP (Figure 1-8, 13c) [154]. The
hypothesis was that changing the structure of FPP may lead to alterations in the activity
of particular Ca1a2X targets due to the direct interaction of the substrates in the enzyme
active site. 3BFPP 13c was a substrate for FTase when the target Ca1a2X sequence
mimicked the proteins H-Ras and K-Ras4B, but was poorly utilized by FTase when the
target Ca1a2X structure mimicked the RhoB Ca1a2X motif. However, FPP was an
efficient substrate with all three Ca1a2X sequences. The analog apparently changed the
ability of FTase to react with a particular Ca1a2X peptide without significantly affecting

23

the reactivity of other Ca1a2X peptide sequences. Interestingly, the reactivity of the
analog did not appear to be due to the interaction of the isoprenoid with the Ca1a2X
target prior to the chemistry step of the reaction. These results suggested that the
pathway after the chemistry step of the reaction may also be important for FTase
Ca1a2X sequence selectivity.
Chehade et al previously developed a series of analogs where the ω-terminal
isoprene of FPP was replaced with an aniline moiety or substituted aniline moieties
[159, 161]. 8-anilinogeranyl diphosphate (AGPP, Figure 1-8 26a) was a substrate for
FTase and the analog dependent steady-state transfer kinetics to H-Ras and an H-Ras
based Ca1a2X peptide were nearly identical to the natural substrate of the enzyme.
Modeling studies indicated that the aniline moiety behaved as an isostere for the ωisoprene of FPP, and AGPP likely binds to FTase in a conformation similar to FPP.
However, addition of a p-NO2 group (26b) to the aniline moiety or substitution of the
aniline H atoms with fluorine (26c) decreased FTase catalytic efficiency. Understanding
the structural relationships between FTase reactivity and lipid structure will be crucial for
the development of new FTase transferable, Ca1a2X selective analogs of FPP.
In addition to studying the prenyl transferase reaction and inhibiting the function
of FTase protein targets, analogs of FPP may also be useful as unique cellular tags to
study protein prenylation in cells. The anthranillate analog of AGPP 26d (Figure 18)[165] and the nitro-benzo-oxadiazol analog 27 (Figure 1.8, NBD-GPP)[166] are
fluorescent AGPP based analogs. The ortho- substituted anthranillate analog 26d is an
FTase inhibitor while the NBD-GPP 27 isoprenoid analog is a substrate for FTase. The
NBD-GPP 27 analog has proved very useful in studying cellular prenylation of FTase
substrates allowing researchers to follow cellular protein prenylation in real time.
The analogs ETAZ-AGPP (Figure 1-8, 28)[161], the benzophenone analogs
(Figure 1-8, 25a-b)[150], and DATFP (Figure 1-8, 29)[167] are photoactivatible crosslinking compounds. In these compounds the ω-terminus of FPP is replaced with
photoactivatible units that can be covalently attached to regions of the FTase enzyme or
protein binding partners that interact directly with the lipid. The benzophenone analogs
25a-b are FTase inhibitors, yet the ETAZ-AGPP 28 and DATFP 29 analogs are
substrates for FTase. Another azido function containing molecule, farnesyl azide 30,
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has been used by Kho et al for a tagging-via-substrate methodology to specifically label
cellular proteins and isolate those proteins for mass spectral identification [168]. A better
understanding of the structural parameters that distinguish substrate analogs from
inhibitors will be essential for the design of new probes of the prenylation pathway and
the prenyltransferase enzymes.
Objectives
Solid Phase Parallel Chemistry, Structural Diversity, and Prenyl Function
Inhibition
The lipid structure of FPP appears to affect both transferability of target peptides
and protein target function. The FPP binding site is made up primarily of aromatic amino
acid residues, and the molecule interacts directly with a target protein throughout FTase
catalysis [80]. AGPP is a transferable analog of FPP with kinetics nearly identical to the
natural substrate, yet it has drastically different chemical and physical properties [159,
161]. We hypothesized that with the right combination of interactions between FTase,
the protein target, and alternative lipid structures, some analogs could be efficiently
transferred to proteins by FTase, yet unable to support the protein function normally
supported by a farnesyl lipid.
In order to study the affect of changing the FPP structure on protein target
activity we needed an array of compounds with varying chemical structures and
properties. The AGPP skeleton allows simple structure diversification. AGPP was
therefore an excellent lead compound for the development of structurally diverse
transferable FTase analogs that could be used to probe the relationship of the
isoprenoid structure and isoprenoid function. The typical solution phase route to
producing AGPP and AGPP analogs was slow and not amenable to a library synthesis
[159, 161]. In order to develop large numbers of ω-terminally substituted FPP analogs
we utilized a solid-phase parallel chemistry method. Solid-phase chemistry allows the
production of small molecules rapidly without tedious purification steps between every
chemical manipulation by doing all reaction on solid-phase. Parallel chemistry is the
synthesis of multiple compounds simultaneously and is especially amenable to solidphase methodologies.
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We designed and synthesized a library of AGPP analogs with various functional
groups in the ortho-, meta-, and para- positions of the AGPP aniline ring. We found that
a number of analogs appeared to be FTase transferable. As expected, based on the
interaction of the isoprenoid and peptide target in the FTase active site the analog ability
to transfer was dependent on the identity of the Ca1a2X sequence. However, the ability
of the analog to transfer did not appear to be dependent on the hydrophobicity of the
analogs. Instead, the analog reactivity was much more dependent on the size and
position of the aniline ring substitution. Since many of the transferable analogs were
much more hydrophilic than the natural substrate of the reaction, we tested the ability of
theses analogs to support oncogenic H-Ras function in the Xenopus signal transduction
model system. We found that several analogs that were efficiently transferred to FTase
target substrates were unable to support normal farnesyl group function in this system.
These results indicated that FPP analogs could be designed with low hydrophobicity
that could be transferred to FTase protein targets, yet were unable to support normal
prenyl group function in target proteins. These analogs will be key lead compounds for
the development of a new class of prenyl group function inhibitors.
FTase Mechanism of Product Release
The FTase reaction mechanism involves multiple interactions between FTase the
isoprenoid donor and Ca1a2X sequence [80]. It has been supposed that the mechanism
of the FTase reaction occurs through FPP binding to the E•product complex to stimulate
the release of product from the enzyme [74]. The consequence of this is direct
regeneration of the E•FPP complex which is highly committed toward catalysis, and
association of FPP to the free enzyme is tight. FPP dissociation from the free enzyme is
in fact slower than the overall rate of catalysis. However, it appears that the Ca1a2X
peptide can inhibit the FTase reaction [55, 71]. In the generally accepted kinetic
mechanism Ca1a2X peptide inhibition occurs through binding of the Ca1a2X sequence to
the free enzyme apparently blocking access of the isoprenoid diphosphate to the
enzyme active site. However, if FPP is so tightly bound to the enzyme and the E•FPP
complex is so highly committed to catalysis it is unreasonable for the Ca1a2X peptide to
inhibit the FTase reaction especially at concentrations well below isoprenoid
concentrations.
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We hypothesized that the generally accepted FTase mechanism was incomplete
and required inclusion of peptide stimulated product release to account for Ca1a2X
substrate inhibition. We tested this, using peptide competition reactions and found that
the Ca1a2X selectivity of the FTase enzyme was highly dependent upon peptide
stimulated product release rather than isoprenoid stimulated product release. These
results suggested that peptide selectivity for the FTase enzyme was highly dependent
on the kinetic flux between the FPP stimulated and peptide stimulated product release
pathways. These results also suggested that although FPP stimulated product release
may be faster than peptide stimulated, the peptide stimulated release pathway may be
more efficient.
Chemical Manipulation of FTase Ca1a2X peptide Selectivity
Chemical genetics is a research method that uses small molecules to change the
way proteins work. The FTase reaction is an excellent target for chemical genetic
research because the isoprenoid lipid forms a significant portion of the binding pocket
for a target Ca1a2X sequence motif. We hypothesized that by changing the ω-terminal
isoprene unit of FPP the interactions with a target Ca1a2X motif would be altered leading
to chemical genetic changes in the activity of the FTase enzyme and different protein
targets. Such alterations would be analogous to amino acid mutations in the enzyme
active site, potentially leading to enhanced reactivity of particular Ca1a2X sequences as
well as decreases in the reactivity of other Ca1a2X peptides. The reactivity of the FPP
analogs with different Ca1a2X peptide structures varied a great deal, and did not
correlate with the differences in reactivity with FPP as the isoprenoid donor. Most
importantly we have found that by changing the structure of FPP the target selectivity of
FTase ca be altered.
FPP analogs as unique cellular protein tags
FPP analogs are not only useful as inhibitors and FTase reactivity probes they
have also been used to tag endogenous proteins with unique properties that could be
used to track cellular FTase targets. Tritiated farnesyl diphosphate analogs and farnesyl
diphosphate precursors have been used for years to track the endogenous modification
of proteins by FTase [169, 170]. Treatment of cells with tritiated farnesol led to the
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discovery that a cell contains endogenous kinases that phosphorylate the allylic alcohol
producing intracellular farnesyl diphosphate that can be utilized by FTase. We
hypothesized that the isoprenoid alcohol precursors of AGPP would be taken up into a
cell, endogenously diphosphorylated and incorporated into cellular proteins by FTase.
To test this we developed antibodies to the anilinogeranyl modification and discovered
that the anilinogeranyl moiety of AGPP is incorporated into cellular proteins, and the
analogue is competitive with endogenous pools of FPP. In the event that a particular
allylic alcohol analog structure would not be converted to diphosphate endogenously,
we also developed a diphosphate anion masking scheme to build cell permeant analogs
of FPP.
GGPP analogs and GGTaseI
We found important effects with the FPP analogs on FTase activity. We
hypothesized that the technology developed for studying FTase would also be
applicable to the related GGTaseI enzyme. We developed two analogs of AGPP with an
extended isoprenoid chain and measured the affect of changing the terminal isoprene of
GGPP on the kinetics of GGTaseI. Like FTase with AGPP, the longer chain analog was
a substrate for GGTaseI with kinetics similar to GGPP. The ability of GGTaseI to utilize
target peptides was also altered by the GGTaseI substrate analogs, which indicated
similar interactions between the isoprenoid diphosphate and target peptides in the
GGTaseI reaction as in the FTase reaction. In addition, we found that the antibody
reagents developed for the AGPP analogs were also useful for the longer chain
anilinofarnesyl analogs.

Copyright © Jerry Troutman 2006
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CHAPTER 2 PRENYL FUNCTION INHIBITION

Introduction
A wide variety of proteins, including Ras, require post-translational prenylation for
their proper membrane localization and activity [171-175]. Protein farnesyltransferase
(FTase) catalyzes the transfer of a farnesyl group from farnesyl diphosphate (FPP, 1
Figure 2-1) to proteins with a cysteine residue located in a C-terminal Ca1a2X sequence
motif where C is the modified cysteine, a1 and a2 are often an aliphatic amino acid, and
X is typically Ser, Met, or Gln [50, 84, 176, 177]. Farnesylation is the first and obligatory
step in an ordered series of post-translational modifications that direct membrane
localization and potentially protein:protein interactions for a variety of proteins involved
in cellular regulatory events [19, 42, 178, 179]. Subsequent to farnesylation, the a1a2X
peptide is cleaved by the endoprotease RCE1 [65, 180] followed by methylation of the
now terminal farnesylated cysteine residue by the carboxymethyl transferase ICMT.
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Figure 2-1 Analog structures
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The Xenopus laevis oocyte is a convenient in vitro system for studying
farnesylation dependent cellular signal transduction [143, 181]. Microinjection of
bacterially expressed, oncogenic H-Ras (H-Ras Q61L) promotes meiotic maturation in a
process accompanied by activation of mitogen-activated protein kinase (MAPK) [143,
181, 182]. Maturation of the oocytes can be easily scored by the appearance of a white
spot on the dark hemisphere of the oocytes which signifies germinal vesicle breakdown
(GVBD) in the oocytes. Since, bacteria lack the enzymes required for protein
isoprenylation and subsequent processing, the ability of recombinant H-Ras to induce
meiotic maturation is completely dependent on intracellular farnesylation of the protein
[183]. Depletion of the endogenous isoprenoid pools by treatment of the oocytes with
inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase) such as
lovastatin, blocks the ability of bacterially expressed H-Ras to induce maturation.
Microinjection of H-Ras modified in vitro by FTase with FPP analogs into Xenopus
laevis oocytes allows the biological signal transduction functions of the lipidated protein
to be studied [142, 181].
Proteins modified with the 20 carbon geranylgeranyl group from geranylgeranyl
diphosphate (GGPP 2, Figure 2-1) are more hydrophobic than the 15 carbon farnesyl
group and both classes of prenylated proteins are processed by the same RCE1
endoprotease and ICMT methyltransferase. Replacement of the farnesyl group with
FTase transferable lipid analogs of similar or greater hydrophobicity than FPP are
effective in allowing all of the subsequent downstream processing events to take place
[181]. Substitution of the smaller, less hydrophobic 10 carbon geranyl group from
geranyl diphosphate (GPP, 3 Figure 2-1) for the farnesyl group significantly delays the
membrane association of H-Ras [181]. Importantly, it was concluded that the reduced
hydrophobicity of the geranyl group impaired processing downstream of prenylation by
slowing either the endoproteolysis or carboxyl methylation steps [181]. Once C-terminal
processing of the geranylated H-Ras was complete, normal palmitoylation followed by
membrane association was observed. These observations suggest that the precise
structure of the farnesyl group is not critical for the function of the protein as long as it is
sufficiently hydrophobic to allow downstream processing and membrane localization.
However, it was not possible to distinguish whether the significantly smaller size of the
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geranyl group impeded the processing of H-Ras by the RCE1 endoprotease, the ICMT
methyltransferase and/or other unknown farnesyl lipid interactions.
The above observations suggest that FTase catalyzed transfer of FPP analogs
with hydrophobicity lower than GPP 3 or with significantly different structures may
completely block the membrane localization of Ras by preventing the downstream
processing or membrane interactions of the alternatively prenylated C-terminus. Altering
the downstream biological function of a prenylated protein with unnatural analogs of
FPP is an attractive antineoplastic strategy. Synthetic modifications to the farnesyl
moiety of FPP have generated both FTIs and alternative substrates transferable for
FTase [153, 157, 159-161, 184, 185]. Definition of the structural features responsible for
efficient transfer of unnatural analogs to Ras requires the synthesis of additional,
structurally diverse FPP analogs that are transferable by FTase, and a rapid method for
determining the ability of the analogs to act as FTase substrates.
Parallel synthesis of directed libraries is an effective strategy for rapidly
introducing focused diversity into a target template [186-189]. Directed libraries are
particularly useful for generating groups of closely related molecules to explore
structure-activity relationships [190]. We have previously prepared a limited set of
alternative substrates for FTase by replacing the terminal isoprene of FPP with
substituted anilines in an effort to define some of the structural features responsible for
efficient transfer of unnatural analogs to Ras [159, 161]. These 8-anilinogeranyl
diphosphates AGPP 4a (Figure 2-1) were prepared by solution phase synthesis where
the key step was reductive amination of an α, β unsaturated aldehyde to form the
anilinogeranyl skeleton. This approach was appealing because it was carried out under
mild conditions. However, all intermediates and products required purification by
chromatography.
In this chapter, I will describe the synthesis of a series of FPP analogs with a
wide range of molecular surface areas, shapes and lipophilicities by both solid and
solution phase methods. An assay for the rapid determination of FTase transferability
was developed to test the ability of these analogs to react with a variety of Ca1a2X
sequences that represented the C-terminal sequence motifs of H-Ras, K-Ras4B, RDJ-2
and a canonical GGTaseI Ca1a2X sequence. A number of the analogs were alternative
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substrates for mammalian FTase, and the reactivity was dependent on the Ca1a2X
sequence target. Utilizing the Xenopus laevis oocyte system, we found that H-Ras
modified with hydrophobic anilinogeranyl diphosphate derivatives support H-Ras
dependent oocyte maturation. However, hydrophilic anilinogeranyl diphosphate
derivatives prevent H-Ras dependent oocyte maturation. These hydrophilic FPP
analogs are Ras function inhibitors (RFIs) and serve as lead compounds for a unique
class of potential anti-cancer therapeutics.
Results
Analog Synthesis
We have adapted our solution methods to provide a solid phase organic
synthesis (SPOS) route to anilinogeranyl FPP analogs (Figure 2-2). The advantage of
an SPOS approach is that it allows for the rapid preparation of additional analogs and
reduces the number of tedious purification steps needed. The THP resin 5 was
prepared from the Merrifield-Cl resin as previously described [191]. Attachment of
synthetic intermediates to the resin through the THP group provides a traceless linker
for the alcohols 10a-am and the final diphosphate compounds 4a-am (Table 2-1).
Preparation of resin 5 was achieved by combining a 5-fold excess of 8-oxo-geraniaol 6
with support 5 in the presence of 0.2 equiv of PPTS at 60

C. Under these conditions,

excess alcohol 6 can be recovered for reuse. The optimized reaction conditions gave a
resin loading of 72% for the solid support-linked α,β-unsaturated aldehyde 7. Aldehyde
loading was determined by cleavage and recovery of alcohol 6 by treatment of resin 7
with PPTS/MeOH/DCE at 60 C. With resin 7 in hand, we employed a solid-phase
parallel synthetic strategy to prepare a directed library of the anilinogeranyl analogs
10a-am. Diversity was introduced into the library by selecting the commercially available
substituted anilines 8a-am listed in Table 2-1. Optimum yields of the desired resinbound anilinogeraniols 9a-am were obtained by performing the reductive amination with
10 equiv of the anilines and 12 equiv of acetic acid in 1:1 THF/DCE and subsequent
reduction with 10 equiv of NaBH(OAc)3. Cleavage of the anilinogeraniols 10a-am from
the resin-bound amines 9a-am was achieved by treatment of the solid support with
DCE/MeOH/PPTS at 60

C.
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In solution, FPP analogs are typically prepared by sequential conversion of the
allylic alcohols into corresponding chlorides followed by diphosphorylation to provide
diphosphates [159, 192, 193]. Utilizing this approach reduces some of the advantages
of SPOS, as it requires two solution-phase manipulations after release of the
anilinogeraniols 10a-am from the resin. In previous solution-phase work, we employed
an excess of Ph3PCl2 to convert alcohol 10a to its corresponding chloride, which was
immediately transformed to the diphosphate 4a. Direct cleavage of the resin-linked THP
ethers to the corresponding allylic chlorides or bromides would reduce the number of
solution steps to one, diphosphorylation. We observed that addition of Ph3PCl2 to the
resin-bound ethers and subsequent diphosphorylation resulted in poor yield of
diphosphates. Alternatively, stirring the THP resin 9a-am with 3 equiv of Ph3PBr2 in
DCM

for

4

h

followed

by

addition

of

10

equiv

of

tris(tetra-n-

butylammonium)hydrogendiphosphate in MeCN gave the desired diphosphates 4a-am
in moderate yield. Employing Ph3PBr2 not only reduced the reaction time but also
increased the yield of the desired diphosphates. The release of bromides 11a-am from
the THP resin by Ph3PBr2 provides a traceless linker path to the FPP analogs 4a-am. In
practice, bromides 11a-am were not isolated but were converted directly to the
anilinogeranyl

diphosphates

4a-am

by

addition

of

tris(tetra-n-

butylammonium)hydrogendiphosphate in dry MeCN in the same reaction vessel.
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Figure 2-2 Synthesis of AGPP library of analogs
Reagents and yields: (a) PPTS, DCE, 60˚C; (78%); (b) aniline 8a-am, HOAc,
NaBH(OAc)3, THF/DCE(1:1), rt; (c) PPTS, MeOH/DCE(1:1), 60˚C; (70-41%); (d)
PPh3Br2, MeCN, rt; (e) PPh3Br2, MeCN, rt; (f) ((nBu)4N)3HP2O7, MeCN
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R2= see Table 2-1

Table 2-1 Analog FTase Reaction Rates and Structural Properties
Reaction rates measured using 3 µM peptide and 12 µM analog in Tris-HCl buffer
(pH=7.4) containing DTT reducing agent and DM as the detergent. Rates are reported
as µM per sec per µM enzyme. Rates below detection limits are reported as < values.
Each rate was measured in the 96 well plate assay as described in the experimental
section. Sizes of the terminal isoprene or aniline are reported in cubic angstroms and
were estimated using the PreADME online molecular descriptor software. The partition
coefficient LogP was estimated for the alcohol precursors based on RP-HPLC capacity
factors. Note the large difference in rates depending on the peptide target.
NH2

R2

H
N

R1

R2
1

2

3-

10: R =OH, 4: R =P2O7

8

R

#

logP

size
3
Å

FPP
AGPP
NAGPP
pbnz
mbnz
obnz
pPhO
mPhO
oPhO
pPh
oPh
piPr
oiPr
pEtO
mEtO
oEtO
pSMe
oSMe
pCF3O
mCF3O
oCF3O
pEt
mEt
oEt
pI
mI
oI
pBr
mBr
oBr
mMeO
oMeO
mCF3
pCN
mCN
pMe
mMe
pF
mF
oF

1
4a
4b
4c
4d
4e
4f
4g
4h
4i
4j
4k
4l
4m
4n
4o
4p
4q
4r
4s
4t
4u
4v
4w
4x
4y
4z
4aa
4ab
4ac
4ad
4ae
4af
4ag
4ah
4ai
4aj
4ak
4al
4am

6.1
3.6
3.1
5.6
5.4
5.9
5.1
5
5.7
5.2
5.8
5.2
5.2
4.7
3.9
4.7
4.1
5.1
4.9
4.9
5.1
4.7
4.6
4.8
4.9
4.8
5.3
4.6
4.5
5
3.3
4.1
4.6
2.9
3.1
3.6
3.3
3.5
3.7
4.1

102
114
134
202
202
202
198
198
198
187
187
159
159
155
155
155
149
149
149
149
149
144
144
144
146
146
146
142
142
142
140
140
139
135
135
129
129
118
118
118

Rate
CVLS
-1
-2
(s •10 )
6 ± 0.9
3.6 ± 0.1
28 ± 1
<0.9
<0.9
<0.9
<0.9
<0.9
<0.9
<0.9
<0.9
<0.9
<0.9
<0.9
<0.9
<0.9
<0.9
<0.9
7±1
11 ± 2
<0.9
1.2 ± 0.5
2.2 ± 0.8
<0.9
6.4 ± 0.6
17 ± 3
2.7 ± 0.6
13 ± 1
1.5 ± 0.4
7.7 ± 0.4
8±2
9±1
5.8 ± 0.4
7.1 ± 0.7
3.2 ± 0.2
12 ± 1
4.9 ± 0.3
7.7 ± 0.4
1.6 ± 0.7
3.3 ± 0.3
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Rate
CVIM
-1
-2
(s •10 )
4.2 ± 0.4
<0.6
ND*
<0.6
<0.6
<0.6
<0.6
<0.6
<0.6
<0.6
<0.6
7.8 ± 0.9
<0.6
3.7 ± 0.3
<0.6
<0.6
6.6 ± 0.9
3.6 ± 0.3
13.2 ± 0.6
5.2 ± 0.5
5.2 ± 0.1
6±1
7.8 ± 0.4
<0.6
8±1
16 ± 3
6.0 ± 0.7
12 ± 2
<0.6
0.8 ± 0.1
4.6 ± 0.6
4±1
1.8 ± 0.3
13.6 ± 0. ± 7
1.2 ± 0.1
3.1 ± 0.2
0.6 ± 0.1
0.7 ± 0.1
0.6 ± 0.2
<0.6

Rate
CAHQ
-1
-2
(s •10 )
14 ± 2
7.2 ± 0.7
ND*
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
2.9 ± 0.1
1.6 ± 0.3
<1
<1
<1
<1
1.6 ± 0.2
1.6 ± 0.3
1.7 ± 0.4
4.0 ± 0.6
3.1 ± 0.4
5±1
<1
1.4 ± 0.1
5±1
1.6 ± 0.3
1.7 ± 0.1
3.4 ± 0.4
4.3 ± 0.6
4.8 ± 0.4
10.5 ± 0.6
3.7 ± 0.5

Rate
CVIL
-1
-2
(s •10 )
1.0 ± 0.1
0.6 ± 0.1
ND*
<0.4
<0.4
<0.4
<0.4
<0.4
<0.4
<0.4
<0.4
<0.4
<0.4
<0.4
<0.4
<0.4
<0.4
<0.4
<0.4
0.7 ± 0.3
<0.4
<0.4
<0.4
<0.4
<0.4
0.4 ± 0.1
<0.4
2.8 ± 0.7
0.9 ± 0.4
<0.4
<0.4
<0.4
5.1 ± 0.5
<0.4
3.0 ± 0.1
0.6 ± 0.2
0.6 ± 0.3
0.7 ± 0.1
1.6 ± 0.1
<0.4

The resulting diphosphates 4a-am were first converted to the NH4+ form by ion
exchange chromatography and then purified by reverse-phase HPLC (RP-HPLC).
Complete removal of the tetra-n-butylammonium counterions from the sample prior to
reverse-phase HPLC was required for effective purification. However, efficient recovery
of the NH4+ form of the diphosphates 4a-am from the ion exchange chromatography
was highly dependent on the buffer conditions employed. This observation is
unsurprising, as the various diphosphates 4a-am are expected to have a wide range of
solubility in aqueous buffer related to the structure of the parent anilines 8a-am.
Optimization of the ion exchange conditions by altering the concentration of NH4HCO3
and including compound-dependent proportions of MeCN cosolvent had a profound
influence on the yield of individual diphosphates 4a-am recovered.
FTase Analog Transfer
Fluorescence assay for FTase transfer
In order to examine the reactivity of large numbers of FPP analogs, we desired a
method that could rapidly sort the molecules into groups of FTase substrates and nonsubstrates. Poulter et al. developed a continuous fluorescence assay with N-dansylGCaaX pentapeptides (Figure 2-3) that is often used to analyze FTase activity [194]. In
this assay a fluorescence enhancement results upon farnesylation of an N-dansylGCaaX peptide due to the increase in local hydrophobicity near the dansyl reporter
group. However, this assay was not immediately amenable for our purposes; because,
the assay utilized only a single cuvette and was therefore limited in throughput. We
adapted the single cuvette method to a microtiter plate assay which would allow the
analysis of many analogs at once. In individual wells of a 96-well plate, FPP and a
Ca1a2X peptide (N-dansyl-GCVLS) were mixed, and the initial fluorescence was read in
a microplate fluorescence reader. The reaction was then initiated by the addition of
FTase and allowed to continue until fluorescence enhancement had ceased. The final
fluorescence value was expected to represent complete consumption of the input
peptide substrate. (Figure 2-4) To confirm total consumption of the peptide reactant the
reaction mixture was separated by RP-HPLC with fluorescence and absorbance
detection of the dansyl moiety. We found with excess FPP all peptides were completely
consumed in the reaction. Fluorescence enhancement from the FTase reaction was
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similar to that previously found in the single cuvette assay, and the increase in RPHPLC retention time of the dansyl peak corresponded to the increase in hydrophobicity
due to peptide farnesylation. The micro-titer plate assay allowed simple and rapid
analysis of the transferability of FPP to the dansyl-GCVLS pentapeptide (Table 2-1).
FTase reaction rate is enhanced by AGPP analogs
In order to measure the reactivity of the analogs with the CVLS peptide we
measured the fluorescence increase of FTase reactions containing excess analog and
the CVLS peptide. The fluorescence enhancement differed depending on the
hydrophobicity of the isoprenoid. Reactions that did not go to completion within several
hours were stopped using a solution of acetic acid and isopropanol and the extent of
modification was determined by RP-HPLC analysis of the dansyl absorbance peaks. A
time-dependent increase in fluorescence was observed for over half of the analogs in
the AGPP analog library suggesting that a wide variety of functional groups in various
positions in the aniline ring were acceptable to the FTase enzyme (Table 2-1, Figure 25a).
The analog reactivity ranged from non-transferable to analogs that transferred as
fast as, or faster than FPP. Interestingly, the mI-AGPP 4y and pBr-AGPP 4aa analogs
reacted faster than FPP with the CVLS peptide. However, the mBr-AGPP 4ab and oIAGPP 4z analogs were poorly transferred to the CVLS peptide. In addition, none of the
analogs with functional groups larger than an EtO group were efficiently transferred by
FTase. These results indicated that the transfer rate of the analogs was highly
dependent upon the size of the aniline substituent as well as the position of the
substituent in the aniline ring of AGPP.
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Figure 2-3 Dansyl peptide structures
Structures of dansylated peptides representing the Ca1a2X motifs of H-Ras, RDJ2, KRas4B, and a canonical GGTaseI substrate.
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Figure 2-4 Fluorescence enhancement of N-dansyl-GCVLS modified with FPP
FPP and the N-dansyl-GCVLS peptide were mixed in individual wells of a 96 well plate
in Tris-HCl buffer pH=7.4, DTT and DM. The (+) FTase reaction was treated with FTase
enzyme and the (-) FTase reaction was treated with buffer only and the fluorescence
increase over time was measured in a microplate reader at 2 second intervals. FmaxFmin is the difference between the (+) FTase and (-) FTase reactions, and the slope is
the rate of fluorescence change over time. Note that the initial velocity of the
fluorescence increase over time and the Fmax-Fmin can be used to calculate the rate of
the FTase reaction.
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Figure 2-5 Reaction rates of analogs with N-dansyl-GCaaX motif peptides
FTase catalyzed analog reaction rates with each peptide relative to the reaction rate
with FPP. Rates are given in table 2-1. Cross-hatched bar is to show the location of
FPP. a) analog reactions with N-dansyl-GCVLS b) analog reactions with N-dansylGCAHQ c) analog reactions with N-dansyl-GCVIM d) analog reactions with N-dansylGCVIL. Note that FPP is not always the fastest analog transferred and peptide identity
as well as analog identity affects transfer rates relative to FPP.
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Reaction rate changes depending on the structure of the Ca1a2X sequence and
the analog structure
The crystal structure of a non-hydrolyzable FPP analog bound to FTase and a
Ca1a2X target solved by Reid et al. indicated that the ω-terminal isoprene of FPP and
the a2 position of the target protein Ca1a2X motif are in van der Waals contact with one
another [49]. In addition, the position of the a2 residue affects the placement of the Cterminal X residue in the FTase specificity pocket. We hypothesized that by changing
the ω-isoprene of FPP the ability of FTase to catalyze the modification of different
Ca1a2X sequences will be affected by the structure of the isoprenoid lipid. To determine
the effects of different Ca1a2X structures on the reactivity of different Ca1a2X sequences
we measured the rate of modification of three additional Ca1a2X sequences. The
Ca1a2X sequences corresponded to the C-terminal sequence of two canonical FTase
protein substrates RDJ-2 (CAHQ) and K-Ras4B (CVIM) (Figure 2-3 structures, Table 21 and Figure 2-5 reactivity). We also tested the ability of the analogs to react with a
canonical GGTaseI Ca1a2X substrate CVIL. GGTaseI peptide substrates can often
readily bind to the FTase enzyme. However, the canonical GGTaseI Ca1a2X sequences
are thought to bind to the E•FPP complex in a different conformation than the canonical
FTase substrates. In this alternate conformation the GGTaseI Ca1a2X substrates have
an even more pronounced interaction with the isoprenoid substrate, where the ωisoprene of the isoprenoid forms part of the binding site for both the a2 and X residues
of the canonical GGTaseI peptide substrates. The increased interaction between the
peptide and isoprenoid may therefore be even more sensitive to the structure of the ωisoprene.
We hypothesized that the hydrophobicity of the peptide would affect the FTase
reaction rate since the rate limiting step is product release and the overall product
volume is dominated by the peptide portion of the product. We found that the rate of the
peptide reactions with FPP correlated with the retention time of the product in the FPP
reaction (Figure 2-6). The most hydrophilic peptide, CAHQ, reacted the fastest, followed
by the CVLS, CVIM and CVIL peptides. The FTase active site is relatively hydrophobic
and these results are consistent with the idea that product release is rate-limiting due to
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interactions with the enzyme active site. The interactions of the more polar farnesylated
peptide products appear to be more easily disrupted than the less polar.
Since the peptide reactivity appeared to correlate with the hydrophobicity of the
peptide substrate with FPP, we tested whether the reactivity of the AGPP analogs also
correlated with peptide target hydrophobicity (Table 2-1, Figure 2-5 a-d). We found that
with the analogs the peptide reaction rate did not correlate with the HPLC retention time
of the peptide substrates, and differed substantially depending on both the structure of
the analog and the peptide. The CVIM peptide reacted readily with a much larger
number of analogs than any of the other peptides, where several analogs that were not
reactive with the CVIL, CAHQ and CVLS peptides reacted rapidly with the CVIM
peptide. In addition, the analogs that transferred with a rate faster than FPP with the
other peptides were not necessarily the same analogs that were good substrates with
the CVLS peptide. The mI-AGPP 4y and pBr-AGPP 4aa analogs were still rapid
substrates reacting three times faster than FPP with the CVIM peptide. However, the
pMe-AGPP 4ai and mCF3-AGPP 4af analogs which were among the fastest transferred
to CVLS were considerably slower than FPP when the Ca1a2X substrate was the CVIM
peptide rather than CVLS. These results indicated that there were major differences
between the reactivity of the analogs with different peptides and that the change in
reactivity did not correlate with the change in reactivity with FPP as the isoprenoid
donor.
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-1

FTase reaction rate (s )

Figure 2-6 Correlation of peptide HPLC retention and reaction rate with FPP
C18 retention capacity of each FTase target peptide correlated with the rate of the
FTase reaction with FPP from table 2-1. The HPLC retention time of each of the
peptides was measured and the capacity factors calculated as described for the LogP
measurements in the experimental section. Reaction rates are reported as reciprocal
seconds • 10-2. Note that there is an excellent linear correlation between peptide
hydrophobicity and reaction rate with FPP as the isoprenoid donor for the reaction, yet
this was not the case with the various analogs.
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Analog reactivity does not correlate with analog hydrophobicity
Since the reactivity of the analogs did not appear to correlate with the
hydrophobicity of the peptide substrate we tested whether the reactivity of the AGPP
analogs correlated with the analog hydrophobicity. In order to determine the
hydrophobicity of the AGPP series of analogs we used an RP-HPLC assay to estimate
the apparent LogP (LogPapp). LogP is a measure used for the hydrophobicity of a
molecule and represents the partition coefficient of a compound in water saturated
octanol verses octanol saturated water [195]. The RP-HPLC method uses the HPLC
capacity factor for a range of compounds with known LogP values as standards to
determine the apparent LogP of unknown compounds. We found that the LogPapp of the
analogs ranged from 2.9 for pCN-AGPP 4ag and 5.3 for oI-AGPP 4z. Surprisingly, the
hydrophobicity of the analogs did not correlate with the rate of the FTase reaction. In
order to have a molecule with similar size to FPP but greatly reduced hydrophobicity we
synthesized an additional analog containing an isoxazole moiety in the position of the
ω-isoprene. The isoxazole-GPP analog 12 was transferable by FTase and had an
extremely low LogPapp of 0.7. Taken together these results suggest that very hydrophilic
analogs of FPP can be made that are substrates for the FTase enzyme depending on
both the analog structure and the target peptide structure(Table 2-1).
Additional Isoprene Substitutions
To further explore the ability of the ω-terminal isoprene substituted analogs to be
utilized as substrates for FTase, Thangaiah Subramanian synthesized four analogs in
which the aniline nitrogen atom was replaced with an O (13), CH2 (14) S (15), or CH2O
(16). All four substitutions were acceptable for the FTase catalyzed modification of
CVLS (Figure 2-7). However, there were major differences in the transfer rate of the
analogs. When the nitrogen atom was replaced with a methylene or CH2O group, the
rate of the reaction with CVLS was comparable to that with FPP and AGPP. With both
sulfur and oxygen substituting the aniline nitrogen, the reaction rate was considerably
slower. These results indicated that the aniline nitrogen could be replaced, but the
reactivity of the analogs will change relative to the rate with AGPP.
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Figure 2-7 Transfer of non-aniline analogs to a CVLS peptide
FTase reactions were prepared as described in table 2-1 and the experimental section
with each of the exploratory analogs and the CVLS peptide. In these analogs the AGPP
nitrogen atom is replaced with an O, CH2, S or OCH2 . Note that the sulfur and oxygen
substituted compounds are transferred much slower than the other analogs.
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Analogs with aromatic rings replacing the ω-isoprene of FPP were acceptable
substrates for the FTase enzyme. We were interested in whether this was also true
when the β-isoprene of FPP was replaced with an aromatic ring. In order to determine
whether the β-isoprene could also be replaced Subramanian Thangiah synthesized six
additional phenoxy substituted isoprene analogs 17-20. We tested the ability of these
analogs to transfer to the CVLS peptide, and found that several of the β-substituted
phenoxy analogs were FTase transferable substrates. The analogs 18, 19 and 20 were
all acceptable substrates for FTase. Surprisingly, the fluorine substituted diaromatic
compound 17b was a substrate, while 17a and 17c were not substrates. Interestingly,
although 17a was not a substrate for the enzyme, switching the position of the ω-PhO
residue from the meta- to the para- position (18) resulted in a transferable analog.
These results indicated that the β, ω substituted analogs could be acceptable
substrates for the FTase enzyme. In addition, the results from compounds 17b, 17a and
18 indicated that the transferability of these molecules will be highly dependent on the
structural features. Additional AGPP analogs were also synthesized with increasing
functionalization in the aniline ring of AGPP. The methylene dioxy-AGPP analog 21 was
an acceptable substrate for the FTase enzyme. Two other analogs were synthesized as
potential fluorescent transferable FTase substrates where coumarin units (22a-b) were
placed in the position of the ω-isoprene unit. However, it is currently not clear whether
these analogs are substrates.
H-Ras Function Inhibition
H-Ras biological function depends on prenyl analog hydrophobicity and
hydrophilic analogs are Ras Function Inhibitors.
The delay in post-prenylation maturation for geranylated H-Ras relative to
farnesylated H-Ras in Xenopus has been attributed to the difference in hydrophobicity
of the two lipids [181]. The significantly less hydrophobic geranyl group appears to
interfere with maturation of the lipidated H-Ras by delaying one or more downstream
processing events. However, it is also possible that the downstream processing
enzymes or membrane localization may require a lipid with a minimum size for high
activity. The reduction in lipid hydrophobicity by shortening the 15 carbon farnesyl to the
10 carbon geranyl group cannot address this point. With the suite of FPP analogs in
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table 2-2, we were able to separate the effect of lipid size from hydrophobicity in the HRas stimulated maturation of oocytes.
Incorporation of aromatic rings and heteroatoms into the analogs decreases their
hydrophobicity relative to hydrocarbons of the same size. As a result, the size and
hydrophobicity of the analogs are no longer directly related. FPP 1 and AGPP 4a are
almost identical in size but differ substantially in hydrophobicity. On the other hand, both
the 10 carbon geranyl group 3 and the anilinogeranyl group 4a have a logP of 3.6 near
the middle of the range, but differ in surface area by 135 Å2. In order to evaluate the
effect of the lipid physical properties on Ras function, we prepared H-Ras modified in
vitro with FPP 1, GPP 3 and the analogs in table 2-2 (AGPP 4a, pNO2-AGPP 4b,
pCF3O-AGPP 4r, mCF3O-AGPP 4s, mEt-AGPP 4v, mI-AGPP 4y, pBr-AGPP 4aa, pCNAGPP 4ag, and isoxazole-GPP 12) for microinjection into oocytes. The extent of H-Ras
modification for each analog is shown in table 2-2. Lipidated H-Ras is somewhat
unstable in solution, forming aggregates and precipitates upon standing for very short
periods. The rate and extent of aggregation was dependent on the lipid analog
structure. In particular, in vitro modification of H-Ras with pBr-AGPP 4aa results in
complete denaturation of the H-Ras within five minutes of initiating the FTase reaction.
The aggregated H-Ras was clearly visible in the microinjection needle under the
microscope. Except for pBr-AGPP 4aa, aggregation could be controlled by allowing no
more than 20 minutes to elapse from initiation of H-Ras lipidation and completion of
oocyte microinjection. Previous studies employed detergent to keep lipidated H-Ras in
solution. In our hands, the use of sufficient detergent to prevent aggregation of the
anilinogeranyl-analog modified H-Ras resulted in inconsistent oocyte maturation results.
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Table 2-2 In vitro modification of H-Ras with isoprenoids
Ras was modified in an in vitro reaction with each of the given prenyl analogs and the
extent of modification is given as a percentage of total Ras protein in the reaction
mixture. Note that even though all of the analogs transfer they do not appear to transfer
to Ras with equal efficiency.
% H-Ras
modified in
Isoprenoid
vitro for
microinjection*
1 FPP
>90
3 GPP
70
4a AGPP
>90
4b pNO2-AGPP
>90
>90
4r pCF3O>90
4s mCF3O0
4t oCF3O4v mEt-AGPP
70
4y mI-AGPP
>90
4aa pBr-AGPP
>90
4ag pCN>90
12 isoxazole50
*The extent of H-Ras lipidation was estimated from images of SDS-PAGE separations
of in vitro FTase reactions.
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Lovastatin treated oocytes were microinjected with 5 pmols of in vitro analog
modified H-Ras and scored for germinal vesicle breakdown (GVBD) over the
subsequent 24 to 48 hour period. Microinjection of H-Ras pre-modified with the lipid
analogs was employed to ensure that the intracellular behavior was not dependent on
the ability of endogenous FTase to effectively transfer the analogs. The effective dose
of analog modified H-Ras microinjected into each oocyte was greater than 4.5 pmols
each for FPP 1, AGPP 4a, pNO2-AGPP 4b, pCF3O-AGPP 4r, mCF3O-AGPP 4s, mIAGPP 4y, pBr-AGPP 4aa, and pCN-AGPP 4ag, but only 2.5 pmols for isoxazole-GPP
12 and 3.5 pmols for m-Et-AGPP 4v and GPP 3 due to incomplete lipidation (Table 22). The time required for 50% maturation of the oocytes was calculated from sigmoidal
curves fitted to the GVBD time dependence for each of the analogs (Table 2-3). FPP 1,
GPP 3, AGPP 4a, mCF3O-AGPP 4s, pCF3O-AGPP 4r, mI-AGPP 4y, and mEt-AGPP
4v, stimulated GVBD, while pCN-AGPP 4ag, pNO2-AGPP 4b and isoxazole-GPP 12 did
not. Relative to FPP 1, GVBD was delayed for all the analogs other than AGPP 4a.
Farnesylated H-Ras is the natural substrate for the downstream maturation steps and is
expected to undergo efficient processing and appropriate membrane localization in the
oocyte. However, the time required for maturation of 50% of oocytes injected with
farnesylated H-Ras was highly dependent on the frog from which they were harvested.
Maturation times varied from 4-10 hours for different batches of oocytes stimulated by
farnesylated H-Ras. Accordingly, individual experiments were conducted with oocytes
simultaneously harvested from a single frog. We found that the order in which the
analog modified H-Ras stimulated 50% maturation relative to farnesylated H-Ras was
essentially identical from experiment to experiment. This observation gave us
confidence to combine and analyze data obtained from experiments using oocytes from
multiple frogs after appropriate normalization. We expressed the maturation half-time for
analog modified H-Ras as the ratio of the time required for 50% maturation of analog
modified H-Ras to that of farnesylated H-Ras (Table 2-3).
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Table 2-3 Maturation kinetics of microinjected oocytes
Stage V or VI oocytes were incubated with lovastatin for 16 hr and then microinjected as
described below. Microinjected oocytes were monitored for GVBD at the indicated times
and the results expressed as a percentage of the number of viable injected oocytes (1420/group). The small number of oocytes that did not survive 3 hr post injection were
removed from the experiment. A. Induction of GVBD following microinjection of premodified activated H-Ras into lovastatin treated oocytes. The t1/2 was 8.8 hr for
farnesylated H-Ras and 13 hr for anilinogeranylated H-Ras. The ratio of t1/2(AGPP) to
t1/2(FPP) is 1.5. B. Induction of GVBD following co-microinjection of activated H-Ras and
isoprenoid diphosphate into lovastatin treated oocytes. The t1/2 was 5 hr for FPP and 6.9
hr for AGPP coinjected with H-Ras. The ratio of t1/2(AGPP) to t1/2

Isoprenoid

Fold increase in maturation time relative to 50% GVBD for
FPP 1*

In vitro modified H-Ras
Coinjected H-Ras and
1 FPP
1
1
3 GPP
1.4 ± 0.3
1.7 ± 0.2
4a AGPP
1.6 ± 0.5
1.5 ± 0.3
1.3 ± 0.2
1.7 ± 0.3
4r pCF3O-AGPP
1.6 ± 0.3
2.0 ± 0.8
4s mCF3Ond**
nd**
4t oCF3O-AGPP
4v mEt-AGPP
1.2 ± 0.1
3.3 ± 1.0
4y mI-AGPP
1.6 ± 0.3
1.0 ± 0.1
4aa pBr-AGPP
No assay
1.4 ± 0.2
b
nd
ndb
4b pNO2-AGPP
4ag pCN-AGPP
ndb
ndb
12 isoxazolendb
ndb
*The time required for 50% GVBD for FPP ranged from 4-10 hours (see text for details).
Average and standard deviation for fold increase are calculated from at least three
independent experiments.
**Not detected.
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The 5 pmols/oocyte dose of modified H-Ras is in excess of that required to
induce maximal rates of oocyte maturation. Previous studies of prenyl function showed
that 2 pmols/cell of farnesylated H-Ras induced maximal rates of maturation [181].
Under suboptimal conditions of 0.5 pmols/cell of modified H-Ras, the oocyte system is
very sensitive to structural alterations of the lipid, which affects its biological activity. For
example, under suboptimal conditions, microinjection of 0.5 pmols of geranyl modified
H-Ras results in maturation half-times that are 2.5 to 3.3 times longer than farnesyl
modified H-Ras [181]. The increase in maturation time is closely associated with delays
in the downstream endoproteolysis, carboxyl methylation and subsequent palmitoylation
[181]. In contrast, the maturation of oocytes microinjected with 5 pmols/cell of 70%
lipidated geranyl H-Ras (3.5 pmols of modified protein) is only delayed by 40% relative
to farnesylated H-Ras. Conditions of high H-Ras dose reveal any signal transduction
activity, expressed as GVBD, which is supported by the analogs. These observations
suggest that lipid analogs that do not support GVBD in oocytes microinjected with these
high doses of modified H-Ras are extremely compromised in their ability to support
oncogenic Ras function.
In each experiment, unmodified H-Ras was injected into both lovastatin treated
and untreated oocytes to test for the completeness of the isoprenoid depletion and as
an additional check on the quality of the oocytes. As previously reported, untreated
oocytes injected with activated H-Ras underwent GVBD, whereas those pre-incubated
with lovastatin failed to mature. Progesterone stimulates GVBD via a Ras-independent
pathway, and is therefore unaffected by lovastatin treatment [196]. In each experiment,
a small number of the oocytes injected with the individual analog modified H-Ras were
withheld and treated with progesterone to test the overall oocyte quality and to ensure
that the manipulations did not interfere with maturation. In all cases, the progesterone
treated oocytes matured.
Table 2-3 shows that the ability of the analogs to support oocyte maturation fell
into three categories. The first category is represented by oCF3O-AGPP 4t which does
not support oocyte maturation because it is not transferred to H-Ras by FTase.
Microinjection of the H-Ras/oCF3O-AGPP 4t reaction mixture was no different from
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injection of unlipidated H-Ras into the lovastatin treated oocytes. In the second category
are GPP 3, AGPP 4a, mCF3O-AGPP 4s, pCF3O-AGPP 4r, mI-AGPP 4y, and mEtAGPP 4v which are transferred by FTase to H-Ras in vitro and support GVBD.
Interestingly, the half-time for maturation stimulated by these analogs was delayed from
20-60% relative to farnesylated H-Ras. The third category consists of analogs pCNAGPP 4ag, pNO2-AGPP 4b, and isoxazole-GPP 12 which are transferred by FTase to
H-Ras in vitro but do not support GVBD. These analogs are Ras function inhibitors
(RFIs). The lipid chains of FPP 1 and the transferable analogs are similar in length, size
and excluded volume, but have different hydrophobicities. The delay in oocyte
maturation kinetics does not show any correlation with the length or surface area of the
lipid moiety. Rather, it appears that H-Ras is capable of initiating GVBD if the lipid
alcohol has a logP of at least 3.6, yet they were unable to support oncogenic H-Ras
function when the LogP of the parent alcohol was less than 3.2.
In situ lipidation of H-Ras by hydrophobic FPP analogs rescues Ras biological
function in X. laevis oocytes.
The loss of H-Ras function in the experiments described above is independent of
differences in their rates of transfer by FTase. However, partial loss of the in vitro
lipidated H-Ras to aggregation was inevitable and prevented evaluation of the pBrAGPP 4aa analog. The possibility existed that different substitution patterns on the
analog might affect the ability of the lipid to support oocyte maturation. Analogs mEtAGPP 4v and pBr-AGPP 4aa share the same logP and have similar surface areas and
excluded volumes. However, they differ in structure. Previous studies showed that the
X. laevis FTase was competent to transfer alternative lipids with similar or greater
hydrophobicity than FPP to H-Ras in situ [181]. The rate of transfer was sufficiently high
that the maturation half-time for co-injected H-Ras and in vitro modified H-Ras was
indistinguishable. These results suggest that the substrate specificity of X. laevis FTase
is sufficiently similar to mammalian FTase to allow efficient modification of the H-Ras by
other, structurally unrelated analogs.
We co-injected 5 pmols each of the lipid diphosphates and H-Ras into lovastatin
treated oocytes and scored for GVBD. The half-times for oocyte maturation are shown
in Table 2-3. Consistent with the in vitro modification results, coinjection of H-Ras and
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FPP or the analogs GPP 3, mCF3O-AGPP 4s, pCF3O-AGPP 4r, mI-AGPP 4y, mEtAGPP 4v, pBr-AGPP 4aa or AGPP 4a results in maturation of the oocytes, while
coinjection of H-Ras and analogs oCF3O-AGPP 4t, pNO2-AGPP 4b, pCN-AGPP 4ag,
and isoxazole-GPP 12 failed to promote maturation. Interestingly, the p-Br-AGPP
analog 4aa, promotes oocyte maturation about as effectively as GPP 3. The mEt-AGPP
4v was the only FPP analog which showed a significant increase in the half-time to
maturation upon co-injection with H-Ras. On the other hand, co-injection of the H-Ras
with mI-AGPP 4y results in a slight enhancement in the rate of oocyte maturation
compared to pre-modified protein. The half-time to maturation for co-injected H-Ras with
both FPP and mI-AGPP 4y are identical. None of the analogs accelerated the
maturation of the oocytes relative to farnesylated H-Ras. Thus, it is likely that the X.
laevis FTase is able to transfer the FPP analogs to H-Ras in situ. However, these
results suggest that mEt-AGPP 4v is a poor substrate for X. laevis FTase catalyzed
transfer to H-Ras. With the exception of mEt-AGPP 4v it appears that the rate of in situ
FTase catalyzed modification of H-Ras by the analogs was not rate limiting for oocyte
maturation. From these data, it is not possible to determine if the X. laevis FTase was
able to transfer the analogs unable to support maturation to coinjected recombinant HRas.
Discussion
Implications
These results have important implications for the development of RFIs as
potential alternatives to FTIs. It is now well established that isoprenylation is required for
Ras function, and that oncogenic Ras activity may be inhibited by pharmacologic
inhibitors of FTase (FTIs). However, while the farnesylation of Ras, and a variety of
additional proteins, is blocked by FTI treatment, the Ras protein that is most often
mutated in human cancer (K-Ras) undergoes alternative prenylation. Since,
geranylgeranyl-modified Ras is effectively targeted to cellular membranes and retains
its transforming ability, K-Ras function is not disrupted by FTI treatment. Our work
suggests that the hydrophilic RFI lipid structures may act by interfering with membrane
localization rendering the modified protein non-functional. The results seen with H-Ras,
lead us to predict that modification of oncogenic K-Ras4B with RFI prenyl analogs
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would both prevent its transforming ability and block GGTaseI-mediated alternative
prenylation.
Hydrophobicity and FTase Transfer
Another important implication from this chapter is that the structural parameters
that control transferability do not appear to affect the ability of the analogs to support HRas biological function. This provides an orthogonal relationship between transferability
and prenyl group function that could be exploited for the design of new potent
transferable analogs that transfer very well to proteins, yet poorly support prenylated
protein membrane localization. The assay used in this chapter to screen the majority of
the FTase analogs was limited in its ability to characterize the efficiency of transfer of
the analogs relative to FPP. The next important step for the characterization of these
analogs would be to determine if they can compete with FPP and can they be
incorporated into cellular proteins. The Xenopus model system avoids issues related to
cell penetrance due to the fact that the compounds are directly injected into the
cytoplasm of the cell.
Analog Reactivity Dependent on Both Substrate Structures
The lipid binding pocket of the FTase enzyme is considerably hydrophobic and
evolutionarily designed to bind hydrophobic isoprenoid chains. However, the enzyme
binds a wide variety of Ca1a2X sequences with very different chemical properties. In
particular the a2 binding site of the enzyme accepts a variety of amino acids that do not
conform to the classical Ca1a2X aliphatic amino acid paradigm. Not only can this region
of the enzyme bind a variety of different amino acids, the a2 binding site also can form
aromatic interactions with a number of potent FTase inhibitors. The aniline moiety of
AGPP replaces the ω-isoprene of FPP which also forms part of the a2 binding site.
AGPP may be less polar and therefore less able to interact with the hydrophobic
farnesyl binding site of FTase, but it is possible that the loss of binding energy to the
hydrophobic groove may be made up for with aromatic stacking interactions.
FTase Accepts a Diverse Array of Substrate Structures
We also found that both the structure of the isoprenoid and the structures of the
target peptide affect the transferability of the FTase analogs. A number of the analogs
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could be rapidly transferred to particular Ca1a2X sequences, while they were unable to
react with other Ca1a2X peptides. These studies imply that it may be possible to
selectively modify particular Ca1a2X sequences of proteins with certain analogs even in
the presence of multiple other Ca1a2X sequences. However, the assay used to
determine peptide reactivity was limited and does not directly address the efficiency of
the reactions with the different peptides. Enzyme catalytic efficiency is highly dependent
on both the rate of an enzyme reaction and the enzyme affinity for particular substrates.
Issues relating to target selectivity will be addressed in later chapters of this
dissertation.
Experimental
General
Reaction temperatures refer to the external bath. All solvents were purchased from
VWR (EM Science-Omnisolv high purity) and used as received. All other reagents were
purchased from Aldrich, Alfa Aesar or GIBCO. Merrifield-Cl resin was purchased from
Argonaut technologies. 1H and

13

C NMR Spectra were obtained in CDCl3 with a Varian

Inova spectrometer operating at 400 and 100.6 MHz respectively. Chemical shifts are
reported in ppm from CDCl3 internal peak at 7.27 ppm for 1H and 77.4 ppm for 13C. ESIMS were performed at the University of Kentucky Mass Spectra Facility. HPLC analysis
was performed with an Agilent 1100 series purification system equipped with a diode
array detector and autoinjection system. All the reactions except for resin preparation
were performed in PTFE tubes using a Quest 210 apparatus manufactured by Argonaut
Technologies.
Credits: Zhongwen Wang and I were responsible for the development and
implementation of the solid phase synthetic route. Thangiah Subramanian was
responsible for re-synthesis and optimization. All molecules for the Xenopus study were
synthesized by me and all Xenopus assays were performed by Mike Roberts.
Synthesis
Preparation of aldehyde resin 5
THP resin 3 (0.50 g, 0.82 mmols), geranyl aldehyde 4 (1.35 g, 8.2 mmols), PPTS
(41.2 mg, 0.164 mmols), and 2.5 ml of anhydrous DCE were combined and stirred at 60
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ºC for 48 hours. The resin was recovered by filtration and washed sequentially with
DCM (3x), DMF/H2O (1:1) (4x), DMF (3x) and DCM (3x), followed by vacuum drying at
rt. to afford 636 mg of light yellowish resin 5 (74% based on recovery of aldehyde 4 after
treatment of resin 5 with PPTS/MeOH).

Unreacted geranyl aldehyde 4 can be

recovered from the filtrate and reused. .
Reductive amination and cleavage (8a-8al, 2a-2al)
Reductive amination and cleavage (Compounds 8a-8al)
Aldehyde resin 5 (100 mg, 0.10 mmols), the appropriate aniline 6a-ad (0.50
mmols), acetic acid (36 mg, 0.60 mmols), 2 ml anhydrous THF and 1 ml anhydrous
DCE were combined in individual reactor tubes and agitated at rt. under N2 for 12 hours.
NaBH(OAc)3 (42 mg, 0.20 mmols) was added and the slurry agitated at rt. under N2 for
an additional 60 hours. The resin was filtered and washed sequentially with THF (4x),
aq. NaHCO3 (3x), H2O (3x), THF (4x) and anhydrous methanol (1x). PPTS (50 mg,
0.20 mmols) in 1 ml of anhydrous methanol and 1 ml of anhydrous DCE was added and
the slurry and agitated at 60 ºC under N2 for 20 hours. After cooling to rt., the resin was
filtered and washed with 2 ml of methanol. The filtrate and washing were combined and
evaporated to dryness under reduced pressure. Each residue was dissolved in 5 ml
chloroform and washed with water (1x) and the organics evaporated to dryness under
reduced pressure. The crude products were purified by RP-HPLC (Ranin Microsorb 89203-C5, 5µm, 300 Å, C-18 (10mm x 250 mm) column with an isocratic mobile phase:
65%Acetonitrile-35%H2O; Monitored at 254 nm and 298 nm).
Reductive amination and cleavage (compounds 2a-ai)
Aldehyde resin 5 (100 mg, 0.10 mmols), the appropriate aniline 6a-ad (0.50
mmols), acetic acid (36 mg, 0.60 mmols), 2 ml anhydrous THF and 1 ml anhydrous
DCE were combined in individual reactor tubes and agitated at rt. under N2 for 12 hours.
NaBH(OAc)3 (42 mg, 0.20 mmols) was added and the slurry agitated at rt. under N2 for
an additional 60 hours. The resin was filtered and washed sequentially with THF (4x),
aq. NaHCO3 (3x), H2O (3x), THF (4x) and anhydrous CH3CN (1x). Ph3PCl2 (66 mg,
0.20 mmols) in 2 ml of anhydrous CH3CN was added and the slurry and agitated at
room temperature under N2 for 2 hours. The resin was filtered and washed with 1 ml of
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anhydrous CH3CN.

The combined filtrate was directly introduced into glass tubes

containing tris(tetra(tert-butyl)ammonium)diphosphate ( 451mg, 0.50 mmols). The
mixtures were stirred at room temperature for 30 mins under N2. Volatiles were removed
under vacuum after which the residue was suspended in 4 ml of 25 mM NH5CO3.and
extracted with ether (3x). The aqueous phase was applied to an NH4+ form ionexchange column and eluted with two-column volume 25 mM NH4HCO3 buffer. The
eluent was applied to a fresh NH4+ form ion-exchange column and eluted with a further
two-column volume 25 mM NH4HCO3 buffer.

The combined aqueous phase was

lyophilized, the residue dissolved in a minimum volume of 25 mM NH4HCO3 buffer and
the diphosphates 2a-ad purified by RP-HPLC (Varian Dynamax, 10 µm, 300 Å, C-4
(10mm x 250 mm) column with an gradient mobile phase: 100% 25 mM NH4OAc buffer
for 3 mins, 100% 25 mM NH5AcO buffer to 80% MeCN 20% 25 mM NH5AcO buffer over
20 mins; Monitored at 254 nm and 298 nm).
Protein Farnesyl Transferase Transfer Rates
Reaction rates of the analogs with each N-dansyl-GCaaX peptide were
determined in triplicate measurements using a continuous spectrofluorometric assay
adapted for a 96-well plate. The following assay components were assembled in
individual wells of a 96-well plate and incubated at 30° C for 20 minutes: 180 µL of
assay buffer (52 mM Tris-HCl, 12 mM MgCl2, 12 µM ZnCl2 pH 7.4), 40 µL of detergent
(0.125% n-dodecyl- β-D-maltoside in assay buffer), 40 µL of reducing agent (50 mM
DTT in assay buffer) 20uL of FPP or AGPP (200 µM in 25 mM NH4HCO3) and 20 µL of
N-dansyl-GCaaX peptide(final concentration 3 µM). Fluorescence was detected using a
time based scan at 30° C for 120 minutes. The velocity of each reaction was determined
by converting the rate of increase in fluorescence intensity units (FLU/s) to µM/s with
equation 2-1.
Equation 2-1: vi=(R·P)/(FMAX-FMIN)
Where vi is the velocity of the reaction in µM/s. R is the rate of the reaction in FLU/s. P
is equal to the concentration of modified product in µM (see below). FMAX is the
fluorescence intensity of fully modified product. FMIN is the fluorescence of a reaction
mixture that contained 20 µL of assay buffer in the place of FTase. Complete
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modification of peptides was assumed when fluorescence stabilized for more than 10
minutes and was confirmed by RP-HPLC analysis of the reaction mixture.
Analog Structure Properties
LogP determination
The apparent LogP values for the corresponding alcohols of diphosphates were
estimated from the capacity factors (k’) using high performance reverse phase liquid
chromatography (HPLC) (added high performance and abbreviation) [197, 198]. A
BioBasic-8 RP-C8 column was used as the stationary phase, and the mobile phase
consisted of a mixture of 20mM phosphate buffer (pH=6.0) and methanol (3:7) as
described by Niemi et al. [199] Solutions with known LogP values were dissolved in 3:7
phosphate buffer in methanol [1mM progesterone (logP 3.87), 1mM norgestrel (logP
3.7), 100 mM anthracene (logP 4.54), 1mM hydrocortisone (logP 1.53), 0.01 mM
nitrobenzene (logP 3.3), 0.01 mM anisole (logP 1.85), 1 mM perylene (logP 2.11) 0.05
mM naphthalene (logP 3.3)] 5 up of each standard was injected and monitored at 254
and 280 nm. A standard curve was generated from the log of the capacity factor k
calculated with equation 2 where Rt is the retention time and R0 is the time for a 5 µL
injection of 1mM benzoic acid to pass through the column.
Equation 2-2: k=(Rt-R0)/R0
The log of the capacity factor was plotted against the known logP values to generate a
standard curve R2 0.97. A Pasteur pipette tip was placed into each of the neat alcohols
and the drawn up solution was taken up in 1000 up of mobile phase and 1 µL was
injected onto the column. The capacity factor for each of the alcohols was calculated
from equation 2-2 and the standard curve was used to determine the apparent logP of
the alcohol.
Surface area calculation
Surface area calculations were achieved using the online PreADME molecular
descriptor calculation software.
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H-Ras Preparation and Microinjection
H-Ras protein
Oncogenic H-RasQ61L was expressed in the Rosetta DE3 strain of E. Coli
(Novagen, CA, USA) using the pTrc-His A plasmid (Invitrogen corporation, CA, USA).
Expression was induced by 1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG) when
the optical density of bacteria reached 0.6, and the bacteria harvested after 4 hrs [200].
Bacteria were pelleted by centrifugation, resuspended in 20 mM Tris, pH 8.0 containing
0.5 M NaCl, 1mM BME, 1mM MgCl2, 10% glycerol and 20 mM imidazole, lysed using a
French Press, and H-RasQ61L purified on a nickel column by Fast Protein Liquid
Chromatography using an imidazole gradient. Aliquots from the resulting fractions were
separated on a 12% SDS-PAGE gel, and proteins stained by incubation with coomassie
blue (0.625 g in 250 ml 50% MeOH, 10% acetic acid) for 1 hr followed by destaining
(3:1 MeOH:Acetic acid). Fractions shown to contain pure (>90%) H-RasQ61L by SDSPAGE were dialyzed against Tris and protein content measured using the BCA Protein
Assay Kit (Pierce, IL, USA), and this value was used as the concentration of protein in
subsequent experiments.
Pre-Modification of Ras in vitro using FPP Analogs.
100 µM RasQ61L was incubated in assay buffer (52 mM Tris-HCl, 12 mM
MgCl2, 12 µM ZnCl2, 5.8 mM DTT), with 100 µm FPP or FPP analogs, 1 µM
recombinant FTase and 0.04% n-dodecyl-β-D-maltoside in a total volume of 15µl for 20
min at 37°C [159]. The reaction mixture containing the lipidated H-RasQ61L was then
immediately injected into lovastatin treated oocytes as described below.
Oocyte extraction and microinjection
Oocytes were isolated from Xenopus laevis females (Xenopus Express, Inc.,
Florida, USA) that were primed with gonadotropin before shipment and allowed to
acclimatize to their new environment for a minimum of 30 days after arrival before
surgery. Frogs were housed in tanks with water and room temperature kept at 17°C and
given a 12/12 hr light/dark cycle for optimal egg production. Frogs were anesthetized
with 0.01% MS-222 (Argent, Washington, USA), the oocytes surgically removed, and
the frog returned to the communal tank for recovery. Oocytes were defoliculated by
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incubation with 3 mg/ml type 3 collagenase (Worthington Chemical Corp., NJ, USA), in
30 ml Barth’s medium (88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 0.82 mM MgSO4,
0.33 mM Ca(NO3)2, 0.41 mM CaCl2, 20 mM HEPES, pH 7.5), for 60-90 min. Following
defoliculation, oocytes were washed 3X in Barth’s medium (30 ml each time), followed
by 3 X in one half Leibowitz L15 medium (Invitrogen, NY, USA) (30 ml each time), and
allowed to recover for at least 4 hr before manipulation. Following recovery, stage V and
VI oocytes were selected and incubated overnight (16 hr) in one half L15 medium +/- 50
µm lovastatin (LKT laboratories, MN, USA). Following incubation in lovastatin, any
oocytes that were not of uniform pigmentation and otherwise healthy were discarded,
and the remaining oocytes microinjected with H-RasQ61L pre-modified as described
above, or H-RasQ61L was co-injected with the FPP analogs synthesized in our
laboratory [161, 163]. 50 nL total volume was injected per oocyte. All microinjections
were done using a Nanoject II microinjector (Drummond Scientific Company, PA, USA)
mounted on a micromanipulator (Narishige, NY, USA). Oocytes were scored hourly for
germinal vesicle breakdown (GVBD), as evidenced by the appearance of a white spot in
the otherwise dark colored animal hemisphere. Progesterone was used as a positive
control to induce GVBD in lovastatin treated and untreated oocytes and was also used
to determine whether any oocytes that did not undergo GVBD following microinjection of
the FPP analogs were still responsive to maturation signals.
Gel Shift Assay
Following modification of Ras for exactly 20 min as described above, a 1 µl
sample was taken and immediately mixed with 4 µl 2 X Laemmli SDS sample buffer.
Samples were boiled for 5 min, then loaded onto 12% SDS-PAGE gels and modified
Ras separated from unmodified Ras by running at 200V for 80 min. Proteins were
stained by incubation with Coomassie blue (0.625 g in 250 ml 50% MeOH, 10% acetic
acid) for 1 hr followed by destaining (3:1 MeOH:Acetic acid). Ras modified with a prenyl
group shows higher electrophoretic mobility than unmodified Ras. The extent of protein
modification by each analog was estimated from images of the gel analyzed using NIH
Image 1.63.
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The solid phase work has been reported in the following citation:
1. Subramanian T, Wang Z, Troutman JM, Andres DA, Spielmann HP. “Directed library
of anilinogeranyl analogues of farnesyl diphosphate via mixed solid- and solution-phase
synthesis.” Org Lett. 2005 May 26;7(11):2109-12
Credits:
1. Post-doctoral researcher, Michael J. Roberts was responsible for all Xenopus assays
and Ras modifications
2. Post-doctoral researcher Thangiah Subramanian was responsible for yield
optimization of the solid phase reaction scheme, resynthesis of many of the
compounds, the use of Ph3PBr2 as a cleavage reagent replacing Ph3PCl2, and as cited
in the text the synthesis of the exploratory FPP analogs.
3. Post-doctoral researcher Zhongwen Wang in collaboration with me was responsible
for the development of the solid-phase synthetic scheme, most notably using the α,βunsaturated aldehyde as the first isoprenoid linked resin reagent.

Copyright © Jerry Troutman 2006
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CHAPTER 3 FARNESYL TRANSFERASE TARGET SELECTIVITY IS DEPENDENT
ON PEPTIDE CATALYZED PRODUCT RELEASE
Introduction
The mechanism of the protein prenyltransferases is unexpectedly complex
(Figure 3-1) [49, 82]. Substrate association is assumed to proceed through a
functionally ordered mechanism where FPP (1) (Figure 3-2) binds FTase first, giving the
enzyme-FPP complex (E•FPP) followed by Ca1a2X substrate association forming the
enzyme-FPP-Ca1a2X peptide complex (E•FPP•CaaX) [72, 201]. After thioether
formation, the modified peptide remains associated with FTase in an enzyme-product
complex (E•product) [72, 74]. Product release is the rate determining step (kcat) for the
FTase reaction mechanism [72, 80]. An unusual feature of the FTase mechanism is that
product dissociation is greatly enhanced by binding of either a new FPP or Ca1a2X
peptide substrate [74]. Apparently, two competing pathways can lead to the release of
farnesylated peptide, depending on whether FPP or Ca1a2X peptide binds to the
E•product complex. However, for the farnesylation of CVIM, FPP stimulates release
slightly faster than does peptide [74]. It is generally accepted in the literature that FPP is
the substrate primarily responsible for stimulating product release [74, 154]. The steadystate kinetic constant kcat/Km is often used to describe the selectivity of an enzyme for
its substrates (Equation 3-1) [202]. The kcat/Kmpeptide is also the catalytic efficiency of
FTase, and measures the ability of the enzyme to catalyze a reaction at low substrate
concentrations. Unlike the selectivity constant, catalytic efficiency does not depend on
the competitive interaction of an alternative substrate target. In the case of FTase, the
kcat/Kmpeptide should describe FTase selectivity for different Ca1a2X peptide substrates
[154, 203]. For example, kcat/Kmpeptide for the H-Ras CVLS peptide is twice that
measured for the K-Ras CVIM peptide. If kcat is dominated by FPP stimulated product
release, kcat/Kmpeptide should describe FTase selectivity. Therefore, the expected ratio of
products from the farnesylation of two competing Ca1a2X substrates is given by
equation 3-1. Interestingly, the ratio of products from the FTase catalyzed farnesylation
of competing Ca1a2X peptides has not been reported. However, there are a number of
reports suggesting that FPP binding may not be the sole, or even dominant mechanism
for product release [49, 74, 80, 203]. A crystal structure of FTase bound to both the
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farnesylated peptide and FPP (E•FPP•product) revealed that the product prenyl chain is
displaced from the active site into an external hydrophobic groove (“exit groove”) and
the new FPP is bound in the active site [49]. Surprisingly, the farnesylated peptide was
not dissociated from the crystal by the presence of excess FPP. However, the
farnesylated product was dissociated by additional peptide. Complicating matters
further, Hartman et al [203]. found that some FTase reaction products do not dissociate
from the enzyme even in the presence of excess FPP or peptide. However, the addition
of a different un-farnesylated Ca1a2X peptide stimulated product release. These
observations are inconsistent with FPP stimulated product release as the sole
mechanism for dissociation, and indicate that Ca1a2X substrate stimulated product
release may also be important.
Equation 3-1 kcat/Km as a selectivity factor
Va and Vb are the rates of modification of the individual reaction components A and B,
A and B are the concentrations of the reactants in the mixture, the Km is the MichaelisMenten constant for each substrate, et is the total enzyme concentration.
Vmaxa . A . et
kcata
B
.A
Kma . 1
A
Va
Kmb
Kma
Vb

Vmaxb . B . et
Kmb . 1

A
Kma
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kcatb
B

Kmb

.B

Figure 3-1 Minimum reported FTase reaction mechanism
FTase kinetic pathway where E is the FTase enzyme, E-FPP is the FTase•FPP
complex, E•FPP•CaaX is the FTase•FPP•CaaX peptide complex, E-Product is the
FTase bound product complex, E-Product-FPP is the FTase bound to both FPP and the
reaction product, and E-CaaX is the peptide bound FTase inhibitory complex. Note that
E•FPP is formed after product release and is not likely to dissociate to the free enzyme.
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Figure 3-2 Analog Structures
Structure of farnesyl diphosphate (1, FPP) 8-anilinogeranyl diphosphate (2, AGPP)
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A wide range of Ca1a2X sequences have been identified as potential FTase
substrates [56]. However, farnesylation has only been confirmed for some of them.
Understanding FTase substrate specificity may be critical for understanding which
Ca1a2X motifs are farnesylated. Hartman et al. reported that the kcat/Kmpeptide varies over
400 fold for 14 Ca1a2X peptides with different X-groups [203]. However, it is unclear
whether the product distribution for the competition of peptides for farnesylation by
FTase will be adequately predicted by the kcat/Kmpeptide since product release can be
stimulated by either of the two peptides or FPP [74].
The FTase reaction is unique because the FPP lipid moiety forms a substantial
part of the binding surface for the target Ca1a2X peptide [80, 204]. Crystallographic
studies of FTase with a bound Ca1a2X substrate and a non-hydrolyzable FPP analog
indicate that the ω-terminal isoprene unit of the lipid is in direct contact with the a2
residue of the Ca1a2X motif [80, 205]. Unnatural FPP analogs with structures that differ
from FPP may be useful in determining the molecular features of both the lipid and
Ca1a2X peptide that contribute to the FTase mechanism [149, 154, 163, 192]. 8anilinogeranyl diphosphate (AGPP (2)) contains an aniline moiety which replaces the ωterminal isoprene of FPP (1). AGPP (2) is a good substrate for FTase with steady-state
transfer constants Kmanalog and kcat/Kmanalog nearly identical to those of FPP (1) [159,
161]. Recent studies with other FPP analogs have shown that the lipid structure can
significantly affect the Ca1a2X target selectivity of the FTase enzyme [154].
In this chapter, I describe studies to measure the ability of FTase to selectively
modify peptides corresponding to six different Ca1a2X motifs with the isoprenoid donors
FPP and AGPP. The reactivity and the selectivity of FTase for the peptides were similar
for both isoprenoid donors. Surprisingly, we found that the Ca1a2X substrate selectivity
of the enzyme is not predicted by the selectivity factor kcat/Kmpeptide. The ratio of
products from competition reactions between two Ca1a2X peptides correlated with the
ratio of Kmpeptide instead of the kcat/Kmpeptide ratios. We further analyzed the steady-state
peptide dependent kinetics of the FTase reaction and found that there were at least
three Ca1a2X substrate concentration dependent binding states in the FTase reaction
mechanism. We propose that the binding states are due to peptide binding to the E•FPP
complex, the E•product complex and a substrate inhibition complex. These results
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demonstrate the importance of peptide stimulated product release in the mechanism of
FTase and the involvement of this pathway in the selectivity of the FTase enzyme for
different Ca1a2X targets.
Results
Individual Ca1a2X peptide reactivity is similar with both FPP and AGPP
In order to determine if kcat/Kmpeptide is the selectivity factor for FTase, we
measured the apparent kcat/Kmpeptide and Kmpeptide for six dansylated-GCa1a2X peptides
with saturating concentrations of the isoprenoids FPP and AGPP utilizing a continuous
fluorescence assay (Table 3-1). The steady state kinetics of the K-Ras4B (CVIM) and
H-Ras (CVLS) full length proteins and the corresponding Ca1a2X peptides with FPP
have been extensively characterized [50, 76, 90, 154, 206]. We confirmed that
kcat/Kmpeptide for the dansylated-GCVIM (Dns-GCVIM) and dansylated-GCVLS (DnsGCVLS) substrates were identical to those previously reported in the literature [154].
The other four substrates correspond to Ca1a2X motifs from physiologically important
proteins, three of which are canonical FTase substrates: CenpF-F (CKVQ) [207], the
DNAJ homologue, RDJ2 (CAHQ) [200], and the hepatitis delta virus (HDV) large
antigen protein (CRPQ) [113], and the fourth, a canonical GGTaseI-I substrate Ca1a2X
motif (CVIL) [56, 208].
The catalytic efficiency (kcat/Kmpeptide ) of the Ca1a2X substrates varied over a 11and 20-fold range with FPP and AGPP, respectively (Table 3-1). The difference in
reactivity of the peptides with each isoprenoid was similar, where CVLS was the most
reactive peptide with both isoprenoids. FTase showed slightly enhanced catalytic
efficiency with AGPP relative to FPP for the CRPQ peptide. Interestingly, the catalytic
efficiency with the canonical GGTaseI substrate CVIL was decreased over three-fold
with AGPP relative to FPP.
Peptide selectivity is not predicted by kcat/Kmpeptide rather, it is correlated with
Kmpeptide
We performed competition reactions between pairs of Ca1a2X peptides in order
to determine whether kcat/Kmpeptide is the selectivity factor for FTase. The products from
competition reactions for pairs of Ca1a2X peptides with either FPP or AGPP were
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separated by RP-HPLC and quantified by integration of the dansyl absorbance (Table
3-2). The competition reactions were stopped prior to 50% consumption of either
Ca1a2X substrate in order to ensure that the peptide concentration did not fall below its
Kmpeptide. We found that the ratio of kcat/Kmpeptide for any of the pairs of Ca1a2X peptides
examined did not predict the actual ratio of products formed (Table 3-2). For example, a
1:1 product ratio of farnesyl-CVIM (fCVIM) to farnesyl-CVLS (fCVLS) was expected if
kcat/Kmpeptide is the selectivity factor for FTase (Table 3-2). Instead, we found a product
ratio of 3:1 fCVIM:fCVLS (Table 3-2). The CVIM peptide was three-fold more
competitive over the CVLS peptide than predicted by the ratio of kcat/Kmpeptide. We also
found that the ratio of products was invariant for reactions where from 10% to 50% of
the CVIM peptide was consumed. Results from competition reactions with AGPP as the
isoprenoid donor mirrored those of FPP. However, the product ratios of competition
reactions for pairs of Ca1a2X peptides with either 12 µM FPP or AGPP did correlate with
the ratio of the apparent Kmpeptide with a slope of 0.8 for FPP and 2.1 for AGPP (Figure
3-3). In order for equation 3-1 to accommodate these observations, the ratio of kcat for
the competing substrates must be equal to an isoprenoid dependent constant. However,
inspection of the experimentally determined values for kcat (Table 3-1) indicates that this
is not the case.
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Table 3-1 peptide steady-state kinetic parameters
Kinetic parameters Kmpeptide, kcat and kcat/Kmpeptide for N-dansyl-GCa1a2X peptides with
FPP or AGPP as the isoprenoid donor at 6.7 µM and peptide at varying concentrations
in Tris-HCl buffer (pH=7.4) plus reducing agent and detergent. Note that FPP and
AGPP are nearly identical based on the steady state rate constants, except with the
CVIL and CRPQ peptides.
donor

peptide

FPP
FPP
FPP
FPP
FPP
FPP
AGPP
AGPP
AGPP
AGPP
AGPP
AGPP

CVLS
CVIM
CAHQ
CKVQ
CVIL
CRPQ
CVLS
CVIM
CAHQ
CKVQ
CVIL
CRPQ

Kmpeptide
(µM)
0.8 ± 0.1
0.30 ± 0.06
2.0 ± 0.3
1.5 ± 0.3
6.6 ± 0.6
5±1
0.5 ± 0.1
0.18 ± 0.06
2.4 ± 0.5
1.7 ± 0.2
16 ± 2
10 ± 1

71

kcat
(s )•10-2
14 ± 2
4.3 ± 0.5
20 ± 2
8±1
23 ± 2
8±1
12 ± 2
1.6 ± 0.3
21 ± 3
11 ± 1
17 ± 1
21 ± 2
-1

kcat/Kmpeptide
(µM-1•s-1)•10-2
18 ± 3
14 ± 3
10 ± 2
5±1
3.5 ± 0.4
1.6 ± 0.4
24 ± 6
9±3
9±2
7±1
1.1 ± 0.1
2.1 ± 0.3

Table 3-2 Ratios of products
Ratios of products from reaction mixtures containing FPP or AGPP at 6.7 µM each with
two N-dansyl-GCa1a2X peptides at 3 µM each. Product ratios were determined from
HPLC analysis of competition reactions containing two peptides and FPP. Product was
quantified by integration of 340 nm trace chromatogram. Note that the ratio of the
Kmpeptide change with the product ratio but not the ratio of the kcat or kcat/ Kmpeptide
Reactants
peptide
A

peptide
B

CVIM
CVLS
CVLS
CKVQ
CAHQ
CAHQ
CVIM
CVLS
CVIL

CVLS
CKVQ
CAHQ
CAHQ
CVIL
CRPQ
CRPQ
CRPQ
CRPQ

FPP
product
ratio
fA:fB
3±1
1.4 ± 0.2
1.8 ± 0.1
0.7 ± 0.1
1.5 ± 0.2
2.4 ± 0.2
13.4 ±
3.5 ± 0.2
1.5 ± 0.3

peptide

kcat/Km
ratio
fA:fB
0.8 ± 0.2
3.6 ± 0.9
1.8 ± 0.5
0.5 ± 0.1
2.9 ±`0.7
6±2
9±3
11 ± 3
0.5 ± 0.1

AGPP
peptide

Km
ratio
fB:fA
2.7 ±
1.9 ±
2.5 ±
1.3 ±
3.3 ±
2.5 ±
17 ± 5
6±1
1.3 ±

kcat
ratio
fA:fB
0.31 ±
1.8 ± 0.3
0.7 ± 0.1
0.4 ±
0.9 ± 0.1
2.5 ± 0.4
0.54 ±
1.8 0.3
0.35 ±

*ND: not determined
**NA= not applicable
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product
ratio
agA:agB
2.1 ± 0.1
2.8 ± 0.8
2.4 ± 0.1
0.9 ± 0.1
ND*
2.6 ± 0.1
23 ± 2
14.9 ±
0.5 ± 0.1

peptide

kcat/Km
ratio
agA:agB
0.4 ± 0.2
3±1
2.7 ± 0.9
0.8 ± 0.2
NA**
4±1
4±2
11 ± 3
0.52 ± 0.09

Kmpeptide
ratio
agB:agA
3±1
3.4 ± 0.8
5±1
1.4 ± 0.3
NA**
4±1
60 ± 20
20 ± 4
0.6 ± 0.1

kcat
ratio
agA:agB
0.13 ±
1.1 ± 0.2
0.6 ± 0.1
0.52 ±
NA**
1.0 ± 0.2
0.08 ±
0.6 ± 0.1
0.81 ±

Figure 3-3 Comparison of the Ratio of products with the Kmpeptide
Product ratio verses the ratio of the Kmpeptide for each competition reaction in Table 3-2
a) FPP or b) AGPP. Note that the slope of the two graphs differ where the Kmpeptide ratio
correlates directly with the product ratio with FPP but is two times the product ratio with
AGPP. R value for both lines is greater than 0.95
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Product ratio is dependent on the isoprenoid donor concentration
Since the observed product ratios were not predicted by the ratio of kcat/Kmpeptide
but did correlate with an isoprenoid dependent ratio of the apparent Kmpeptide we
examined the dependence of the product ratios on the concentration of isoprenoid
diphosphate. There are two isoprenoid diphosphate bound states in Figure 3-1 and the
experimental Km for both FPP and AGPP is 46 nM with the CVLS peptide. We did not
expect any change in the product ratios, as the isoprenoid concentrations used in the
competition reactions were well above saturation for the isoprenoid donor. We
measured the ratio of product from the CVIM and CVLS peptides over a range of FPP
and AGPP concentrations. (Figure 3-4) The product ratio decreased with increasing
concentrations of the isoprenoid donor, trending towards the ratio expected from
equation 3-1. These unanticipated results suggest that the mechanism shown in Figure
3-1 is incomplete.

74

Figure 3-4 Product ratio dependence on isoprenoid concentration
CVIM/CVLS peptide pair product ratios were measured from reaction mixtures
containing 3µM of the CVIM and CVLS peptide with a) FPP or b) AGPP at increasing
concentrations. Note that the effect of increasing concentration of FPP on the product
ratio is much greater than the effect with increasing AGPP concentrations
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Overall rate of competition reactions is governed by the rate of the peptide with
the lowest Kmpeptide
In order to characterize the unusual dependence of the product ratios on
Kmpeptide, we examined the overall velocity of the competition reactions relative to the
velocity of reactions for the individual peptides. For competition reactions between
CVIM and CVLS peptides the overall reaction rate was the same as for the CVIM
peptide alone. CVIM has both a lower Kmpeptide and rate of transfer than does CVLS. We
examined the dependence of the overall competition velocity on the component Ca1a2X
peptide Kmpeptide and rates of transfer. Competition reactions between the CKVQ/CAHQ
and CRPQ/CVIL peptide pairs with AGPP as the isoprenoid donor were run in parallel
with the corresponding single peptide reactions at the same individual substrate
concentrations (Figure 3-5). The total peptide concentration in the competition reactions
was twice that of the single peptide reactions. The overall rate of the CKVQ/CAHQ
competition reaction was the same as for the reaction of the CKVQ peptide alone. Of
the pair, the CKVQ peptide has the lower Kmpeptide and the slower reaction rate.
Similarly, the overall rate of the CRPQ/CVIL reaction was the same as for the lower
Kmpeptide CRPQ substrate alone. However, under these conditions, the reaction rate of
the CRPQ peptide is higher than that of the CVIL. We conclude that the overall rate of
the competition reactions is governed by the rate of the peptide with the lowest Kmpeptide
.
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Figure 3-5 Rate of the competition and individual peptide reactions
Reactions were prepared that contained the peptide pair indicated in parallel with each
individual peptide reactions at the same enzyme and peptide concentration. Error bars
represent values from triplicate reactions 4-5a: Competition of CAHQ and CKVQ
peptides for AGPP modification. 4-5b: Competition of CAHQ and CKVQ peptides for
AGPP modification. Note that the rates of the competition reactions are the same as the
rates of the single peptide reaction where the peptide is the one with the lowest Kmpeptide
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There are a minimum of three peptide binding states in the FTase steady-state
reaction
In the generally accepted FTase mechanism, FPP association with the E•product
complex is solely responsible for stimulating product release (Figure 3-1). As noted
above, Ca1a2X peptides can stimulate product release, suggesting that peptide also
interacts with the E•product complex. In addition, substrate inhibition of the FTase
reaction by both Ca1a2X peptides and full length proteins, including CVLS and H-Ras,
have previously been reported [55, 71]. In order to characterize Ca1a2X peptide
stimulated product release, we investigated the FTase reaction using peptide
concentrations higher than required to reach maximum velocity. Much to our surprise,
we found increasing concentrations of the CKVQ substrate in reactions with both FPP
and AGPP had more complex effects than simple inhibition (Figure 3-6). As previously
reported, the reaction rate increased to a maximum, before falling as the concentration
of peptide was increased. Surprisingly, at even higher concentrations of peptide, the
rate again increased slightly to a smaller second maximum before finally approaching
zero. To our knowledge, the second peptide concentration dependent rate increase has
not been previously described. To confirm these observations, we examined the FTase
reaction for the Ca1a2X concentration dependence of the CVLS and CAHQ peptides
with FPP. The appearance of two peptide substrate concentration dependent maxima in
the CVLS and CAHQ reaction profiles was similar to what we observed for CKVQ. The
second rate maximum for the CVLS peptide was less pronounced than for CKVQ.
Interestingly, with increasing concentrations of CAHQ we found that the rate dipped
slightly after the first maxima, then rose gradually to a second, higher maximum before
decreasing.

78

Figure 3-6 Steady state reaction of FPP with peptides
Response of reaction rate with increasing concentrations of peptide well above
concentration required to reach the first Vmax. Note the second increase in the reaction
rate after the first Vmax point has been reached.
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The presence of two peptide substrate concentration dependent maxima and
substrate inhibition in the steady-state reaction profile requires a minimum of three
peptide binding states. The generally accepted mechanism (Figure 3-1) has only two
peptide bound states. The second peptide bound state, E•CaaX is thought to result from
dissociation of FPP from the E•FPP complex, followed by peptide binding to FTase.
Previous reports have shown that E•CaaX is non-productive, and is unable to bind FPP
to form the reactive E•FPP•CaaX complex [72]. Rather, the productive E•FPP complex
is generated by peptide dissociation from E•CaaX followed by FPP binding. In this
model, formation of the inhibitory E•CaaX requires peptide to out-compete FPP for
association with the free enzyme. However, FPP has a much higher affinity for FTase
than do the Ca1a2X peptides, and CVLS peptide affinity for E•FPP is 70 fold higher than
for the free enzyme [90]. Also, the E•FPP complex is highly committed towards catalysis
since FPP dissociates at a rate 2.5 times slower than kcat [55].
Here we propose a more complex model for the FTase reaction mechanism that
takes these observations into account (Figure 3-7). In common with the generally
accepted mechanism, the first peptide bound state is the E•FPP•CaaX complex. The
second state is the E•product•CaaX complex which is responsible for peptide stimulated
product release. This state is formed in competition with E•product•FPP. Release of
product from the E•product•CaaX complex would leave the third state, E•CaaX. In this
scheme, product dissociation from E•product•CaaX (Figure 3-7) would form the
inhibitory E•CaaX complex as a natural consequence of catalysis. Additionally, higher
concentrations of Ca1a2X peptide will drive formation of the inhibitory E•CaaX complex
at the expense of E•FPP by favoring formation of E•product•CaaX relative to
E•product•FPP without requiring dissociation of FPP from E•FPP.
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Figure 3-7 FTase reaction mechanism
Extended mechanism incorporating peptide stimulated product release. The mechanism
is split into two pathways path A representing FPP stimulated product release and path
B representing peptide stimulated product release. E is the FTase enzyme, E-FPP is
the FTase•FPP complex, E•FPP•CaaX is the FTase•FPP•CaaX peptide complex, EProduct is the FTase bound product complex, E-Product-FPP is the FTase bound to
both FPP and the reaction product, and E-CaaX is the peptide bound FTase inhibitory
complex, E-Product-CaaX is the new peptide bound enzyme product complex
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Path A

Competition by two Ca1a2X peptides for the E•product complex suggests a
mechanistic explanation for the observations that the peptide with the lowest Km
controls the overall FTase reaction rate. In this scheme, the overall rate will depend on
the relative affinity of the peptides and isoprenoid diphosphate for the E•product
complex, as well as the rate of product release from the E•product•CaaX and
E•product•FPP complexes. If one of the competing peptides binds the E•product
complexes

more

efficiently

and/or

stimulates

faster

product

release

from

E•product•CaaX, then its rate will determine the overall rate. Consequently, the kcat for
both peptides in equation 3-1 will be the same. Secondly, increasing isoprenoid will
compete with the peptides for E•product and increase flux through path A of Figure 3-7.
Consequently, the ratio of products formed under high concentrations of isoprenoid
donor in a competition reaction between two peptides will be less dependent on peptide
stimulated release. These conclusions are consistent with the experimental findings that
the peptide with the lowest measured Kmpeptide determines the overall rate and that the
ratio of kcat for each of the competing substrates will be equal to an isoprenoid
dependent constant.
Discussion
Peptide verses FPP stimulated release efficiency
The efficiency of the FPP and peptide stimulated release pathway could be
dependent on the binding affinity of the peptide or FPP to the E•product complex as well
as the rate of release due to binding of either substrate. Under competition conditions
this scheme becomes even more complex due to a third route to product release with
the alternative peptide substrate. It is possible that peptide binding affinity to the
E•product complex is attenuated depending on the identity of the isoprenylated Ca1a2X
sequence in the active site of the enzyme. The Ca1a2X binding affinity to the E•product
complex may be completely unrelated to the binding affinity to the free enzyme or the
enhanced affinity with the E•FPP complex. For example, a TKCVIC peptide can
stimulate the release of a farnesylated TKCVIL peptide product from the FTase active
site, yet the affinity of TKCVIC for the E•FPP complex is 7-fold lower than the affinity of
TKCVIL [203]. In addition, FPP binding affinity for the E•product complex will not
necessarily correlate with the binding affinity to the free enzyme. The relative efficiency
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of peptide stimulated release verses FPP stimulated release is not known. However,
large quantities of isoprenoid were required for the competition reaction product
distribution to approach the ratios predicted from the kcat/Kmpeptide suggesting that
peptide stimulated release may be more efficient that isoprenoid stimulated. In addition,
AGPP stimulated product release appears to be even less efficient than FPP stimulated.
AGPP is less hydrophobic than FPP and may not associate with E•product complex as
readily as the natural substrate.
Altering FTase selectivity
The isoprenoid and target peptide interact directly with one another throughout
the FTase reaction, and changes in the structure of the isoprenoid may alter the
interactions between them. Changing the interactions of the isoprenoid with the target
Ca1a2X motif could lead to the selective modification of particular Ca1a2X substrates
with unnatural probes specific for certain Ca1a2X sequences. The reactivity of the
canonical FTase Ca1a2X substrates was nearly identical with both FPP and AGPP as
the isoprenoid donors. However, with AGPP as the isoprenoid donor the selectivity was
markedly decreased for the canonical GGTaseI substrate over the CRPQ Ca1a2X
sequence. AGPP is more readily utilized to modify the HDV large antigen based Ca1a2X
peptide over the GGTaseI target peptide in contrast to FPP which is more readily
utilized to modify the GGTaseI Ca1a2X substrate. To our knowledge this is the first
example of an analog switching the Ca1a2X selectivity of the FTase enzyme. Further
alterations of the isoprenoid diphosphate may therefore lead to analogs that further alter
FTase target selectivity for different Ca1a2X sequences.
FTase clearance mechanism
Peptide stimulated product release may be essential to allow slowly turned over
FTase substrates to be cleared from the enzyme active site. A wide variety of peptides
including GGTaseI substrate peptides have a high affinity for the FTase•FPP complex
and thioether formation occurs. However, some of these Ca1a2X sequences such as the
GGTaseI substrate TKCVIL are not readily released from the active site with excess
FPP or substrate peptide [203]. In order for FTase to be functional after formation of a
slowly dissociating or single turnover product a cell may require product release to be
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stimulated by an alternative Ca1a2X substrate. The GGTaseI reaction mechanism is
similar to that of FTase and it is likely that the peptide stimulated release mechanism
also exists for the GGTaseI enzyme.
Experimental
General
AGPP and FPP were synthesized as described previously. All RP-HPLC was
performed on an Agilent 1100 HPLC system equipped with a microplate autosampler,
diode array and fluorescence detector. The HPLC analysis was performed with a
microsorb C18 column with 0.01% TFA in water (A) and 0.01% TFA MeCN (B) as the
mobile phase. Peptides were purchased from peptidogenics and each contained a
dansyl group N linked to a glycine linker followed by a C residue then a variable aaX
sequence (VLS, VIM, AHQ, RPQ, VIL or KVQ). Spectrofluorometric analyses were
performed in a 96-well flat bottom, non-binding surface, black polystyrene plate
(Excitation wavelength, 340 nm; emission wavelength 505 nm with a 10 nm cutoff). The
plate reader was a SpectraMax GEMINI XPS fluorescence well-plate reader.
Absorbance readings were determined using a Cary UV/Vis spectrophotometer.
Steady-state peptide kinetics
The kinetic constants Kmpeptide and kcat with FPP, and AGPP for each dansylGCaaX peptide were determined in triplicate measurements using a continuous
spectrofluorometric assay adapted for a 96-well plate. The following assay components
were assembled in individual wells of a 96-well plate and incubated at 30° C for 20
minutes: 180 µL of assay buffer (52 mM Tris-HCl, 12 mM MgCl2, 12 µM ZnCl2 pH 7.4),
40 µL of detergent (0.125% n-dodecyl- β-D-maltoside in assay buffer), 40 µL of
reducing agent (50 mM DTT in assay buffer) 20uL of FPP or AGPP (200 µM in 25 mM
NH4HCO3)

and

20

µL

of

N-dansyl-GCaaX

peptide

(variable

concentration).

Fluorescence was detected using a time based scan at 30° C for 120 minutes. The
velocity of each reaction was determined by converting the rate of increase in
fluorescence intensity units (FLU/s) to µM/s with equation 3-2.
Equation 3-2: vi=(R·P)/(FMAX-FMIN)
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Where vi is the velocity of the reaction in µM/s. R is the rate of the reaction in FLU/s. P
is equal to the concentration of modified product in µM (see below). FMAX is the
fluorescence intensity of fully modified product. FMIN is the fluorescence of a reaction
mixture that contained 20 µL of assay buffer in the place of FTase. Complete
modification of peptides was assumed when fluorescence stabilized for more than 10
minutes and was confirmed by RP-HPLC analysis of the reaction mixture.
Final analysis peptide concentrations were chosen based on preliminary
determination of the Kmpeptide with 0.5, 1, 5 and 10 µM dansyl-GCaaX concentrations
(see below). The final analysis used 8 peptide concentrations which were: 1/6, 1/5, 1/4,
1/2, 3/4, 1, 2, and 3 times the estimated Kmpeptide value except with the CVIM peptide
where we used concentrations at 0.3, 0.45, 0.675, 0.9, 1.8, 2.7, 3.6, and 4.5 times the
estimated Kmpeptide. The reaction was then initiated by the addition of 20 µL of FTase
(final concentration 5 nM with the CLVS, CAHQ, CVIL and CRPQ peptide, 10nM with
the CVIM peptide). Fluorescence enhancement determined as described above.
Complete modification of peptides was assumed when fluorescence stabilized for
more than 10 minutes and was confirmed by RP-HPLC analysis of the reaction mixture.
If the reactions that contained higher concentrations of peptides did not go to
completion the Fmax-Fmin value was extrapolated using a linear plot of the Fmax-Fmin
for each of the lower concentration reactions that did go to completion. Alternatively the
extent of input peptide modified was determined by RP-HPLC analysis of the dansyl
moiety peak absorbance corresponding to the unmodified and modified peptides. The
percent of modified peptide relative to the total input peptide was used to calculate the
concentration of product in the mixture.
The velocities of the reactions were plotted against the concentration of peptide
and were fit to the Michaelis-Menten equation (Equation 3-3) to give the apparent kcat
(appkcat) and Kmpeptide (appKmpeptide) values. Where et was the total enzyme
concentration and [Pep] was the total input peptide. The kcat/Kmpeptide value was derived
from a Lineweaver-Burke plot of the same data points.
Equation 3-2: vi/et=(appkcat*[Pep])/(appKmpeptide+[Pep])
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Substrate inhibition analysis
The steady-state reaction profiles with high concentrations of peptide were
analyzed as described above with peptide concentrations 4, 5, 6, 7, 8, 9, and 10 fold
higher than the appKmpeptide.
Peptide competition
Competition reactions were prepared with the same components given for the
kcat/Kmpeptide analysis except two peptides were added to the mixture at a single
concentration. Peptides A and B were diluted to 45 µM in Tris-HCl buffer (pH=7.4) and
the concentration checked by reading the Abs of the solution at 340 nm (εdansyl=4250
Abs·M-1·cm-1). 20 µL of peptide A and 20 µL of peptide B were then added to reaction
mixtures as described above except only 160 µL of assay buffer was added. Separate
reactions were prepared as a standard with FPP or AGPP and only one peptide as
described above. The reactions were then initiated with the addition of FTase and
analyzed spectrofluorometrically (Reactions containing CVIM peptide used 20 nM final
FTase concentration all other used 10 nM). The reactions were stopped prior to
consumption of more than 50% of either peptide by adding 20 µL of a stop solution
(isopropyl alcohol and acetic acid 8:2). HPLC analysis was then performed with 100 µL
of the reaction mixture loaded onto C18 column and eluted with a linear gradient of 0-30
min 10% B to 100% B at a flow rate of 1 mL/min. Peaks on the 340 nm trace
chromatogram that corresponded to both the standard reactions and fluorescent peaks
were then integrated. The ratios of products were calculated according to equation 3-4.
Equation 4-4: (IAmod/ IAtot)/(IBmod /IBtot)
Where IAmod is the integral of the modified peptide A, IAtot is the integral of the
modified peptide A plus the unmodified peptide A, IBmod is the integral of the modified
peptide B and IBtot was the integral of the modified peptide B plus the unmodified peptide
B. Alternatively, the ratios were calculated using the integrals of the standard peptides
fluorescence relative to competition product fluorescence giving less than a 5%
difference in the calculated ratio.
Overall rate of competition reactions
The overall rate of the competition reaction was determined using equation 2 and
the amount of total peptide modified based on RP-HPLC analysis. Alternatively peptide
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competition reactions were scaled up to a 1000 µL solution and sampled for RP-HPLC
analysis every 45 minutes for 6 hours.
Increasing FPP and AGPP concentrations effect on product ratio
To determine the effect of increasing isoprenoid concentration the FPP and
AGPP concentrations in the competition mixtures were increased from 0.5-66 µM with
FPP and 0.5-400 µM AGPP.

Copyright © Jerry Troutman 2006
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CHAPTER 4 FARNESYL DIPHOSPHATE ANALOG COMPETITION FOR FARENSYL
TRANSFERASE
Introduction
An interesting feature of the FTase reaction mechanism (Figure 4-1) is the
association between the isoprenoid lipid and the target Ca1a2X sequence in both the
E•product•FPP and E•FPP•CaaX complexes [80]. In each of these complexes, FPP
binds at the same hydrophobic surface and interacts directly with the terminal residues
of the target Ca1a2X sequence. Pre-steady state kinetic studies have shown that FPP
association with the free enzyme enhances Ca1a2X peptide affinity up to 70 fold [90].
The interaction between the target Ca1a2X motif and the isoprenoid suggests that
changes in the structure of FPP may be analogous to amino acid mutations in the active
site of the enzyme, where the reactivity of the Ca1a2X motif can be modulated by
changes in the structure of FPP [154]. The ω-isoprene of FPP associates directly with
the a2 residue of the target Ca1a2X peptide, but it is not clear how altering the ωisoprene structure affects Ca1a2X peptide reactivity.
Isoprenoid analogs of FPP have been used to study the physical interactions
between the isoprenoid, FTase and the Ca1a2X peptide. The analog, 8-anilinogeranyl
diphosphate (AGPP, 2a, Figure 4-2) contains an aniline moiety in the place of the ωterminal isoprene of FPP. AGPP is transferable to Ca1a2X substrates with steady-state
kinetics nearly identical to FPP, and the aniline moiety appears to act as an isostere for
the terminal isoprene of FPP [159, 161]. AGPP has been used to probe the endogenous
modification of proteins by FTase and is competitive with FPP both in vitro and in cell
culture [159, 209]. However, when the aniline moiety of AGPP is replaced with a p-NO2
aniline 2b or a pentafluoro-aniline the analog dependent steady-state transfer efficiency
is severely reduced [161].
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Figure 4-1 FTase reaction mechanism
Extended mechanism incorporating peptide stimulated product release. The mechanism
is split into two pathways path A representing FPP stimulated product release and path
B representing peptide stimulated product release. E is the FTase enzyme, E-FPP is
the FTase•FPP complex, E•FPP•CaaX is the FTase•FPP•CaaX peptide complex, EProduct is the FTase bound product complex, E-Product-FPP is the FTase bound to
both FPP and the reaction product, and E-CaaX is the peptide bound FTase inhibitory
complex, E-Product-CaaX is the peptide bound enzyme product complex
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Path A

Figure 4-2 Analog Structures
Structure of farnesyl diphosphate (1, FPP) 8-anilinogeranyl diphosphate (2a, AGPP)
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2b-aq see table 4-1
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Understanding the ability of substrate analogs to compete with the natural
substrate will improve the ability to develop new analogs to probe the FTase reaction
mechanism as well as the development of potential inhibitors of prenylated protein
function. In chapter 2, I described the synthesis of a library of AGPP analogs with a
variety of functional groups in the ortho-, meta- and para- positions of the AGPP aniline
ring. In this section, I utilize this library of molecules to probe the relationships of the
AGPP structure on Ca1a2X peptide reactivity and competitiveness with FPP. We have
found that the position and size of the aniline ring substitution has a major affect on the
reactivity of the AGPP analogs. With simple conservative substitutions in the AGPP
aniline ring, the reactivity of the analogs range from molecules that transfer more
efficiently than FPP to analogs that are inhibitors of the FTase catalyzed farnesylation of
Ca1a2X substrates. We also found that the structure of the analogs affected the
competitiveness with FPP and that the molecular features that improved peptide
reactivity improved FPP competitiveness for the CVLS peptide. These results
demonstrate that with only subtle alterations in the structure of an FPP analog, FTase
activity can be effectively modulated depending on the structure of the analog. These
results also suggest that the natural substrate of FTase can be improved upon, to
develop molecules that can efficiently and competitively be transferred to FTase target
Ca1a2X sequences.
Results
Peptide target reactivity is dependent on size and position of substitutions in the
aniline moiety of AGPP
In order to determine how changing the structure of AGPP affects the reactivity of
an FTase target peptide we measured the steady-state transfer kinetics of a dansylatedGCVLS (CVLS) pentapeptide with a library of structurally diverse AGPP analogs. (Table
4-1) The CVLS peptide corresponds to the Ca1a2X sequence of H-Ras, and the steadystate transfer kinetics of both H-Ras and the CVLS peptide have been extensively
characterized. Utilizing a continuous fluorescence assay we found kcat, Kmpeptide and
kcat/Kmpeptide values with CVLS and FPP that were identical to those previously reported
for both CVLS and a full length H-Ras protein.
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Over half of the 50 molecule AGPP library 2a-aq was transferred to the CVLS
peptide by FTase. The ability of the peptide to react with the various analogs was highly
dependent on the size and position of the functional group substitution in the AGPP
aniline ring. Analogs with functional groups larger than an ethoxy group 2ac-2aq were
poorly transferred to the CVLS peptide independent of the aniline ring position that was
substituted. However, when the aniline ring was substituted with a fluorine atom at
either the meta- 2d or ortho- 2c positions the CVLS peptide reacted with a catalytic
efficiency (kcat/Kmpeptide) nearly identical to that with FPP and AGPP. Surprisingly, with
the pF-AGPP 2e analog the catalytic efficiency of the enzyme with the CVLS peptide
was increased.
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Table 4-1 Michaelis-Menten Peptide Kinetics
Steady state kinetic parameters were measured with varying concentrations of Ndansyl-GCVLS peptide FPP and each of the AGPP analogs with FTase in Tris-HCl
buffer (pH=7.4) plus detergent and reducing agent. Note that some analogs increase
efficiency and/or decrease the Kmpeptide
R
FPP
H
pNO2
oF
mF
pF
oMe
mMe
pMe
mCN
pCN
oMeO
mMeO
pMeO
oI
mI
pI
oCF3O
mCF3O
pCF3O
oCl
mCl
pCl
oBr
pBr
oCF3
oEt
mEt
pEt
oEtO
mEtO
pEtO
oSMe
pSMe
oiPr
piPr
oPh
pPh
oPhO
mPhO
pPhO
oPhCH2
mPhCH2
pPhCH2

#

CVLS

1
14 ± 2
2a
12 ± 2
2b 160 ± 20
2c
15 ± 3
2d
10 ± 1
2e 9.5 ± 0.4
2f 16.6 ± 0.9
2g 6.9 ± 0.5
2h
60 ± 20
2i
13 ± 1
2j
70 ± 3
2k 8.8 ± 0.9
2l
53 ± 5
2m 140 ± 40
2n
Slow**
2o
24 ± 2
2p
17 ± 3
2q
Slow**
2r
40 ± 10
2s
27 ± 6
2t
10 ± 1
2u
13 ± 2
2v
30 ± 10
2w
13 ± 1
2x
27 ± 8
2y
30 ± 10
2z
17 ± 2
2aa
8±2
2ab
NR*
2ac
NR*
2ad
NR*
2ae
NR*
2af
NR*
2ag
NR*
2ah
NR*
2ai
NR*
2aj
NR*
2ak
NR*
2al
NR*
2am
NR*
2an
NR*
2ao
NR*
2ap
NR*
2aq
NR*

CVLS

Km
(µM)

kcat/Km
-1 -1
-2
(µM •s )•10

0.8 ± 0.1
0.5 ± 0.1
15 ± 2
0.9 ± 0.2
0.34 ± 0.08
0.26 ± 0.04
4.0 ± 0.4
0.17 ± 0.06
4±1
1.0 ± 0.1
10.2 ± 0.6
0.9 ± 0.2
4.3 ± 0.6
30 ± 10
>10
0.9 ± 0.1
1.4 ± 0.4
>10
2.3 ± 0.6
3.1 ± 0.9
0.8 ± 0.2
1.0 ±0.2
1.9 ± 0.8
1.0 ± 0.2
1.7 ± 0.5
>10
7±1
3.8 ± 0.8
NR*
NR*
NR*
NR*
NR*
NR*
NR*
NR*
NR*
NR*
NR*
NR*
NR*
NR*
NR*
NR*

18 ± 3
24 ± 6
10.7 ± 0.2
16 ± 1
26 ± 3
35 ± 4
4.2 ± 0.5
38 ± 8
16 ± 1
11.5 ± 0.3
6.8 ± 0.1
9.3 ± 0.6
12 ± 2
5±2
ND***
26 ± 3
12 ± 4
ND***
19 ±1
8.7 ± 0.3
10.3 ± 0.3
13 ± 3
18 ± 1
13 ± 3
16 ± 2
0.9 ± 0.1
2.4 ± 0.6
2.1 ± 0.1
NR*
NR*
NR*
NR*
NR*
NR*
NR*
NR*
NR*
NR*
NR*
NR*
NR*
NR*
NR*
NR*

kcat
-2
(s )•10
-1

* NR=No Reaction
** slow indicates that some reaction did occur, but not enough to characterize
*** ND=not determined due to the inability to measure kcat
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When the functional group in the aniline ring was smaller than an ethoxy group
2b-2ab the reactivity of the molecules was highly dependent on the position of the
aniline ring that was functionalized. Aside from the fluorine substituted analogs the
reactions with the meta- substituted analogs were in general the most efficient. In
particular, the position of an Iodine and Methyl functional group in the aniline ring
drastically altered the catalytic efficiency of FTase with the CVLS peptide. The efficiency
of the CVLS reaction with both the mI-AGPP 2o and mMe-AGPP 2g analogs was much
higher than the efficiency with the natural substrate. However, when the functional
group of the Iodo and methyl AGPP analogs was shifted to the para- and orthopositions the efficiency of the reactions was drastically reduced. In particular, reactions
containing the oI-AGPP 2n analog and the CVLS peptide resulted in little to no product
formation even in the presence of enzyme concentrations well above what was required
for complete modification of the CVLS peptide with the other iodine substituted analogs.
The individual kcat and Kmpeptide were significantly affected by the functionalized position
of the aniline ring, even-though the effects may not have been observed in the
kcat/Kmpeptide. We found that AGPP analogs with para-functional group substitutions, in
general, increased both the kcat and Kmpeptide of the CVLS substrate relative to the orthoand meta- isomers. On the other hand, we found that the ortho- substituted analogs
tended to reduce the kcat of the CVLS peptide reactions. These results indicated that
the reactivity of the Ca1a2X peptide was highly dependent on the position and size of the
aniline ring substitution in AGPP.
Non-substrate ortho- substituted analogs are potent FTase inhibitors
A number of the AGPP analogs were not substrates for the FTase catalyzed
modification of the CVLS peptide, but analogs that were not substrates may still bind to
the enzyme and act as an inhibitor. To determine if the non-substrate analogs were
FTase inhibitors we mixed FPP and each analog 1:1 in excess of the CVLS peptide,
and determined the reaction rate relative to the rate with FPP alone (Figure 4-3). We
found that the rate of farnesylation was decreased over 50% with the ortho- but not the
meta- and para- substituted AGPP non-substrate analogs. In order to more closely
examine the ability of these analogs to inhibit the FTase reaction we measured the
analog concentration dependence on the FTase inhibition. The Ki of the ortho-
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substituted non-substrate analogs were well below the previously reported Km of FPP
(KmFPP = 46 nM). (Table 4-2) These results indicated that these analogs could readily
bind to the enzyme, but the reaction with the CVLS peptide was compromised.
Analogs are competitive with FPP for target modification
In order for an analog to be utilized in cells they must be competitive with FPP.
Previous studies to determine the kinetic factors that predict FTase selectivity for
peptide targets suggested that simple steady-state catalytic efficiency measurements do
not predict the selectivity of the enzyme for Ca1a2X peptides in competition with one
another. AGPP is competitive with FPP both in vitro and in cell culture [159], but it is not
clear how well steady-state kinetic measurements predict the ability of AGPP to
compete. Instead of relying on steady-state kinetic measurements we directly measured
the ability of AGPP and the analogs to compete with FPP. We mixed AGPP and FPP
1:1 in excess of the CVLS peptide and analyzed the resulting CVLS modified product by
HPLC and integration of the dansyl peak absorbance. We found that the resulting
product ratio was 2:1 farnesyl to anilinogeranyl modified CVLS peptide. This was
significantly less anilinogeranylated peptide than would have been predicted based
solely on previous steady-state kcat/KmAGPP measurements (kcat/KmAGPP=1.8 µM-1•s-1
KmAGPP =46 nM kcat/KmFPP =2.2 µM-1•s-1 KmFPP =46 nM)[159, 161].
We found that a number of the analogs were utilized by FTase even in the
presence of FPP. The competitiveness of the analogs with functional groups larger than
fluorine was highly dependent on the position of the aniline ring that was functionalized.
The meta- substituted analogs were the most competitive followed by the ortho- and
para- substituted analogs. Several of the functionalized AGPP analogs were even more
competitive than AGPP including all three of the fluorine substituted analogs. The
structure dependence of analog competition with FPP appeared to correlate with the
structure dependence on peptide reactivity.
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Figure 4-3 Farnesylation Inhibition
N-dansyl-GCVLS was mixed with FPP and an equimolar amount of the analog. FTase
was added and the percent inhibition was calculated by comparing the rate of reactions
containing the analog and FPP to the reaction rate with FPP alone. Note that only the
ortho- substituted analogs inhibit greater than 50%.
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Table 4-2 Analog Ki
Analog Ki values were calculated from reaction rates of FPP/analog competition
reactions for an N-dansyl-GCVLS peptide, where the analog concentration was varied
and the FPP concentration was held at 6.7 µM. Note that the Ki of the ortho- substituted
AGPP analogs is lower than the KmFPP which is 40 nM.
R

#

KiXPP
(nM)

oCF3O 2q 3.0 ± 0.3
oEtO
2ac
12 ± 1
oSMe
2af 2.4 ± 0.2
oiPr
2ah 4.4 ± 0.2
oPh
2aj 3.6 ± 0.4
oPhCH2 2ao
18 ± 1
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Figure 4-4 Analog/FPP competition for CVLS
Ratios of products, analog modified CVLS:farnesylated CVLS were found from
reactions set up with 3µM peptide and 6 µM of the analog and FPP. Reactions were
allowed to continue until all peptide was consumed and were then analyzed by RPHPLC. Fluorescence detection indicated the retention time of each of the products and
integration of peaks at 340 nm was used to quantify products. Analogs pNO2-AGPP 2b
and mCN-AGPP 2i increased absorption at 340 nm so product from reactions
containing these analogs was calculated based on input peptide relative to peptide
unmodified. * indicates that the ortho- analogue was not available.
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Discussion
FPP Analog Reactivity and Peptide Substrate Inhibition
We found that a number of the AGPP analogs were FTase transferable
substrates with transfer properties that could not have been predicted by the analysis
presented in chapter 2. In chapter 2, I described the reactivity of the analogs based on
reaction rates with high concentrations of peptide and analog. However, the
concentration of peptide that would be required to be saturating would differ depending
on the analog and at concentrations that are too high the analog reaction may be
inhibited by the peptide. When using only the reaction rate to study the analog reactivity
analogs that induce a low Kmpeptide will also increase the ability of the peptide to inhibit
the reaction with that analog. In other words analogs that appeared in the earlier
analysis to be poor substrates, in fact increased the reactivity of the peptide. The effects
of peptide inhibition therefore make it very difficult to study the FTase reaction without a
steady-state kinetic evaluation with variable peptide concentrations.
Cellular protein Incorporation
A number of the analogs that were rapidly transferred in the FTase reaction were
not competitive with FPP. In chapter 2 the pCN-AGPP analog was utilized in the
Xenopus studies and was a Ras function inhibitor. However, the analysis in this chapter
indicates that the pCN-AGPP analog would be a poor choice to study analog
incorporation into cells that contained endogenous FPP due to the extremely poor ability
to compete with FPP. Instead, the equally hydrophilic mCN-AGPP analog may be a
much more competitive and therefore potent analog to use for cell studies. Several of
the analogs were more competitive than AGPP which is competitively incorporated into
cellular proteins. This indicates that numerous analogs could be used for cellular protein
incorporation.
Reactivity and Hydrophobicity
Previous studies have suggested that reactive FPP analogs must be hydrophobic
to bind the active site of the FTase enzyme. However, we found that the relatively
hydrophilic analogs containing a nitrile group in both the para- and meta- positions of
the AGPP aniline ring were highly reactive in the FTase transfer reaction. In particular,
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the position of a nitrile group in the aniline ring of AGPP had a major affect on the ability
of the analog to compete with FPP. The hydrophobicity of the mCN-AGPP 2i and pCNAGPP 2j analogs based on RP-HPLC retention times of the parent alcohols are much
lower then farnesol. Surprisingly, the mCN-AGPP 2i analog reaction with CVLS was as
efficient as the reaction with FPP and the analog competed with FPP giving nearly 1:1
product ratios. However, the pCN-AGPP 2j analog was unable to effectively compete
with FPP. These results indicated that the structure of the AGPP analogs was much
more significant than the hydrophobicity of the analogs on FTase transferability and
competitiveness.
Competition with FPP Occurs at Free Enzyme
The transferable analogs may compete with FPP for either the E•product
complex or the free enzyme. Since AGPP does not compete with FPP as well as would
be expected based on the catalytic efficiency of the analog, it is likely that the analog is
competing primarily for the free enzyme. This suggests that the ability of the analogs to
compete with FPP may also be dependent on the identity of the target Ca1a2X
sequence. Different functional groups in the aniline ring of AGPP may more readily
interact with particular product amino acid residues and therefore enhance
competitiveness depending on the identity of those residues. Peptide, FPP and the
analog may stimulate product release and the ability of the analog to compete would be
highly dependent on the mechanism of product release. Under competition conditions
the kcat/Kmpeptide would likely predict selectivity assuming only isoprenoid or only peptide
stimulated product release. However, with both mechanisms of product release it is
possible that AGPP poorly stimulates release of the isoprenylated target yet can
effectively compete for free enzyme under peptide stimulated release conditions.
Relationships of Analog Structure on Transfer and Competition
As described earlier the rate limiting step of the FTase reaction is product release
from the enzyme active site. The kcat of the reaction represents the rate of product
release. An increase in kcat and Kmpeptide suggests that the product from a reaction is
rapidly released from the enzyme active site, while a decrease in the kcat indicates that
the reaction product is slowly released from the enzyme active site. The larger ortho-
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substituted analogs reacted very slowly with the enzyme, but were potent inhibitors
indicating that they most likely bind, but the product of the reaction is not rapidly
released. However, the para- substituted analog products were released rapidly as
indicated by the high kcat and Kmpeptide values for the reactions. The meta- substituted
analogs were most like the parent molecule AGPP and the natural substrate FPP. In
several cases the efficiency of the FTase reaction was even increased with by the metasubstituted AGPP analogs. These results suggest that by simply moving the functional
group from one position to another in the AGPP aniline ring there were drastic effects
on the reactivity of the FTase enzyme. These changes in reactivity are likely a direct
result of changing the interactions between the isoprenoid, the target peptide and the
enzyme itself.
Implications
In this chapter, I have shown that the FTase enzyme can accept analogs of
AGPP with a wide variety of functional groups in the ω-terminal isoprene position of
FPP. The analogs affect the reactivity of a CVLS target peptide depending on both the
size and position of the functional group in the AGPP aniline moiety. Analogs with orthosubstituted anilines were potent inhibitors of the FTase reaction, while analogs with
para- substituents were rapidly transferred yet unable to effectively compete with FPP.
The AGPP analogs that contained meta- substitutions often enhanced the catalytic
efficiency of the FTase reaction with a CVLS peptide and effectively competed with FPP
for the modification of the CVLS peptide. This chapter demonstrates that subtle
alterations in the structure of a transferable analog of FPP can drastically alter FTase
activity towards a peptide substrate. Such analogs will be important for understanding
and exploiting the activity of the FTase enzyme for the design of selective FTase
inhibitors or the design of unnatural probes to alter FTase protein target activity.

Experimental
General
Analogs and FPP were synthesized as described previously. All RP-HPLC was
performed on an Agilent 1100 HPLC system equipped with a microplate autosampler,
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diode array and fluorescence detector. The HPLC analysis was performed with a
microsorb C18 column with 0.01% TFA in water (A) and 0.01% TFA CH3CN (B) as the
mobile

phase.

N-dansyl-GCVLS

peptide

was

purchased

from

peptidogenics.

Spectrofluorometric analyses were performed in a 96-well flat bottom, non-binding
surface, black polystyrene plate (Excitation wavelength, 340 nm; emission wavelength
505 nm with a 10 nm cutoff). The plate reader was a SpectraMax GEMINI XPS
fluorescence well-plate reader. Absorbance readings were determined using a Cary
UV/Vis spectrophotometer.
Steady-state peptide kinetics
The kinetic constants Kmpeptide and kcat with FPP, and the analogs with the Ndansyl-GCVLS peptide were determined in triplicate measurements using a continuous
spectrofluorometric assay adapted for a 96-well plate. The following assay components
were assembled in individual wells of a 96-well plate and incubated at 30° C for 20
minutes: 180 µL of assay buffer (52 mM Tris-HCl, 12 mM MgCl2, 12 µM ZnCl2 pH 7.4),
40 µL of detergent (0.125% n-dodecyl- β-D-maltoside in assay buffer), 40 µL of
reducing agent (50 mM DTT in assay buffer) 20uL of FPP or AGPP (200 µM in 25 mM
NH4HCO3)

and

20

µL

of

N-dansyl-GCaaX

peptide

(variable

concentration).

Fluorescence was detected using a time based scan at 30° C for 120 minutes. The
velocity of each reaction was determined by converting the rate of increase in
fluorescence intensity units (FLU/s) to µM/s with equation 4-1.
Equation 5-1: vi=(R·P)/(FMAX-FMIN)
Where vi is the velocity of the reaction in µM/s. R is the rate of the reaction in FLU/s. P
is equal to the concentration of modified product in µM (see below). FMAX is the
fluorescence intensity of fully modified product. FMIN is the fluorescence of a reaction
mixture that contained 20 µL of assay buffer in the place of FTase. Complete
modification of peptides was assumed when fluorescence stabilized for more than 10
minutes and was confirmed by RP-HPLC analysis of the reaction mixture.
Final analysis peptide concentrations were chosen based on preliminary
determination of the Kmpeptide with 0.5, 1, 5 and 10 µM dansyl-GCaaX concentrations
(see below). The final analysis used 8 peptide concentrations which were: 1/6, 1/5, 1/4,
1/2, 3/4 1, 2, and 3 times the estimated Kmpeptide value except with the CVIM peptide.
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The reaction was then initiated by the addition of 20 µL of FTase (final concentration 5
nM). Fluorescence enhancement was determined as described above.
Complete modification of peptides was assumed when fluorescence stabilized for
more than 10 minutes. If the reactions that contained higher concentrations of peptides
did not go to completion the Fmax-Fmin value was extrapolated using a linear plot of
the Fmax-Fmin for each of the lower concentration reactions that did go to completion.
Alternatively the extent of input peptide modified was determined by RP-HPLC analysis
of the dansyl moiety peak absorbance corresponding to the unmodified and modified
peptides. The percent of modified peptide relative to the total input peptide was used to
calculate the concentration of product in the mixture.
The velocities of the reactions were plotted against the concentration of peptide
and were fit to the Michaelis-Menten equation (Equation 4-2) to give the apparent kcat
(appkcat) and Kmpeptide (appKmpeptide) values. Where et was the total enzyme
concentration and [Pep] was the total input peptide. The kcat/Kmpeptide value was derived
from a Lineweaver-Burke plot of the same data points.
Equation 4-2: vi/et=(appkcat*[Pep])/(appKmpeptide+[Pep])
FPP competition
Competition reactions were prepared with the same components given for the
kcat/Kmpeptide analysis except two analogs were added to the mixture and the peptide
concentration was held constant. FPP and the analog were diluted to 200 µM in 25 mM
NH4HCO3. 10 µL of FPP and 10 µL of analog were then added to a 280 µL solution of
peptide, DTT and detergent in 52 mM Tris-HCl buffer pH=7.4 (final concentrations
DTT=6.7 mM, DM=0.033%, Peptide=3µM, analog= 6.7 µM and FPP=6.7 µM). The
concentration of peptide was determined by absorbance of the dansyl group and
isoprenoid diphosphate concentration was determined by consumption of isoprenoid in
FTase reactions with the CVLS peptide where the isoprenoid was limiting. The reactions
were initiated with the addition of FTase and analyzed spectrofluorometrically (20 nM
final FTase concentration). The reactions were stopped after 2 hours with a mixture of
acetic acid and iPrOH. HPLC analysis was then performed with 100 µL of the reaction
mixture loaded onto C18 column and eluted with a linear gradient of 0-30 min 10% B to
100% B at a flow rate of 1 mL/min. Peaks on the 340 nm trace chromatogram that
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corresponded to standard reaction fluorescent peaks were then integrated. The ratios of
products were calculated using Ianalog/IFPP, where Ianalog is the integral of the peptide
modified with the analog and IFPP is the integral of the peptide modified with FPP.
Inhibition
Inhibition Screen
The analog ability to inhibit FTase transfer of FPP was initially determined by
measuring the percent inhibition in farnesylation rate in the presence of equimolar
amounts of FPP and the analog. Reactions were prepared as described for the FPP
competition analysis and the rate of FPP modification was determined based on the rate
of fluorescence increase over time with or without the analog present. The % inhibition
was determined using equation 4-3.
Equation 4-3: % inhibition=[1-(rateFPP/rateI)]*100
Where the rateFPP was the rate of the CVLS reaction without the analog present and the
rateI was the rate of the reaction with the analog present.
Ki determination
The Ki of the analogs was determined for analogs which showed no product
formation with 3 µM peptide. The Ki was determined from reactions containing 3 µM
peptide 16 µM FPP and varying concentrations of the analogs (0.016-16 µM). The data
was fit to the 3 parameter hill function in equation 4-4 and the Ki was calculated from
equation 4-5.
Equation 4-4: v/vo=(a·Ib)/(IC50b+[I]b)
Where I is the concentration of the inhibitor, IC50 is the IC50 of the inhibitor, v/vo is the
rate of the inhibited reaction divided by the rate of the uninhibited reaction and a and b
are coefficients for Hill function fitting.
Equation 4-5: Ki=IC50/(1+([FPP]/KmFPP))
Where [FPP] is the concentration of FPP and KmFPP is the known Km for FPP.

Copyright © Jerry Troutman 2006

104

CHAPTER 5 ORTHO SUBSTITUTION AND THE SELECTIVE MODIFICATION OF A
K-RAS PEPTIDE
Introduction
The oncoprotein Ras must be prenylated for both membrane localization and to
participate in cellular transformation [57]. Constitutive activation of Ras is transforming
in a wide variety of cell types and mutations that activate Ras have been found in 30%
of all cancers [26, 108, 210]. A wide variety of other proteins with C-terminal Ca1a2X
boxes have also been implicated in oncogenesis and tumor progression [18, 211].
Consequently, development of inhibitors of both FTase and GGTaseI are subjects of
major drug discovery programs [212, 213]. Several FTase inhibitors (FTIs) are currently
in phase I, II and III clinical trials for the treatment of cancer [15, 17, 92, 94]. However,
K-Ras is the most prevalent mutated Ras isoform found in human cancers, and cells
transformed by K-Ras are often resistant to FTI treatment. The K-Ras Ca1a2X sequence
(CVIM) is normally farnesylated, but in the presence of an FTI it can be alternatively
prenylated by GGTaseI [107]. Alternative prenylation of K-Ras is thought to contribute to
K-Ras FTI evasion.
Over 30 proteins are known FTase substrates [49] and as many as 700 proteins
in the human genome contain a C-terminal Ca1a2X box [56]. The Ca1a2X sequence
alone is all that is required for FTase recognition and small peptides corresponding to
the Ca1a2X sequence often mimic the reactivity of full length proteins [204, 214]. The
Ca1a2X sequence of a protein is often unique to a single protein or to subsets of
proteins [56]. An alternative mechanism to inhibit the function of prenylated proteins is
to selectively modify particular Ca1a2X sequences with lipid groups that do not support
normal prenyl group function [141]. Numerous analogs of FPP such as 8-anilinogeranyl
diphosphate (AGPP, 2a) are utilized by farnesyl transferase to modify Ca1a2X proteins
both in vitro and in cell culture [159]. The aniline moiety of AGPP appears to act as an
isostere for the ω-isoprene unit of FPP and reacts with various Ca1a2X peptides with
steady-state kinetics nearly identical to FPP [161]. However, subtle changes in the
structure of AGPP drastically alter FTase activity [161].
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Figure 5-1 Analog Structures
Structure of farnesyl diphosphate (1, FPP) 8-anilinogeranyl diphosphate (2a, AGPP)
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The reaction mechanism of FTase is unexpectedly complex (Figure 5-2) [49, 82].
Substrate association is assumed to proceed through a functionally ordered mechanism
where FPP (1) binds first, giving the enzyme-FPP complex (E•FPP) followed by Ca1a2X
substrate association forming the enzyme-FPP-Ca1a2X peptide complex (E•FPP•CaaX)
[72, 201]. FPP binding to free enzyme enhances association of the Ca1a2X substrate up
to 70-fold. After thioether formation, a modified peptide remains associated with FTase
in an enzyme-product complex (E•product) [72, 74]. Product release is the rate
determining step (kcat) for the FTase reaction mechanism, and must be stimulated by
the binding of either a new FPP or Ca1a2X peptide substrate to the E•product complex.
Another interesting feature of the FTase reaction mechanism is the close association
between the isoprenoid lipid and the target Ca1a2X sequence in the E•product•FPP and
E•FPP•CaaX complexes. In both complexes, FPP binds at the same hydrophobic
surface and the ω-isoprene of FPP associates directly with the C-terminal amino acids
of the Ca1a2X sequence. The interaction between the target Ca1a2X motif and the
isoprenoid indicates that changes in the structure of FPP may be analogous to amino
acid mutations in the active site of the enzyme.
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Figure 5-2 FTase reaction mechanism
Extended mechanism incorporating peptide stimulated product release. The mechanism
is split into two pathways path A representing FPP stimulated product release and path
B representing peptide stimulated product release. E is the FTase enzyme, E-FPP is
the FTase•FPP complex, E•FPP•CaaX is the FTase•FPP•CaaX peptide complex, EProduct is the FTase bound product complex, E-Product-FPP is the FTase bound to
both FPP and the reaction product, and E-CaaX is the peptide bound FTase inhibitory
complex, E-Product-CaaX is the new peptide bound enzyme product complex
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Since the isoprenoid donor of the FTase reaction interacts directly with the target
Ca1a2X substrate then the activity of an analog may be highly dependent upon the
sequence of the isoprenylation target [80, 154]. In this chapter, to determine the effects
from altering the acceptor peptide sequence and the isoprenoid structure we have
tested the ability of ortho- substituted AGPP analogs to act as substrates with multiple
Ca1a2X peptides. Several analogs that were potent FTIs with a H-Ras based CVLS
peptide as the acceptor were excellent substrates when the isoprenylation target was a
K-Ras4B based CVIM peptide. Several of the analogs enhanced the selectivity of
FTase for CVIM over several other important Ca1a2X sequences. These results suggest
that analogs of the transferable FTase substrate AGPP can convert FTase from a
relatively promiscuous enzyme to an enzyme that selects for specific Ca1a2X
substrates. Selective modification of FTase target substrates is the first step to
designing Ca1a2X sequence selective molecules that can be used to inhibit the function
of specific cellular proteins.
Results
AGPP analog reactivity is dependent on Ca1a2X acceptor sequence
In order to investigate the relationship of the isoprenoid donor and peptide target
structure on the FTase reaction we measured the steady-state transfer kinetics of a KRas4B based CVIM peptide and 15 ortho- substituted AGPP analogs 2a-p. The reaction
kinetics were measured utilizing a continuous fluorescence assay with peptides N-linked
through a glycine linker to a fluorescent dansyl reporter group. We then compared the
catalytic efficiency of these reaction with those previously published with a H-Ras based
CVLS peptide. The CVIM (K-Ras4B) and CVLS (H-Ras) Ca1a2X sequences are two of
the most extensively characterized Ca1a2X substrates in the literature and we found
kcat/Kmpeptide values with FPP identical to those previously published (Figure 5-3) [154].
We found that the kcat/Kmpeptide with the two Ca1a2X peptides differed depending on both
the Ca1a2X substrate sequence and the isoprenoid analog structure. With FPP and
AGPP as the isoprenoid donors the catalytic efficiency with CVLS was nearly two-fold
higher than the catalytic efficiency with CVIM. However, with the oCl-AGPP 2c, oCF3-
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AGPP 2e, oEt-AGPP 2h, oI-AGPP 2i, oCF3O-AGPP 2j, and oSMe-AGPP 2k analogs
the catalytic efficiency of the reaction with CVIM was much higher than the efficiency
with CVLS. Surprisingly, CVIM was efficiently utilized with the oCF3O-AGPP 2j analog
although previously we observed that this analog was not a substrate with CVLS and
was a potent inhibitor of CVLS farnesylation.(Table 5-1) These results indicated that the
reactivity of the analogs was highly dependent on the identity of the Ca1a2X target
sequence.
In chapter 4, I showed that the ortho- substituted AGPP analogs were unable to
effectively compete with FPP for CVLS modification. The ability of the analogs to
compete with FPP may also be dependent on the target Ca1a2X sequence. To test the
ability of the analogs to compete with FPP for the CVIM modification we mixed each
analog and FPP 1:1 in excess of the CVIM peptide and analyzed the resulting product
by HPLC and integration of the dansyl peak absorbance. We found that AGPP
competed with similar effectiveness when CVLS and CVIM were the isoprenylation
targets (Figure 5-4). However, the oCF3O-AGPP 2j, oMe-AGPP 2d, and oMeO-AGPP
2f analog competition with FPP was enhanced when CVIM was the target Ca1a2X motif.
Interestingly, the ability of the oF-AGPP 2b analog to compete was decreased with
CVIM. These results suggested major differences in the activity and competitiveness of
the AGPP analogs depending on the amino acid sequence of the target peptide Ca1a2X
motif.
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Figure 5-3 Peptide transfer efficiency
Steady-state kcat/Kmpeptide values from each of the ortho- substituted AGPP analogs with
the CVLS and CVIM peptides. Kinetics were measured with varying concentrations of
peptide and holding the analog concentration constant at 6.7 µM. All reactions were
performed in Tris-HCl (pH=7.4) buffer containing reducing agent and detergent. Note
that the efficiency of the reactions with CVIM and CVLS change with the different
analogs and that several analogs are effective substrates with CVIM but not CVLS.
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Figure 5-4 Analog Competitiveness with FPP
Ratios of products analog modified Ca1a2X:farnesylated Ca1a2X were found from
reactions set up with 3µM peptide and 6 µM of the analog and FPP. Reactions were
allowed to continue until all peptide was consumed and were then analyzed by HPLC.
Fluorescence detection indicated the retention time of each of the products and
integration of peaks at 340 nm were used to quantify products. Note that the ability of
the analogs to compete is also dependent on the identity of the peptide.

Ratio of product (xCaaX:fCaaX)

2
1.8

CVIM

1.6

CVLS

1.4
1.2
1
0.8
0.6
0.4
0.2
0
H

oF

oMe

112

oMeO

oCF3O

AGPP analog substituent size affects Ca1a2X reactivity
The peptide target selectivity of the FTase enzyme can be predicted by the ratio
of the Ca1a2X Kmpeptide.(see chapter 3) The Kmpeptide values of the different Ca1a2X
sequences suggests that the analogs may increase the selectivity of the enzyme for
particular Ca1a2X peptides. To investigate the structural properties of the orthosubstituted AGPP analogs that affected FTase target selectivity we determined the
steady-state Kmpeptide of four Ca1a2X sequences with all 15 ortho- substituted AGPP
analogs. (Table 5-1) The peptide targets included the CVLS and CVIM Ca1a2X
sequences as well as the Ca1a2X motifs of the DNAJ homologue RDJ-2 (CAHQ) and
the centromere protein, CenpF-f (CKVQ). The analogs that were not substrates were
further screened for their ability to act as a FTI. (Figure 5-5)
The ortho- substituted analog reactivity fell into four general categories of
substrate/inhibition activity that appeared to be dependent on the size of the orthosubstituent. The largest analogs (class 4, 2m-p) were not substrates with any of the
peptides, and three of these analogs (oPh-AGPP 2n, oiPr-AGPP 2m, and oPhCH2AGPP 2p) were able to inhibit the farnesylation of the CVLS, CVIM and CAHQ peptides.
(Figure 5-5) All of the other AGPP analogs tested (Class 1-3, 2a-l) were substrates, but
the activity depended on the target Ca1a2X sequence. The Kmpeptide in reactions where
the analogue functional group substitutions were the smallest were similar to those with
FPP and AGPP (class 1, 2b-c, 2f-g). The medium sized analogs (class 2, 2d-e, 2h-i
and class 3, 2j-l) were selective for CVIM, based on the apparent Kmpeptide. The class 2
analogs showed some reactivity with the CVLS peptide while the class 3 analogs
reacted very poorly with all of the peptides other than CVIM. The class 3 analogs also
potently inhibited the farnesylation of CVLS. These results indicated that the selectivity
of the FTase enzyme for the different Ca1a2X substrates is highly dependent on the size
of the ω-aniline moiety.
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Table 5-1 Kmpeptide for ortho substituted analogs
Kmpeptide kinetics were measured with varying concentrations of peptide and with analog
concentrations constant at 6.7 µM. All reactions were performed in Tris-HCl (pH=7.4)
buffer containing reducing agent and detergent. The size of each of the aniline units
was estimated using the PreADME online molecular descriptor software. The analog
class is based on the ability of each analog to inhibit and act as a substrate for the
FTase enzyme as discussed in the text. Note that the analogs fall into four general
categories of reactivity.
class
1
1
1
1
2
2
1
1
2
2
3
3
3
4
4
4
4

R
FPP
H
oF
oCl
oMe
oCF3
oMeO
oBr
oEt
oI
oCF3O
oSMe
oEtO
oiPr
oPh
oPhO
oPhCH2

#
1
2a
2b
2c
2d
2e
2f
2g
2h
2i
2j
2k
2l
2m
2n
2o
2p

*

Size
102
114
118
129
129
139
140
142
144
146
149
149
155
159
187
198
202

KmCVLS *
(µM)
0.8 ± 0.1
0.5 ± 0.1
0.9 ± 0.2
0.8 ± 0.2
4.0 ± 0.4
>10
0.9 ± 0.2
1.0 ± 0.2
7±1
8±3
>10
>10
NR***
NR***
NR***
NR***
NR***

KmCAHQ
(µM)
2.0 ± 0.3
2.4 ± 0.5
3.3 ± 0.4
1.9 ± 0.1
>10
>10
>10
5.3 ± 0.9
>10
>10
>10
NR***
NR***
NR***
NR***
NR***
NR***

* NR indicates no reaction was observed
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KmCKVQ
(µM)
1.5 ± 0.3
1.7 ± 0.2
0.19 ± 0.07
1.9 ± 0.2
>10
>10
2.9 ± 0.2
1.7 ± 0.2
>10
>10
>10
>10
>10
NR***
NR***
NR***
NR***

KmCVIM
(µM)
0.30 ± 0.06
0.18 ± 0.06
0.23 ± 0.05
1.8 ± 0.3
0.3 ± 0.1
1.0 ± 0.2
0.7 ± 0.1
0.11 ± 0.01
3.6 ± 0.9
1.1 ± 0.1
2.76 ± 0.08
4.4 ± 0.6
4.0 ± 0.6
>10
NR***
NR***
NR***

KiXPP *
CVLS (nM)
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
2.4 ± 0.2
3.0 ± 0.3
12 ± 1
4.4 ± 0.2
3.6 ± 0.4
> 40
18 ± 1

Figure 5-5: Percent inhibition of FTase farnesylation
N-dansyl-GCaaX a)CVIM or b)CAHQ was mixed with FPP and an equimolar amount of
the analog. FTase was added and the percent inhibition was calculated by comparing
the initial rate of reactions containing the analog and FPP to the reaction rate with FPP
alone. Note that the largest analogs inhibit both CVIM and CVLS and that CAHQ
farnesylation is more easily inhibited than CVIM.
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Analogs with similar structures to oCF3O-AGPP are highly selective for
CVIM peptide
The third class of molecules was made up of analogs that only reacted with the
CVIM peptide and inhibited farnesylation of the other peptides. In order to determine
whether or not the analogs were selective for only CVIM we measured the competition
products from reactions containing the class 3 analogs oCF3O-AGPP 2j or oSMeAGPP 2k (Figure 5-6) with competing CVIM and CVLS or CVIM and CAHQ peptide
targets. We found with both analogs only the CVIM peptide was modified at the
detection limits of the assay. Interestingly, even after the CVIM peptide had been
completely consumed with the oCF3O-AGPP 2j analog, very little if any modified CVLS
peptide was detected. (Figure 5-5a)
The reaction rate of the CVIM/CVLS competition reaction with oCF3O-AGPP 2j
appeared to be the same as the reaction rate with only CVIM present. This indicated
that the presence of CVLS had no affect on the modification of CVIM. To determine if
higher concentrations of CVLS could effectively inhibit the modification of CVIM, we
measured the reaction rate with increasing CVLS concentrations. At CVLS
concentrations as much as five times the concentrations of CVIM no inhibition was
observed. Taken together these results suggest that the class 3 analogs convert FTase
from a relatively promiscuous enzyme to one that selects for only the CVIM peptide.
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Figure 5-6 Competition oCF3O and oSMe plus two peptides
Reactions containing two peptides mixed at equimolar concentrations with excess
oCF3O-AGPP or oSMe-AGPP were initiated by the addition of FTase. After several
hours the reaction was stopped and analyzed by HPLC. Below are the fluorescence
chromatograms from each reaction. a) oCF3O-AGPP, N-dansyl-GCVIM, N-dansylGCVLS b) oCF3O-AGPP, N-dansyl-GCVIM, N-dansyl-GCAHQ c) oSMe-AGPP, Ndansyl-GCVIM, N-dansyl-GCVLS d) oSMe-AGPP, N-dansyl-GCVIM, N-dansyl-GCAHQ.
Note that the CVIM peptide is the only peptide modified even after the majority of it has
been consumed.
a)

b)
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c)

d)
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oCF3O-AGPP inhibits CVLS farnesylation only when CVIM is not present
Since the oCF3O-AGPP 2j analog was an inhibitor of CVLS farnesylation yet a
competitive substrate when CVIM was the target Ca1a2X sequence we examined the
affect of CVIM on the CVLS farnesylation inhibition reaction. To do this we prepared a
CVIM spike experiment where CVLS, FPP and oCF3O-AGPP 2j were mixed and
allowed to react for 10 minutes. After the ten minute period CVIM peptide was added to
the reaction mixture and the rate of the reaction was measured. Upon CVIM addition the
reaction rate immediately increased to the modification rate of CVIM with the oCF3OAGPP 2j analog. These results indicated that the presence of the CVIM peptide relieved
FTase inhibition. However, it was not clear whether the CVLS peptide farnesylation was
still inhibited after the addition of the CVIM peptide. We prepared a separate reaction
containing FPP, oCF3O-AGPP 2j, CVLS and CVIM, and allowed the reaction to
progress for several hours, then analyzed the products by HPLC. (Figure 5-7)
Surprisingly, we found that CVLS was farnesylated when CVIM was present, yet without
CVIM in the mixture CVLS was modified to a much lesser extent. Previously we have
shown that the ratio of products from a CVIM/CVLS competition reaction with FPP was
3:1 f-CVIM:f-CVLS. However, in the presence of oCF3O-AGPP 2j the ratio of f-CVIM to
f-CVLS was changed to nearly 1:1. The prenylated CVIM peptide was split between the
oCF3O-AGPP 2j analog and FPP, while the CVLS peptide was only modified with a
farnesyl group. These results indicated that oCF3O-AGPP 2j was an inhibitor of the
farnesylation of CVLS only when the catalytically competent CVIM peptide was not
present.
Selectivity is dependent on Ca1a2X motif X residue
The ω-terminal isoprene unit of FPP is thought to directly interact with the a2
residue of a target Ca1a2X box; however, it was not clear whether the peptide selectivity
of the class 2 and 3 analogs was due to an interaction with the X residue or other
Ca1a2X sequence residues. To determine what residue affected the selectivity induced
by the analogs we switched the a2 residues of CVLS and CVIM to give CVIS and CVLS
and determined the Kmpeptide of each with the analogs.(Table 5-2) The activity of the
ortho- substituted analogs changed with the X residue not the Ca1a2X sequence a2
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residue. In the case of the class 2 and 3 molecules there was a productive interaction
with the CVIM and CVLM peptides, but not with the CVIS and CVLS peptides. These
results suggested that the selectivity of the analogs is dependent on the identity of the X
residue of the target Ca1a2X sequence.
Discussion
Chemical Genetics of FTase
Previous work with the FTase enzyme has demonstrated that the enzyme
catalyzes the modification of a wide variety of Ca1a2X substrates with varying steadystate kinetics. This chapter has shown that by altering the isoprenoid donor of the
FTase reaction the ability of FTase to catalyze the modification of these different Ca1a2X
substrates is changed. Several of the analogs that were effective inhibitors of the
farnesylation of a CVLS peptide were excellent substrates for the enzyme, and induced
unnatural selectivity for peptide with a methionine residue in the Ca1a2X motif X
position. This chapter demonstrates that changing the structure of the isoprenoid alters
the activity of the enzyme in a manner analogous with amino acid mutations in the
active site of the enzyme.
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Figure 5-7 Peptide and FPP competition with oCF3OAGPP
Quaternary competition reactions between two peptides an analog and FPP
Reactions containing two peptides mixed at equimolar concentrations with excess
oCF3O-AGPP equimolar to FPP were initiated by the addition of FTase. After several
hours the reaction was stopped and analyzed by HPLC. Below are the chromatograms
from fluorescence detection of the mixtures. a)FPP, oCF3OAGPP, N-dansyl-GCVIM, Ndansyl-GCVLS b) FPP, oCF3OAGPP, N-dansyl-GCVIM, N-dansyl-GCAHQ. Note that
the CVIM peptide is modified by both the analog and FPP while the competing peptide
is only modified with FPP.
a)

b)
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Table 5-2 Kmpeptide values with CVIS and CVLM peptides
Kinetic parameter Kmpeptide for N-dansyl-GCVIS and N-dansyl-GCVLM for comparison
with N-dansyl-GCVIM and N-dansyl-GCVLS. Kmpeptide was measured with varying
concentrations of peptide and with analog concentrations constant at 6.7 µM. All
reactions were performed in Tris-HCl (pH=7.4) buffer containing reducing agent and
detergent. Note that the Kmpeptide follows the X residue not the a2 residue.
R
FPP
oEt
oI
oCF3O
oSMe

#
1
2x
2x
2j
2x

KmCVLS
0.8 ± 0.1
7±1
8±3
>10
>10

KmCVIM
0.30 ± 0.06
3.6 ± 0.9
1.1 ± 0.1
2.76 ± 0.08
4.4 ± 0.6
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KmCVIS
0.22 ± 0.04
5±1
>10
>10
>10

KmCVLM
0.09 ± 0.01
1.4 ± 0.3
1.5 ± 0.3
4.4 ± 0.4
8±2

Active Site Discrimination of Peptides
There are two possibilities that explain the ability of oCF3O-AGPP 2j to inhibit
CVLS farnesylation, yet act as a substrate with CVIM. The first of these possibilities is
that the product from the reaction of oCF3O-AGPP and CVLS cannot be dissociated by
the CVLS peptide, FPP or oCF3O-AGPP 2j. The second possibility is that the chemical
step of the reaction is compromised with the oCF3O-AGPP analog and CVLS peptide.
Both mechanisms of inhibition could be relieved by the addition of a more competent
peptide to either stimulate product release or react with oCF3O-AGPP 2j. If there was
no discrimination between CVIM and CVLS prior to the chemical step of the reaction,
CVIM relief of product inhibition would lead to an increase in oCF3O-AG-CVLS
formation in the CVIM, CVLS, FPP and oCF3O-AGPP 2j quaternary competition
experiment. However, the amount of CVLS modified with oCF3O-AGPP 2j in the
quaternary competition experiment was the same as when CVIM was not present.
Interestingly, the amount of CVLS modified by FPP relative to CVIM increased in the
presence of oCF3O-AGPP 2j. The most likely cause of this increase is the selective
depletion of the CVIM peptide by the E•oCF3O-AGPP complex. The ability of oCF3OAGPP 2j to inhibit the modification of the CVLS and CAHQ peptides, yet competitively
react with the CVIM peptide is most likely due to a pre-chemical step discrimination
between the CVIM and CVLS peptides by the E•oCF3O-AGPP complex. A selective
target peptide exclusion from the FTase active site demonstrates that changing the
structure of the isoprenoid alters the activity of the enzyme in a manner analogous with
amino acid mutations in the active site of the enzyme.
The exclusion of peptide by an FPP analog has been described previously.
Turek-Etienne et al described a benzophenone based FPP (benzophenone-GPP 3)
analog that inhibits FTase by exclusion of a target peptide from the active site of the
enzyme [215]. Support for this mechanism of inhibition was achieved from a crystal
structure of the analog bound to FTase where the benzophenone portion of the
molecule (3) protruded into the X residue binding site, presumably excluding peptide
from the active site. In this chapter, I have described a similar mechanism except that
differences in the structure of the target peptide appear to affect the ability of the analog
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to exclude particular peptides. Interestingly, we have found that the peptide selectivity of
the molecules reported were dependent upon the X residue of the target Ca1a2X
sequence. These observations are consistent with the peptide exclusion model of
inhibition.
Other Regions of Protein may Affect Reactivity
This chapter was designed to analyze the Ca1a2X selective properties of the
enzyme with respect to interactions in the active site of the enzyme. It is not yet clear if
the peptide selectivity of these analogs with FTase will translate directly to selectivity for
full length protein targets. In particular, the K-Ras4B protein contains an upstream polybasic region that enhances affinity for the enzyme through interactions outside the
enzyme active site. However, H-Ras proteins do not contain an upstream poly-basic
region and the steady-state transfer kinetics are nearly identical to those of the Ca1a2X
peptide alone. We have shown that several of the analogs enhance FTase selectivity for
the K-Ras4B Ca1a2X peptide. Increased affinity by the upstream poly-basic region
would likely only further enhance this selectivity. The ability to target K-Ras4B will be
useful for Ca1a2X selective protein function inhibition.
Experimental
General
AGPP analogs and FPP were synthesized as described in Chapter 2. All RPHPLC was performed on an Agilent 1100 HPLC system equipped with a microplate
autosampler, diode array and fluorescence detector. The HPLC analysis was performed
with a microsorb C18 column with 0.01% TFA in water (A) and 0.01% TFA CH3CN (B)
as the mobile phase. Peptides were purchased from peptidogenics and each contained
a dansyl group N-linked to a glycine linker followed by a C residue then a variable aaX
sequence (VLS, VIM, AHQ, or KVQ). Spectrofluorometric analyses were performed in a
96-well flat bottom, non-binding surface, black polystyrene plate (Excitation wavelength,
340 nm; emission wavelength 505 nm with a 10 nm cutoff). The plate reader was a
SpectraMax GEMINI XPS fluorescence well-plate reader. Absorbance readings were
determined using a Cary UV/Vis spectrophotometer.
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Steady-state peptide kinetics
The kinetic constants Kmpeptide and kcat with FPP, and the analogs with the each
peptide

were

determined

in

triplicate

measurements

using

a

continuous

spectrofluorometric assay adapted for a 96-well plate. The following assay components
were assembled in individual wells of a 96-well plate and incubated at 30° C for 20
minutes: 180 µL of assay buffer (52 mM Tris-HCl, 12 mM MgCl2, 12 µM ZnCl2 pH 7.4),
40 µL of detergent (0.125% n-dodecyl- β-D-maltoside in assay buffer), 40 µL of
reducing agent (50 mM DTT in assay buffer) 20uL of FPP or AGPP (200 µM in 25 mM
NH4HCO3)

and

20

µL

of

N-dansyl-GCaaX

peptide

(variable

concentration).

Fluorescence was detected using a time based scan at 30° C for 120 minutes. The
velocity of each reaction was determined by converting the rate of increase in
fluorescence intensity units (FLU/s) to µM/s with equation 5-1.
Equation 6-1: vi=(R·P)/(FMAX-FMIN)
Where vi is the velocity of the reaction in µM/s. R is the rate of the reaction in FLU/s. P
is equal to the concentration of modified product in µM (see below). FMAX is the
fluorescence intensity of fully modified product. FMIN is the fluorescence of a reaction
mixture that contained 20 µL of assay buffer in the place of FTase. Complete
modification of peptides was assumed when fluorescence stabilized for more than 10
minutes and was confirmed by RP-HPLC analysis of the reaction mixture.
Final analysis peptide concentrations were chosen based on preliminary
determination of the Kmpeptide with 0.5, 1, 5 and 10 µM dansyl-GCaaX concentrations
(see below). The final analysis used 8 peptide concentrations which were: 1/6, 1/5,1/4,
1/2, 3/4, 1, 2, and 3 times the estimated Kmpeptide value except with the CVIM peptide.
The reaction was then initiated by the addition of 20 µL of FTase (final concentration 10
nM with the CLVS, CAHQ, CVIL and CRPQ peptide, 20nM with the CVIM peptide).
Fluorescence

enhancement

was

determined

as

described

above.

Complete

modification of peptides was assumed when fluorescence stabilized for more than 10
minutes. Samples in which the reactions that contained higher concentrations of
peptides did not go to completion the Fmax-Fmin value was extrapolated using a linear
plot of the Fmax-Fmin for each of the lower concentration reactions that did go to
completion.
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The velocities of the reactions were plotted against the concentration of peptide
and were fit to the Michaelis-Menten equation (Equation 5-2) to give the apparent kcat
(appkcat) and Kmpeptide (appKmpeptide) values. Where et was the total enzyme
concentration and [Pep] was the total input peptide. The kcat/Kmpeptide value was derived
from a Lineweaver-Burke plot of the same data points.
Equation 5-2: vi/et=(appkcat*[Pep])/(appKmpeptide+[Pep])
Peptide Competition
Competition reactions were prepared with the same components given for the
kcat/Kmpeptide analysis except two peptides were added to the mixture at a single
concentration. Peptides A and B were diluted to 45 µM in Tris-HCl buffer (pH=7.4) and
the concentration checked by reading the Abs of the solution at 340 nm (εdansyl=4250
Abs·M-1·cm-1). 20 µL of peptide A and 20 µL of peptide B were then added to reaction
mixtures as described above except only 160 µL of assay buffer was added. Separate
reactions were prepared as a standard with FPP or the analog and only one peptide as
described above. The reactions were then initiated with the addition of FTase and
analyzed spectrofluorometrically (Reactions containing CVIM peptide used 20 nM final
FTase concentration all other used 10 nM). The reactions were stopped prior to
consumption of more than 50% of either peptide by adding 20 µL of a stop solution
(isopropyl alcohol and acetic acid 8:2). HPLC analysis was then performed with 100 µL
of the reaction mixture loaded onto C18 column and eluted with a linear gradient of 0-30
min 10% B to 100% B at a flow rate of 1 mL/min. Peaks on the 340 nm trace
chromatogram that corresponded to both the standard reactions and fluorescent peaks
were then integrated. The ratios of products were calculated according to equation 5-3.
Equation 6-3: (IAmod/ IAtot)/(IBmod /IBtot)
Where IAmod is the integral of the modified peptide A, IAtot is the integral of the
modified peptide A plus the unmodified peptide A, IBmod is the integral of the modified
peptide B and IBtot was the integral of the modified peptide B plus the unmodified peptide
B. Alternatively, the ratios were calculated using the integrals of the standard peptides
fluorescence relative to competition product fluorescence giving less than a 5%
difference in the calculated ratio.
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FPP competition
Competition reactions were prepared with the same components given for the
kcat/Kmpeptide analysis except two analogs were added to the mixture and the peptide
concentration was held constant. FPP and the analog were diluted to 200 µM in 25 mM
NH4HCO3. 10 µL of FPP and 10 µL of analog were then added to a 280 µL solution of
peptide, DTT and detergent in 52 mM Tris-HCl buffer pH=7.4 (final concentrations
DTT=6.7 mM, DM=0.033%, Peptide=3µM, analog= 6.7 µM and FPP=6.7 µM). The
concentration of peptide was determined by absorbance of the dansyl group and
isoprenoid diphosphate concentration was determined by consumption of isoprenoid in
FTase reactions with the CVLS peptide where the isoprenoid was limiting. The reactions
were initiated with the addition of FTase and analyzed spectrofluorometrically (20 nM
final FTase concentration). The reactions were stopped after 2 hours with a mixture of
acetic acid and iPrOH. HPLC analysis was then performed with 100 µL of the reaction
mixture loaded onto C18 column and eluted with a linear gradient of 0-30 min 10% B to
100% B at a flow rate of 1 mL/min. Peaks on the 340 nm trace chromatogram that
corresponded to standard reaction fluorescent peaks were then integrated. The ratios of
products were calculated using Ianalog/IFPP, where Ianalog is the integral of the peptide
modified with the analog and IFPP is the integral of the peptide modified with FPP.
Inhibition Screen
The analog ability to inhibit FTase transfer of FPP was initially determined by
measuring the percent inhibition in farnesylation rate in the presence of equimolar
amounts of FPP and the analog. Reactions were prepared as described for the FPP
competition analysis and the rate of FPP modification was determined based on the rate
of fluorescence increase over time with or without the analog present. The % inhibition
was determined using equation 5-4.
Equation 5-4: % inhibition=[1-(rateFPP/rateI)]*100
Where the rateFPP was the rate of the CVLS reaction without the analog present and the
rateI was the rate of the reaction with the analog present.
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FPP and peptide competition
Peptides A and B were diluted to 45 µM in Tris-HCl buffer (pH=7.6) and the
concentration checked by reading the Abs of the solution at 340 nm (εdansyl=4250 Abs·M1

·cm-1). FPP and oCF3O-AGPP were diluted to 200 µM in 25 mM NH4HCO3. 20 µL of

peptide A and 20 µL of peptide B were then added to reaction mixtures along with 10 µL
of FPP and 10 µL of analog were added to reaction mixtures containing 140 µL of assay
buffer (52 mM Tris-HCl, 12 mM MgCl2, 12 µM ZnCl2 pH 7.4), 40 µL of detergent
(0.125% n-dodecyl- β-D-maltoside in assay buffer), 40 µL of reducing agent (50 mM
DTT in assay buffer) Separate reactions were prepared as a standard with FPP or the
analog and only one peptide as described above. The reactions were then initiated with
the addition of FTase (Final concentration 20 nM) and analyzed spectrofluorometrically.
The reactions were stopped prior to consumption of more than 50% of either peptide by
adding 20 µL of a stop solution (isopropyl alcohol and acetic acid 8:2). RP-HPLC
analysis was then performed with 100 µL of the reaction mixture loaded onto C18
column and eluted with a linear gradient of 0-30 min 10% B to 100% B at a flow rate of
1 mL/min. Peaks on the 340 nm trace chromatogram that corresponded to both the
standard reactions and fluorescent peaks were then integrated.
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CHAPTER 6 CELLULAR ACTIVITY OF ISOPRENOID DIPHOSPHATES
Introduction
Monitoring the prenylation state of proteins in cells is a challenging undertaking.
Initially,

prenylation

of

proteins

was

discovered

by

metabolic

labeling

with

[3H]mevalonolactone [216]. In these experiments, some of the tritium label was
incorporated into both farnesylated and geranylgeranylated proteins. Subsequently, a
salvage pathway was discovered where radiolabeled farnesol 1a (FOH) and
geranylgeraniol 2a (GGOH), precursors of FPP 1b and GGPP 2b, were selectively
incorporated into their respective farnesylated or geranylgeranylated proteins [217]. A
significant drawback of these approaches is the inherently low sensitivity of
autoraidographic detection of the weak tritium β-emission. In fact, it can take up to four
weeks to visualize proteins extracted from cells labeled with tritiated mevalonate or
farnesol by autoradiography [141]. Also, the incorporation of tritiated prenyl groups does
not provide a convenient method for isolation of these modified proteins.

129

Figure 6-1 FPP Analogs
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The facile detection, isolation and purification of farnesylated proteins based
solely on their post-translational modification status is essential to understanding the
mechanism of cellular growth inhibition by FTIs. Antibodies are useful both in the routine
detection

and

immunoprecipitation

of

proteins

with

other

post-translational

modifications, such as phosphorylation [218]. However, reports of previous attempts to
produce antibodies to detect farnesylated proteins have had mixed results. Two of these
reports described non-specific antibodies that could not differentiate between proteins
modified by farnesylation, geranylgeranylation or other lipids [113, 219]. The other
report from Baron et al does describe the production of anti-farnesyl antibodies specific
for farnesylation, but the analysis for specificity was limited [220]. These antibodies are
apparently not available commercially and all of the commercially available sources for
anti-farnesyl antibodies cross-react with geranylgeranylated proteins.
An attractive alternative to targeting the natural farnesyl moiety is to detect
proteins modified with unnatural farnesyl analogs. Several unnatural analogs of FPP
appear to be utilized by cells and incorporated into the proteins by FTase, including the
unnatural FPP analog 3-vinyl-farenesol 3a, a pro-drug of the FTase transferable 3-vinylfarnesyl diphosphate (3vFPP) 3b, and 8-azido-farnesol 4 [141]. A tagging-via-substrate
(TAS) approach to the detection and isolation of farnesylated proteins involving the
incorporation of 4 into cellular proteins has been developed by Kho et al. [168] Modified
proteins were isolated from cell lysates using a biotinylated phosphine capture reagent
and subsequently identified by mass spectrometry. However, the sensitivity is relatively
low and the technique does not lend itself to the routine detection of modified proteins.
A more convenient method to simplify the detection of such proteins would be to use
antibodies specific for the unnatural modification.
A variety of FPP analogs that may be useful in implementing this strategy have
been prepared by our group and others [149, 157, 193, 221].

Anilinogeranyl

diphosphate (AGPP) 5b is transferred by FTase to protein substrates with kinetics
similar to those of FPP and does not resemble any known natural protein modification
[159, 161]. Antibodies against an anilinogeranyl (AG) epitope may circumvent the
problems associated with tritium labeling and the preparation of anti-farnesyl antibodies,
and provide a facile way to detect and isolate prenylated proteins.
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We report the preparation of anti-anilinogeranyl antibodies (anti-AG and antiNAG) raised against haptens 12a and 12b that detect proteins modified with
anilinogeranyl or pNO2-anilinogernayl moieties derived from AGPP 5b and NAGPP 6b.
Activated ester haptens 9a-b were synthesized and coupled to immunogenic carrier
proteins and used to raise antibodies directed to the anilinogeranyl modification. The
primary antibodies were able to bind proteins with an intact analog modified C-terminal
Ca1a2X motif. We demonstrate that anilinogeraniol 5a, a prodrug form of AGPP 5b, is
incorporated into cellular proteins in an FTase dependent manner, and that endogenous
protein labeling was competitive with endogenous FPP 1b. Combining the unnatural
FPP analog AGPP with anti-anilinogeranyl antibodies provides a useful reagent system
to monitor the prenylation status and effects of FTIs in cells.
Results
Synthesis of Analog modified Antigen
The preparation of the prenyl analog carrier protein conjugates 12a-b and 13a-b
is outlined in Figure 6-2. The haptens were designed to mimic the C-terminal peptide of
a fully processed prenylated protein that had undergone both endoproteolysis and
carboxyl group methylation. Thioether 8a-b was obtained in 60-74% yield by addition of
a solution of l-cysteine methyl ester HCl in NH3/MeOH to the previously described
chloride 7a-b [161]. The farnesyl thioether 6b was prepared by addition of farnesyl
bromide 6b to l-cysteine methyl ester HCl in NH3/MeOH. Condensation of amines 8a-c
with succinic anhydride in THF:DCM afforded succinates 9a-c in 57%-85% yield after
chromatography [222]. Activated esters 10a-c were prepared from carboxylates 9a-c in
58%-85% yield by reaction with CDI followed by condensation with N-OH phthalimide
[223]. The N-hysdroxysuccimidyl (NHS) ester of a similar farnesyl hapten is reported to
undergo an undesired intramolecular cyclization to an unreactive succinimide [219]. In
contrast to the NHS ester, phthalimides 10a-b were stable and showed no evidence of
intramolecular cyclization. The suitability of phthalimides 10a-b to form conjugates with
carrier protein was modeled under conditions typical for coupling activated esters to
lysine residues. Condensation of benzylamine with phthalimides 10a-b in 1:5
Acetonitrile:5% NaHCO3 gave model amides 11a-b in 51%-76% yield.
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With activated haptens in hand, we proceeded to generate anilinogeranyl ,
pNO2anilinogeranyl and farnesyl immunoconjugates. Phthalimides 10a-c were reacted
with carrier proteins KLH and BSA to provide hapten conjugated proteins 12a-c (AGKLH, NAG-KLH and F-KLH) and 13a-c (AG-BSA, NAG-BSA and F-BSA). BSA has
approximately 32 reactive lysine residues and the extent of covalent modification of
immunoconjugates 13a-c was quantified by measuring the remaining free amino groups
relative to unmodified BSA. BSA, and each of the BSA conjugates 13a-b were reacted
with trinitrobenzene sulfonate and the ratio of free amines in unmodified BSA to
modified BSA were determined by UV absorbance at 335 nm [224]. We found that 50%
of the lysine residues in immunoconjugates 13a-c were modified by the activated esters
10a-c. As KLH is a heterogeneous protein, similar assays to quantify the coupling
efficiency were not performed. By analogy with the BSA results, we assumed a similar
coupling efficiency for the KLH bioconjugates.
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Figure 6-2 Synthesis of analog modified haptens
Reagents: (a)Cysteine methyl ester HCl, NH3/MeOH, 0° C (%). (b) Succinic anhydride,
THF/DCM(%). (c) N-Hydroxyphthalimide, CDI, MeCN (%). (d) R2, NaHCO3(aq)/MeCN
R1

X
7a-b

7a: R1=aniline-CH2C(CH3)CHCH2; X=Cl
7b: R1=pNO2-aniline-CH2C(CH3)CHCH2; X=Cl
7c: R1=geranly; X=Br
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Generation of anti-anilinogeranyl antibodies
Polyclonal antibodies to the anilinogeranyl modification were prepared by
immunizing rabbits with AG-KLH (12a) and NAG-KLH (12b). In our hands, F-KLH (12c)
elicited no immunogenic response. This is in agreement with previous reports in which
attempts to prepare anti-farnesyl antibodies have resulted in weakly binding reagents
that recognize both farnesyl and geranylgeranyl isoprenoid lipids [113, 219, 220]. Due to
the poor immune response to the F-KLH protein, (12c) we abandoned attempts to
prepare an anti-farnesyl antibody. Polyclonal immune sera collected from the rabbits
were screened using an enzyme linked immunosorbent assay (ELISA). No ELISA
response was detected to unmodified BSA, AG-BSA (13a), or NAG-BSA (13b) in preimmune sera. Gratifyingly, sera antibodies raised against AG-KLH 12a (anti-AG) and
NAG-KLH 12b (anti-NAG) were able to bind to AG-BSA (13a) and NAG-BSA (13b)
respectively (Figure 6-3). Interestingly, there was considerable cross-reactivity using the
anti-AG antibody with the anilinogeranyl and pNO2anilinogeranyl modified BSA proteins.
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Figure 6-3 ELISA Assay of Anilinogeranylated BSA Constructs
a) anti-AG and b) anti-NAG ELISA response to AG-BSA (closed squares), NAG-BSA
(open circles) and unmodified BSA (triangles) (0.1µg BSA/well).Note that the anti-AG
antibody cross reacts with NAG-BSA and AG-BSA, yet the anti-NAG antibody only
detects NAG-BSA
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Specificity and Analysis of anti-anilinogeranyl antibodies
The antibodies generated in this study were directed to proteins modified with
cysteine methyl ester analogs of FPP. However, the actual antigen that is presented to
the immune system is unknown as the ester may be hydrolyzed by enzymes in the
whole animal. Additionally, it is possible that in vivo incorporation of unnatural analogs
into proteins will alter the normal Ca1a2X endoproteolysis and carboxyl group
methylation steps. The utility of the polyclonal anilinogeranyl antibodies might well be
limited if they only recognized the cysteine methyl ester form of modified proteins.
Therefore, it was essential to test the ability of these antibodies to recognize proteins
modified by FTase with the anilinogeranyl moiety without subsequent endoproteolysis
and carboxyl group methylation. Bacterially expressed DNAJ-like RDJ2[200] and Q61L
oncogenic H-Ras proteins contain the un-farnesylated and unprocessed CAHQ and
CVLS Ca1a2X motifs respectively. FTase catalyzed in vitro modification of these
proteins with FPP 1b, AGPP 5b, and NAGPP 6b provided lipid thioether linked proteins
with intact Ca1a2X motifs 14a-c and 15a-c (Figure 6-4). These reaction mixtures were
then analyzed by western blot with anti-AG and anti-NAG antibody sera. Figure 6-5
shows that the anti-AG was able to bind to AG-BSA 13a and NAG-BSA 13b derivatized
by the methyl ester haptens as well as the AG-RDJ2 14c and NAG-RDJ2 14d, but,
showed no reactivity to the unmodified RDJ2 14a protein. Identical results were found
when AG-Ras 14c was examined. Additionally, the antibodies were also unreactive
towards farnesylated F-RDJ2 (13b) and F-Ras (14b). Similar results were found with
the anti-NAG antibody except the anti-NAG antibody was significantly more specific for
the pNO2-anilinogeranylated proteins over the anilinogeranylated.
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Figure 6-4 Ca1a2X modification
C-terminal structures of in vitro modified RDJ2 and H-Ras proteins
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Figure 6-5 Western Analysis of Anilinogeranylated RDJ2
Western Blot analysis of unmodified (RDJ2-ve control), anilinogeranyl modified and
Nitroanilinogeranyl modified RDJ2 (AG-RDJ2, NAGRDJ2) and BSA (AG-BSA, NAGBSA) proteins. Probed with anti-AG (AG-Ab) and anti-NAG (NAG-Ab) antibodies. Note
that as in the ELISA assay the anti-AG antibody detects both AG and NAG modified
protein.
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Since there was cross reactivity with the anti-AG antibody we tested the ability of
the anti-AG and anti-NAG antibodies to recognize other aniline analogs incorporated
into proteins by FTase. We reacted H-Ras with the analogs pCN-AGPP 16, mCN-AGPP
17, oCF3O-AGPP 18, mCF3O-AGPP 19, pCF3O-AGPP 20, oF-AGPP 21, mF-AGPP 22,
pF-AGPP 23, oI-AGPP 24, mI-AGPP 25, pI-AGPP 26, oBr-AGPP 27, mBr-AGPP 28,
pBr-AGPP 29, oMeO-AGPP 30, mMeO-AGPP 31, mCF3-AGPP 32, mMe-AGPP 33, and
pMe-AGPP 34. As expected we found that the anti-AG antibody was less specific for
the aniline substitution and was able to cross-react with the analogs containing small
substitutions in the aniline ring of AGPP (Figure 6-6). This included the mCN-AGPP 17,
oF-AGPP 21, mF-AGPP 22, pF-AGPP 23, mBr-AGPP 28, pBr-AGPP 29, mMe-AGPP
33, and pMe-AGPP 34 modified H-Ras proteins. The anti-NAG antibodies recognized
the mCN-AGPP 16, pCN-AGPP 17, and pBr-AGPP 29 modified H-Ras proteins. These
results suggested that the antibodies could be useful for many different anilinogeranyl
diphosphate analogs not just the ones they were designed to recognize.
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Figure 6-6 Cross Reactivity
Western blot analysis of Ras proteins modified with various AGPP analogs as indicated,
and probed with anti-AG and anti-NAG polyclonal antibodies. Each well contains equal
amounts of protein. However, extent of modification was not analyzed. Note that both
antibodies recognize more aniline structure than they were designed to detect, yet they
are specific for the aniline modified proteins and do not detect unmodified.
H
N

R1

R

a)

16-34: R indicated below

b)
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FTase dependent Anilinogeraniol incorporation into cellular proteins
Farnesol 1a, geranylgeraniol 2a and a number of farnesol analogs become
incorporated into cellular proteins when added to the culture media of growing cells
[141, 170, 217, 225]. These compounds are thought to traverse the plasma membrane
and act as substrates for sequential kinase reactions to give FPP 1b, GGPP 2b or the
diphosphate analog which can then be utilized by FTase or GGTaseI to appropriately
modify cellular proteins [170, 226]. The kinases involved in the phosphorylation
reactions have been characterized in plants, but not in mammalian cells. In vitro, both
FPP 1b and AGPP 5b are transferable by FTase to a CVLS substrate with similar kcat
and Km values [159]. Therefore, we speculated that anilinogeraniol might also cross the
plasma membrane of cells, be converted to the diphosphate 5b and become
incorporated into proteins by FTase. However, it was also possible that anilinogeraniol
5a might be toxic to mammalian cells. Accordingly, the acute cytotoxicity of
anilinogeraniol 5a was examined by incubating human embryonic kidney (HEK-293)
cells with up to 100 µM anilinogeraniol 5a for three days. Somewhat surprisingly, we
found that cells treated with anilinogeraniol showed no morphological changes and no
decrease in cell growth relative to controls at any of the concentrations tested.
The anti-AG antibodies were used to probe extracts of HEK-293 cells incubated
in the presence of AGOH 5a to determine if the anilinogeranyl group was incorporated
into cellular proteins. These cells were initially blocked with lovastatin an upstream
inhibitor of endogenous FPP and GGPP formation and treated with GGOH for the
geranylgeranylation of proteins critical to cell survival [227]. Figure 6-7 shows that there
are numerous anilinogeranyl modified proteins in cells treated with AGOH 5a, while no
proteins were detected in the absence of the unnatural FPP analog. In order to
determine whether the protein modification was FTase dependent, cells were incubated
in the presence of AGOH 5a and either the farnesyl transferase inhibitor FTI-277 [93] or
the geranylgeranyl transferase I inhibitor GGTI-2147 [228]. Lane 3 of Figure 6-7 shows
that no anilinogeranyl modified proteins were detected in the presence of the FTI.
However, in the presence of the geranylgeranyl transferase I inhibitor, the pattern of
proteins modified with anilinogeranyl moiety was very similar to that without any inhibitor
present. Interestingly, some additional, lower molecular weight anti-AG reactive bands
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appear when GGTaseI is inhibited. FTase catalyzed transfer of the anilinogeranyl lipid
to protein is the most consistent explanation for these observations. These results also
suggest that FTase may be able to utilize AGPP to modify some normally
geranylgeranylated proteins when GGTaseI is inhibited. This is not unreasonable, as
the normally farnesylated K-Ras4B becomes geranylgeranylated in the presence FTIs
[229, 230].
The AGOH analog must undergo diphosphorylation to be incorporated into
cellular proteins. This diphosphorylation may not be on time-scale that allows
competitive modification of proteins in the presence of FPP. Cells were incubated
without a lovastatin blockade on endogenous FPP formation with 30 µM AGOH and
sampled every few hours. Figure 6-8 shows that anilinogeranyl incorporation into
proteins begins within two hours of incubation with AGOH and is therefore competitive
with the endogenous pools of FPP. Importantly, these experiments demonstrate that
intracellular concentrations of AGPP 5b can be achieved that are high enough to
compete with the endogenous pool of FPP 1b for FTase dependent transfer to proteins.
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Figure 6-7 FTase Dependent Incorporation of Anilinogeranyl Label in Cells
Incorporation and detection of anilinogeranyl modified endogenous proteins. HEK-293
cells were incubated with 30 µM lovastatin and 10 µM GGOH for one day then media
was poured off and the cells were incubated with or without 100 µM AGOH 3a (lane 12), in the presence and absence of an FTI or a GGTI (lanes 2-4). The cells were then
analyzed by western blot with the anti-AG sera. Note the difference in FTI + and – cells,
and the 31 kDa band in the GGTI treated cells.
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Figure 6-8 Endogenous Competition
Cells with no lovastatin blockade were incubated with 30 µM AGOH for the given time
points then were harvested and lysed. 50 µg of total protein was loaded onto an SDSPAGE gel transferred to nitrocellulose and immunodetected using the anti-AG. Note the
time dependent increase in anilinogeranylated proteins.
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Alternative Pro-drug strategy
The labile phosphoanhydride bond and the multiple negative charges of FPP
analogs likely prevent easy diffusion across cell membranes although naturally
occurring isoprenoids such as FPP and geranylgeranyl diphosphate are apparently
taken up through an active transport system [231].

The isoprenoids farnesol,

geranylgeraniol and the unnatural analog 3-vinyl-farnesol (3a) are converted in
mammalian cells to the corresponding pyrophosphates [141, 226, 232]. 3-vinyl-farnesyl
diphosphate is an alternative substrate for FTase and the prodrug 3-vinyl-farnesol is
able to block anchorage-independent growth of ras-transformed cells. Presumably, this
effect is due to FTase catalyzed modification of proteins with the 3-vinyl-farnesyl group.
These observations suggest that alcohol precursors of other FPP analogs may also be
useful prodrugs.
However, it is far from clear that arbitrary farnesol analogs will be efficiently
converted to the corresponding pyrophosphates in cells. An alternative strategy for
creating membrane permeant molecules is to reduce the overall charge and increase
the lipophilicity of the analog. The bioavailability of membrane impermeant phosphate
and phosphonate containing drug molecules has been dramatically increased by
masking the charged groups with acyloxymethyl esters [233-235]. The acyloxymethyl
ester allows the drugs to diffuse across the cellular membrane into the cytoplasm where
general esterases cleave the acyloxymethyl groups revealing the active, charged
species (Figure 6-10) [195, 236].

However, this strategy is unlikely to succeed for

uncharged pyrophosphate tetra-esters, as the anhydride linkage is rapidly hydrolyzed at
physiological pH.

Methylenediphosphonate (MDP) is a structural analog of

pyrophosphate, which does not contain a labile anhydride linkage. Replacing the labile
pyrophosphate with MDP and masking the negative charges with acyloxymethyl esters
may result in membrane permeant FPP analogs. We found no description of monoallylic triacyloxymethyl methylenediphosphonate tetraesters in the literature. We report
the preparation of three such isoprenoids where the pyrophosphate has been replaced
by MDP and the negative charges are masked by frangible pivaloyloxymethyl (POM)
esters.

146

Figure 6-9 Proposed Mechanism of In Vivo Prodrug Activation
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Farnesyl methylene diphosphonate is transferable.
The strategy outlined above requires that the substitution of MDP for the
pyrophosphate in FPP and other analogs results in molecules that are substrates for
FTase. Farnesyl methylene diphosphonate (FMDP) 2 has previously been prepared
and was shown by Eummer et al. to be a competitive inhibitor (IC50=160 nM) of FTase
[185]. However, the assay used in that study was unable to distinguish whether FMDP
was an alternative substrate for FTase or an FTI. To resolve this question, FMDP, 36
was synthesized as previously described, and was shown to be a substrate for FTase in
an in vitro fluorescence assay varying isoprenoid concentration [194]. The catalytic
efficiency for transfer of the farnesyl group from FMDP 36 to a dansyl-GCVLS peptide
substrate by FTase was found to be an order of magnitude lower than that for FPP 1
(Table 6-1). The previous study also reported that treatment of NIH3T3 cells with 36
had no effect on their growth. Eummer at al. suggested that this might be due to FMDP
36 acting as an alternative substrate for FTase, leading to normal farnesylation of Ras.
The results of the in vitro fluorescent assay are consistent with this observation.
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Table 6-1 Kinetics of FMDP
Steady-state transfer kinetics of FPP and FMDP with 1 µM peptide concentration and
varying FPP and analog concentrations. Rates were measured in a single cuvette
fluorescence assay using N-dansyl-GCVLS as the peptide substrate and FTase as the
catalyst in Tris-HCl (pH=7.4) with reducing agent and detergent. Note the order of
magnitude difference in catalytic efficiency.
O
O
P
P
O
X
OO- O1. FPP X=O
36. FMDP X=CH2

Analog
FPP (1)
FMDP (36)

Km(nM)
40
180

kcat (s-1)
0.09
0.06
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kcat/Km (M-1s-1)
2 x 106
3 x 105

Synthesis of masked methylene diphosphonates
The synthesis of tri-POM esters of isoprenoid diphosphonates is summarized in
Figure 6-11. Tetrapivaloyloxymethyl methylenediphosphonate (38) was prepared from
tetramethyl methylenediphosphonate (37) and pivaloyloxymethyl chloride (POM-Cl) in
47% yield as previously described [237]. In analogy to previously reported methods,
treatment of 38 with DABCO provided the tripivaloyloxymethyl methylenediphosphonate
salt 39 in 80-95% yield. The crude DABCO salt 39, was converted to the corresponding
chloride 41 with oxalyl chloride and catalytic DMF in toluene in 90-95% yield. The purity
of the air and moisture sensitive chloride 41 was established by examining the 1H and
31

P NMR spectra of the crude filtrate. The 1H NMR spectrum of 41 showed no trace of

the quaternary DABCO cation 40.36 Tri-POM-methylenediphosphonate isoprenoids 42ac were prepared by combining the corresponding allylic alcohols with chloride 41 in
either dilute toluene or methylene chloride solution containing a three fold excess of
DBU and catalytic DMAP.37 The farnesyl, geranylgeranyl and geranyl isoprenoids 42a-c
were isolated in 40-50% yield after purification by silica gel flash chromatography using
1% TEA added to a hexane:ethyl acetate mobile phase. Significantly lower yields of the
isoprenoids 42a-c were obtained if TEA was omitted from the eluent. Isoprenoids 42a-c
were quite labile and no product was recovered from attempts to purify them using
alumina and fluorosil. Purification by RP-HPLC was unsuccessful due to progressive
decomposition of the tetraesters 42a-c in water or buffer (see below).
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Figure 6-10 Synthesis of POM protected methylene diphosphonates
Reagents and Yields: (a)POMCl, NaI, acetonitrile, reflux (47%).(b) DABCO, acetonitrile,
reflux (90%). (c) (COCl)2, DMF(cat.), rt (96%). (d) ROH, DBU, DMAP(cat.)
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Tetraester stability
Tetraesters 42a-c were water sensitive and can only be stored for a few days at
–20˚

C

without

significant

decomposition. There is evidence that indicates

acyloxymethyl group deprotection occurs chemically at the phosphorous atom in H218O
[238]. If the chemical hydrolysis occurs at the allylic alcohol linkage rather than the
acyloxymethyl group linkage then these compounds may not be able to traverse a cell
membrane as the MDP analog, but rather the parent alcohol. Tetraester stability was
monitored by RP-HPLC for the disappearance of methylene diphosphonates 42a-b and
the concomitant appearance of the parent alcohols (Figure 6-12). (Due to low aqueous
solubility of the tetraesters, decomposition was measured in mixed aqueous/organic
solution. 50 % of tetraester 42a had decomposed after 200 min in water:acetonitrile
(99:1) and 42b decomposed after 500 min in pH=7.4 buffered cell culture
media:acetonitrile (99:1). Under these conditions only 10% of the tetraester 42b was
converted to the parent alcohol 2a after 500 min.
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P NMR spectra of the time

dependent breakdown of methylenediphosphonate 42a in 9:1 water:acetonitrile is
consistent with the formation of the mono-allylic diPOM salt (Figure 6-13). Niemi et al.
prepared and tested the aqueous stability of tetra-, tri- and P,P'-diPOM esters of
dichloromethylenediphosphonate [198]. They found that the tri-POM ester had a half-life
of 78 min in serum and that the insoluble tetra-POM was converted to the P,P'-di- POM
and tri-POM esters in pH 7.4 serum. Together these data suggest that the charged
mono-allylic diPOM salts are the primary decomposition products of tetraesters 42a-c.
Niemi et al have also shown that pivaloyloxymethyl esters of prodrug bisphosphonates
are fully deprotected in the presence of 10% rabbit liver homogenates.
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Figure 6-11 Prodrug Decomposition HPLC
All RP-HPLC data calculated based on relative peak integrals of initial tetraester verses
tetraester or alcohol produced at each time point and fit to exponential curve. a)42a
decomposition in water b) 42b decomposition in cell media. Note that the rate of
decomposition does not match the rate of alcohol formation.
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Figure 6-12 Time dependent decomposition of FTriPOM 9a analyzed by 31P NMR
73 mg (0.1 mmols) of FTriPOM 42a was dissolved in 2 mL of 10% acetonitrile/water. A
31P NMR spectrum was taken at time 0 then again 24 hrs later. Note that the
Tripivaloyloxymethyl ester decomposes into what appears to be the dipivaloyloxy ester,
but from the previous decomposition data in Figure 6-11 it is not from isoprenoid loss
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Discussion
Unnatural analogs as cellular FTase substrate probes
This chapter outlines a general strategy for detecting prenylated proteins using
antibodies directed towards unnatural analogs of FPP 1b bearing unique epitopes that
can be transferred to proteins by FTase. We have found that the farnesol 1a analog
AGOH 5a can be utilized by a cell to modify proteins in an FTase dependent manner
and is not particularly toxic. The structure of the anilinogeranyl moiety is also dissimilar
to any other known cellular components or protein modifications making it an excellent
epitope for selective antibody recognition. In this chapter I have shown that the AGPP
prodrug anilinogeraniol is incorporated into cellular protein in the presence of the
endogenous FPP pool. Previous reports of FPP analog incorporation into cellular
proteins have required lovastatin to block endogenous FPP formation in order to detect
modified proteins. These reagents may be useful for the analysis of FTase mediated
protein modification and cellular events further downstream. The lack of acute cellular
toxicity of AGOH 5a may allow for long-term analysis of proteins modified by FTase by
immunohistochemical methods. These antibodies could be especially useful for
screening the activity and protein targeting of farnesyl transferase inhibitors helping to
identify the targets of these reagents to better understand the role of farnesylated
proteins in cancer biology.
Alternative pro-drugs for FPP analogs
This chapter also described a synthetic methodology to prepare mono-allylic
tripivaloyloxymethyl tetraesters of methylene diphosphonic acid and has shown that
farnesyl methylenediphosphonate is a substrate for protein farnesyl transferase. The
lipophilicity of isoprenoid methylenediphosphonates is significantly increased by
masking the phosphonic acid groups with acyloxymethyl esters. As we increase the
structural diversity of the FTase transferable substrates it is likely that analogs will
eventually be developed that cannot be endogenously diphosphorylated. In the event
that this occurs the tripivaloyloxymethyl methylene diphosphonate masking strategy
may provide a new efficient delivery mechanism for the isoprenoid analogs.
Interestingly, bisphosphonates have proved to be very useful for the treatment of bone
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diseases. The methylene diphosphonate moiety readily chelates Ca2+ ions, and is
directed by the body to bone. It is possible that the isoprenoid methylene
diphosphonates could be directed to bone with a similar mechanism and effect delivery
of such molecules in a whole animal system. However, the stability of the protected
methylene diphosphonates may present a problem for such molecules, and may need
to be improved using alternative cell labile masking approaches.
Experimental
General
All reactions were conducted under dry argon and stirred magnetically, except as
noted. Reaction temperatures refer to the external bath temperatures. Analytical TLC
was performed on pre-coated (0.25 mm) silica gel 60F-245 (Merck) plates and
developed with given solvent conditions. Visualization was achieved by UV irradiation,
iodine or by subjecting the plates to a 15% sulfuric acid, 1% ceric ammonium sulfate,
2% Molybdic anhydride solution followed by heating. Flash chromatography was
performed on Merck silica gel 60 (230-400 mesh ASTM). All chromatography solvents
were purchased from VWR (EM Science-Omnisolv high purity) and used as received.
All reagents were purchased from Aldrich or Alfa Aesar. NMR Spectra were obtained in
CDCl3 (unless otherwise noted) at 200 or 400 MHz. Chemical shifts for the following
deuterated solvents are reported in ppm downfield using the indicated reference peaks:
CDCl3 (CDCl3 internal peak 7.27 ppm for 1H, 77.4 ppm for 13C). ESI-MS were performed
at the University of Kentucky Mass Spectra Facility.
Synthesis
Cysteine Methyl Ester Synthesis (8a-c)
Anilinogeranyl Cysteine Methyl Ester
2-amino-3-(3,7-dimethyl-8-phenylamino-octa-2,6-dienylsulfanyl)-propionic acid methyl
ester 8a
Chloride 7a was prepared from the corresponding alcohol (734mg, 3.0 mmols) in
10 mL of acetonitrile as previously described [159]. A solution of L-cysteine methyl ester
hydrochloride (1.13g, 6.50 mmols) in 20 mL of 7M NH3/MeOH was added to the cooled
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solution (-20º C) of chloride 7a. The reaction initially formed a white precipitate which
quickly disappeared. After 3 hours, the reaction mixture was allowed to warm to room
temperature over one hour. The reaction mixture was partitioned between ether and
water and extracted with ether (3X). The combined organic extracts were then dried
over MgSO4 and solvent was evaporated. Purification by flash chromatography (1:2:8) iPr-OH:EtOAc:Hexane yielded 625 mg (60%) of a yellow oil. Rf=0.32 in 1:2:5 i-Pr-OH:
EtOAc: Hexane 1H NMR (CDCl3, 200 MHz) 7.10 (t, 2H, J=8.0 Hz), 6.63 (t, 1H, J=7.2
Hz), 6.55 (d, 2H, J=8.0 Hz) 5.39 (t, 1H, J=8.0 Hz), 5.23 (t, 1H, J=8Hz), 3.75 (s, 3H), 3.59
(m, 3H), 3.13 (m, 2H), 2.86-2.95 (2d, 1H), 2.65-2.76 (2d, 1H), 2.06-2.19 (m, 4H), 1.63
(s, 3H), 1.62 (s, 3H) 13C NMR (CDCl3, 50 MHz) 174.58, 148.77, 139.42, 132.96, 129.38,
125.75, 120.53, 117.39, 113.08, 54.51, 52.49, 51.96, 39.50, 36.61, 30.14, 26.30, 16.33,
14.98; MS: (ESI, +) (M-H+) 363
Nitroanilinogeranyl cysteine methyl ester
2-amino-3-[3,7-dimethyl-8-(4-nitro-phenylamino)-octa-2,6-dienylsulfanyl]-propionic acid
methyl ester (8b)
Purification by flash chromatography (3:2:5 i-Pr-OH: EtOAc: Hexane) yielded 276 mg
(60%) of a yellow/brown oil. Rf=0.28 (3:2:5 i-Pr-OH: EtOAc: Hexane) 1H NMR (CDCl3,
400 MHz) 8.65 (d, 2H, J=8.0 Hz), 6.52 (d, 2H, J=8.0 Hz), 5.34 (t, 1H, J=12 Hz), 5.20 (t,
1H, J=16 Hz), 3.75 (s, 3H), 3.71 (s, 2H), 3.65 (m, 1H), 3.17 (d, 2H, J=16 Hz), 2.84-2.93
(2d, 1H), 2.64-2.75 (2d, 1H) 2.18 (t, 2H), 2.02(t, 2H) 1.22 (s, 3H), 1.19 (s, 3H) 13C NMR
(CDCl3, 50 MHz) 174.80, 153.92, 139.04, 131.14, 126.60, 120.79, 111.40, 54.48,
52.52, 50.99, 39.25, 36.79, 30.25, 25.98, 25.61, 16.26, 14.92; MS: (ESI, +) (M-H+) 408
Farnesyl Cysteine Methyl Ester
2-amino-3-(3,7,11-trimethyl-dodeca-2,6,10-trienylsulfanyl)-propionic acid methyl ester
(8c)
Into a 100 mL round bottomed flask at 0 °C was added L-Cysteine methyl ester
(1.38 g, 10.2 mmols) in 60 mL of 7M NH3/MeOH. Neat farnesyl bromide (7c) (1.00 g
3.52 mmols) was then added and the solution was stirred at 0° C for four hours. The
reaction mixture was partitioned between ether and water and extracted 3X with ether,
extracts were combined, dried over MgSO4 filtered and evaporated. Purification by flash
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chromatography (1% MeOH:CHCl3) yielded 881 mg (74%) of a clear oil. Rf=0.22 in 5%
MeOH in CHCl3. 1H NMR (CDCl3, 400 MHz): 5.24 (t, 1H, J=8Hz), 5.10 (m, 2H), 3.75 (s,
3H), 3.64 (q, 1H), 3.10-3.25 (m, 2H), 2.86-2.91 (2d, 1H), 2.65-2.71 (2d, 1H), 2.04-2.10
(m, 6H), 2.04(m, 6H) 2.0 (t, 2H), 1.69 (s, 3H), 1.68 (s. 3H), 1.60 (s, 6H);

13

C NMR

(CDCl3, 50 MHz) 174.93, 139.91, 135.71, 131.62, 124.69, 124.11, 120.35, 54.64, 52.35,
39.93, 36.77, 30.15, 26.98, 26.67, 25.86, 17.86, 16.33, 16.21 MS: (ESI, +) (M-H+) 340
General Conditions for Succinylation (9a-c)
Cysteine methyl ester 8c (881 mg, 2.6 mmols) was diluted in 20 mL of 1:1
THF:CH2Cl2 in a 100mL round bottomed flask. Succinic anhydride (280 mg, 2.8 mmols)
was then added and the mixture stirred for 4 hours, followed by evaporation of solvent.
The residue was diluted in ether, washed sequentially with water and brine and then
dried over sodium sulfate and concentrated in vacuo.
Anilinogeranyl cysteine succinate
N-[2-(3,7-dimethyl-8-phenylamino-octa-2,6-dienylsulfanyl)-1-methoxycarbonyl-ethyl]succinamic acid (9a)
Cysteine methyl ester 8a (302 mg, 0.83 mmols) provided 250 mg (65%) of
succinate 9a as a white solid. Purification by flash chromatography (1:4:5: 0.1 i-Pr-OH:
EtOAc: hexane: acetic acid) Rf=0.32 (1:4:5 i-Pr-OH: EtOAc: Hexane.) 1H NMR (CDCl3,
400 MHz) 7.12 (t, 2H, J=8.0 Hz), 6.65 (t, 2H, J=8.0 Hz), 6.58 (t, 2H), 5.34 (t, 1H, J=8.0
Hz) 5.14 (t, 1H, J=8.0 Hz), 4.75 (m, 1H), 3.72 (s, 3H), 3.60 (s, 2H), 3.11 (m, 2H), 2.792.93 (m, 2H), 2.65 (t, 2H, J=8.0 Hz), 2.52 (t, 2H, J=8 Hz), 2.11 (t, 2H, J=8 Hz) 2.02 (t,
2H, J=8 Hz), 1.63 (s, 3H), 1.62 (s, 3H);
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C NMR (CDCl3, 50 MHz) 176.95, 171.84,

171.55, 148.48, 139.80, 132.79, 129.34, 125.86, 120.06, 117.68, 113.36, 52.91, 52.13,
39.42, 33.55, 30.69, 30.19, 29.53, 28.92, 26.22, 16.25, 14.96 MS: (ESI, +) (M-H+) 463
Nitroanilinogeranyl cysteine succinate
N-[2-[3,7-dimethyl-8(4-nitro-phenylamino)-octa-2,6-dienylsulfanyl]-1-methoxycarbonylethyl]-succinamic acid (9b)
Cysteine methyl ester 8b (339 mg, 0.83 mmols) provided 204 mg (57%) of succinate 9b
as a yellow solid. Purification by flash chromatography (1:4:5:0.1) i-Pr-OH: EtOAc:
hexane: acetic acid) Rf=0.3 (3:2:5) i-Pr-OH: EtOAc: hexane 1HNMR (CDCl3, 200 MHz):
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8.03 (d, 2H, J=8.0 Hz), 6.49 (d, 3H), 5.30 (t, 1H, J=8 Hz), 5.11 (t, 1H, J=8 Hz), 4.75 (m,
1H), 3.77 (s, 3H), 3.74 (s, 2H), 3.10 (m, 2H), 2.81-3.02 (m, 2H), 2.57-2.76 (m, 4H), 2.062.19 (m, 4H), 1.67 (s, 3H), 1.64 (s, 3H); 13C NMR (CDCl3, 50 MHz): 176.20, 172.00,
171.50, 153.91, 139.60, 131.17, 126.83, 126.61, 120.39, 111.60, 52.92, 52.33, 51.14,
39.20, 33.65, 30.70, 30.28, 29.42, 26.01, 16.18, 14.80 MS: (ESI, +) (M-H+) 508
Farnesyl cysteine succinate
N-[1-methoxycarbonyl-2-(3,7,11-trimethyl-dodeca-2,6,10-trienylsulfanyl)-ethyl]succinamic acid (9c)
Cysteine methyl ester 8c (881 mg, 2.6 mmols) provided 937 mg (82%) of
succinate 9c as a white solid. Purification by flash chromatography (1:2:7 i-Pr-OH:
EtOAc: hexane) 1H NMR (CDCl3, 400 MHz) 10.55 (bs, 1H), 6.72 (d, 1H, J=8 Hz), 5.17
(t, 1H, J=8 Hz), 5.07 (m, 2H), 4.75-4.80 (q, 1H), 3.73-3.73 (s, 3H), 3.13 (m, 2H), 2.902.94 (m, 1H), 2.80-2.85 (m, 1H), 2.69 (t, 2H), 2.57 (t, 2H), 1.92-2.08 (m, 8H), 1.65 (s,
3H), 1.64 (s, 3H), 1.57 (s, 6H);

13

C NMR (CDCl3, 100 MHz) 177.40, 171.90, 171.64,

140.17, 135.44, 131.38, 124.44, 124.38, n123.85, 123.78, 119.60, 119.55, 52.80, 52.75,
52.01, 51.97, 39.79, 39.72, 33.28, 31.67, 30.55, 29.96, 29.39, 26.80, 26.51, 25.79,
22.74, 17.78, 16.19, 16.10; MS: (ESI, +) (M-H+) 438
General Conditions for Activated Ester Formation (10a-c)
Succinamic acid 8c (59.6 mg, 0.126 mmols) was dissolved in 10mL of dry
acetonitrile in a 100 mL round-bottomed flask. Carbonyldiimidazole (26.4 mg 0.163
mmols) was then added and the mixture was allowed to stir for 5 minutes. Nhydroxyphthalimide (26.4 mg, 0.163 mmols) was added and the solution was stirred for
1.5 hours. The solvent was then evaporated.
Anilinogeranyl cysteine succinyl phthalimide
N-[2-(3,7-dimethyl-8-phenylamino-octa-2,6-diensulfanyl)-1-methoxycarbonylethyl]-succinamic acid 1,3-dioxo-1,2-;dihydro-isoindol-2-yl ester (10a)
Succinate 9a (30 mg, 0.07 mmols) provided 25 mg (63%) of phthalimide 10a as a
yellow/brown oil. Purified by column chromatography (CHCl3). Rf=0.28 (1:1)
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Hexane:EtOAc 1H NMR (CDCl3, 400 MHz): 7.88 (q, 2H), 7.78 (q, 2H), 7.16 (t, 2H), 6.68
(t, 1H), 6.60 (d, 2H), 6.37 (d, 1H), 5.37 (t, 1H), 5.17 (t, 1H), 4.83 (m, 1H), 3.76 (s, 3H),
3.63 (s, 2H), 3.15 (m, 2H), 3.06 (t, 2H), 2.92 (m, 2H), 2.71 (t, 2H), 2.03-2.18 (m, 4H),
1.67 (s, 3H), 1.65 (s, 3H);

13

C NMR (CDCl3, 50 MHz): 171.43, 169.94, 169.12, 161.93,

148.70, 139.79, 134.06, 132.89, 129.34, 125.72, 124.19, 120.08, 117.38, 113.07, 52.86,
52.10, 51.97, 39.43, 33.64, 30.63, 30.21, 26.78, 26.25, 16.26, 14.94 MS: (ESI, +) (MH+) 608
Nitroanilinogeranyl cysteine succinyl phthalimide
N-[1-[3,7-Dimethyl-8-(4-nitro-phenylamino)-octa-2,6-diensulfanyl]-1-methoxycarbonylethyl]-succinamic acid 1,3-dioxo-1,3-dihydro-isoindol-2-yl ester (10b)
Succinate 9b (38 mg, 0.08 mmols) provided 41 mg (85%) of phthalimide 10b as a
yellow oil. Purified by column chromatography (CHCl3). Rf=0.12 (1:1) Hexane:EtOAc
1H NMR (CDCl3, 400 MHz) 8.02 (d, 2H), 7.84 (q, 2H), 7.75 (q, 2H), 6.54 (d, 2H), 6.36
(d, 1H), 5.30 (t, 1H), 5.11 (t, 1H), 4.78 (q, 1H), 3.73 (s, 3H), 3.70 (s, 2H), 3.10 (t, 2H),
3.02 (t, 2H), 2.80-2.98 (m, 2H), 2.69 (t, 2H), 2.11 (m, 2H), 2.00 (t, 2H), 1.63 (s, 3H), 1.59
(s, 3H); 13C NMR (CDCl3 100 MHz) 171.36, 169.17, 161.94, 153.85, 146.06, 139.44,
138.02, 135.02, 131.06, 129.03, 126.60, 126.56, 124.21, 120.32, 111.40, 52.95, 52.24,
51.02, 39.21, 33.60, 30.62, 30.24, 27.02, 26.75, 26.00, 16.22, 14.87
Farnesyl cysteine succinyl phthalimide
N-[1-methoxycarbonyl-2-(3,7,11-trimethyl-dodeca-2,6,10-trienylsulfanyl)-ethyl]succinamic acid 1,3-dioxo-1,2-dihydro-isoindol-2-yl ester (10c)
Succinate 9c (60 mg, 0.14 mmols) provided 80 mg (58%) of phthalimide 10c as a
brown oil. Purified by column chromatography (CHCl3). Rf=0.3 (1:1) Hexane:EtOAc
1

H NMR (CDCl3, 400 MHz) 7.88 (q, 2H), 7.79 (q, 2H), 6.38 (d, 1H), 5.20(t, 1H),

5.09 (t, 2H), 4.82 (m, 1H), 3.76 (s, 3H), 3.74 (s, 2H), 3.11-3.22 (m, 2H), 3.07 (t, 2H),
2.86-3.00 (m, 2H), 2.74 (t, 2H), 1.95-2.10 (m, 8H), 1.68 (s, 3H), 1.66 (s, 3H), 1.60 (s,
6H);

13

C NMR (CDCl3, 100 MHz) 171.44, 169.90, 169.93, 161.91, 140.29, 135.57,

134.96, 131.53, 129.06, 124.50, 124.19, 123.90, 119.64, 52.85, 52.00, 39.88, 39.81,
33.54, 30.62, 30.14, 29.03, 28.23, 26.90, 26.75, 26.59, 25.90, 17.89, 16.31, 16.21.
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General Conditions for Benzyl amine Coupling (11a-c)
Phthalimide 10c (47.2 mg, 0.08 mmols) was dissolved in 1 mL of acetonitrile and
5 mL of 5% NaHCO3 buffer pH=9 in a 25 mL RB flask. Benzylamine (17.3 mg, 0.16
mmols) was then added and the reaction was allowed to stir for 1.5 hours at room
temperature. 10 mL of water was added and organics were extracted with ether (3X),
dried over MgSO4, and organic solvent evaporated.
Anilinogeranyl benzyl amine
2-(3-Benzylcarbamoyl-propionylamino)-3-(3,7-dimethyl-8-phenylamino-octa-2,6Dienylsulfanyl)-propionic acid methyl ester (11a)
Phthalimide 10a (133 mg, 0.22 mmols) provided 59 mg (48%) of amide 11a as a
white solid. Purification by column chromatography (3:7) Hexane: EtOAc. 1H NMR
(CDCl3, 400 MHz) 7.21-7.31 (m, 5H), 7.12 (t, 2H), 6.55-6.66 (m, 4H), 6.23 (bt, 1H), 5.34
(t, 1H), 5.14 (t, 1H), 4.71 (q, 1H), 4.38 (d, 2H, J=6 Hz), 3.70 (s, 3H), 3.59 (bs, 2H), 3.10
(m, 2H), 2.76-2.91 (m, 2H), 2.50-2.61 (m, 4H), 1.99-2.13 (m, 4H), 1.63 (s, 3H), 1.62 (s,
3H)

13

C NMR (CDCl3, 50 MHz): 172.23, 171.94, 171.46, 148.63, 139.77, 138.41,

132.84, 129.42, 129.34, 129.19, 128.94, 128.87, 128.08, 127.93, 127.73, 125.74,
120.08, 117.411, 113.10, 52.82, 52.09, 51.963, 43.85, 39.45, 33.50, 31.71, 31.66,
30.12, 26.25, 16.28, 14.95 MS: (ESI, +) (M-H+) 552
Nitroanilinogeranyl benzyl amine
2-(3-Benzylcarbamoyl-propionylamino)-3-[3,7-dimethyl-8(4-nitro-phenylamino)-octa2,6-dienylsulfanyl]-propionic acid methyl ester (11b)
Phthalimide 10b (13 mg, 0.02mmols) provided 9 mg (76%) of amide 11b as a yellow
solid. Purification by column chromatography (3:4) Hexane: EtOAc. 1HNMR (CDCl3,
400 MHz) 8.01 (d, 2H, J=9.2 Hz), 7.20-7.29 (m, 5H), 6.69 (d, 1H, J=7.6 Hz), 6.48 (d, 2H,
J=9.2 Hz), 6.26 (t, 1H), 5.30 (t, 1H), 5.12 (t, 1H), 4.96 (t, 1H), 4.68-4.72 (m, 1H), 4.38 (d,
2H, J=5.6 Hz), 3.70 (s, 3H), 3.68 (d, 2H, J=5.6 Hz), 3.10 (m, 2H), 2.77-2.91 (m, 2H),
2.51-2.62 (m, 4H), 2.10-2.16 (t, 2H), 2.00-2.03 (t, 2H), 1.62 (s, 3H), 1.60 (s, 3H); 13C
NMR (CDCl3, 50 MHz): 172.22, 171.92, 171.41, 153.89, 139.39, 138.33, 131.04,
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128.88, 127.91, 127.67, 126.56, 120.33, 111.38, 52.86, 52.21, 50.99, 43.88, 39.22,
33.59, 31.67, 31.65, 30.22, 26.00, 16.24, 14.87 MS: (ESI, +) (M-H+) 597
Farnesyl Benzyl amine
2-(3-Benzylcarbamoyl-propionylamino)-3-(3,7,11-trimethyl-dodeca-2,6,10trienylsulfanyl)propionic acid methyl ester (11c)
Phthalimide 11c (47 mg, 0.08mmols) provided 42 mg (67%) of amide 11c as a
white solid. Purification by column chromatography (4:6) Hexane: EtOAc. 1H NMR
(CDCl3, 400 MHz) 7.25-7.34 (m, 5H), 6.623 (d, 1H), 6.28 (t, 1H), 5.20 (t, 1H), 5.09 (t,
2H), 4.75 (q, 1H), 4.44 (d, 2H), 3.75 (s, 3H), 3.09-3.22 (m, 2H), 2.81-2.96 (m, 2H), 2.552.67 (m, 4H), 1.96-2.13 (m, 8H), 1.68 (s, 3H), 1.67 (s, 3H), 1.60 (s, 6H);

13

C NMR

(CDCl3, 50 MHz): 172.21, 171.94, 171.47, 140.29, 138.44, 135.60, 131.54, 128.87,
127.94, 127.64, 124.53, 123.93, 119.72, 52.79, 52.07, 43.89, 39.92, 39.84, 33.47,
31.77, 31.73, 30.12, 26.95, 26.66, 25.91, 17.90, 16.36, 16.23; MS: (ESI, +) (M-H+) 529
General Conditions for Protein Coupling (12a-c and 13a-c)
Phthalimido esters (10a-c) were dissolved in 6 mL of 1:5 acetonitrile and 5%
NaHCO3 in a 100 mL pear-shaped flask. BSA (13) (0.1 mL of 10 mg/mL solution in
phosphate buffered saline (PBS) pH 7.2) or KLH protein (12) (3 mL of 10 mg/mL
solution in PBS pH 7.2) was added and stirred vigorously for 2 hours or until analysis by
TLC in 1:1 hexane:EtOAc showed no residual activated phthalimide ester spot. The
solution was dialyzed overnight in 20% DMSO, PBS pH 7.5 then PBS (3 X 1L, 6 hrs
each).
Tetra(pivaloyloxymethyl) Methylenediphosphonate (38)
A mixture of tetramethyl methylenediphosphonate 37 (3.77g, 17.2 mmols)
sodium iodide (11.1g, 73.7 mmols) and pivaloyloxymethyl chloride (16.1g, 106 mmols)
were heated at reflux overnight in acetonitrile. Solvents were evaporated under reduced
pressure and the residue was partitioned between 100 mL of ether and water. The
organics were washed with water (2X) and 5% NaHCO3 (2X) and dried over Na2SO4.
The ether was evaporated under reduced pressure and the residue dissolved in a
minimal volume of hexanes and placed at 0° C overnight. Crystals were collected and
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dried to constant weight yielding 4.68g (46%) of 38. 1HNMR 5.67 (m, 8H), 2.57 (t, 2H,
J=21.6 Hz), 1.20 (s, 36H)

13

CNMR 177.04, 82.18, 38.93, 27.08 (t, J=143 Hz)

31

PNMR

19.13 (ESI-MS)M-Na+ 655
Tri(pivaloyloxymethyl) Methylenediphosphonate
1,4-(N-(pivaloyloxymethyl)) diazonium-bicyclo[2.2.2]-octane salt (39)
TetraPOM 38 (10.0g, 15.8 mmols) and DABCO (1.70g, 15.2 mmols) in 200 mL of
acetonitrile were heated at reflux overnight after which solvent was evaporated under
reduced pressure. The residue was diluted with 100 mL of ether and washed 4X with
water. The collected aqueous extracts were evaporated under reduced pressure and
the residue taken up in dry toluene and the solvent evaporated under reduced pressure
(3X) leaving 9.59g of triPOM salt 39 as a white oily solid (84.2% yield relative to
DABCO). 1H NMR 5.34 (m, 8H), 3.37 (t, 6H, J=7.2 Hz) 3.00 (t, 6H, J=7.2 Hz), 2.17 (t,
2H, J=19.8 Hz) 1.00 (s, 9H), 0.94 (s, 18H), 0.92 (s, 9H)

13

C NMR 177.71, 177.09,

175.76, 83.34, 82.11, 80.90, 50.67, 45.17, 44.94, 39.27, 38.85, 27.54, 27.22, 22.81

31

P

NMR 26.77 (d, 1P, J=6.23 Hz) 7.92 (d, 1P, J=6.12 Hz) (ESI-MS)M- 517
Tri(pivaloyloxymethyl) methylenediphosphonyl Chloride (41)
TriPOM salt 39 (546 mg, 0.73 mmols) was dissolved in 20 mL of dry acetonitrile
and the solvent evaporated under reduced pressure (3X) followed by the addition of 10
mL dry toluene, 40 µL anhydrous DMF and 0.3 mL oxalyl chloride (3.3 mmols). A white
precipitate formed immediately with evolution of heat and the reaction was stirred at rt
for 45 min. Solids were removed by filtration through a pad of Na2SO4 which was
washed with 5 mL of dry toluene. The combined organics were immediately evaporated
under reduced pressure to give a pale yellow oil used without further purification (377
mg, 96%.) 1H NMR 5.64-5.85 (m, 6H) 3.03 (t, 2H, J=20 Hz) 1.23 (s, 27H)

31

P NMR

28.74 (d, 1P, J=10.95 Hz), 15.74 (d, 1P, J=10.95Hz)
General synthesis of Tri-POM esters (42a-c)
Farnesyl tri(pivaloyloxymethyl) methylenediphosphonate (42a)
Chloride 41 (697 mg, 1.3 mmols) diluted in 5 ml of dry toluene or anhydrous
methylene chloride was added drop wise to a cooled (-20° C), stirred solution of
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farnesol 1a (94mg, 0.42 mmols) DBU (198 mg, 1.3 mmols) and DMAP (5 mg, 0.04
mmols) in 10 mL of dry toluene. Stirring was continued for 2 hours followed by the
addition of 50 ml of ether. The organic layer was washed 2X each with 10 ml of 0.1N
HCl, water and freshly prepared 5% NaHCO3, then dried over Na2SO4 and evaporated
under reduced pressure. Farnesyl ester 42a was obtained in 40% yield (121 mg) after
silica gel flash chromatography with 7:3 Hexane:EtOAc + 1% triethylamine. 1H NMR
5.61-5.71 (m, 6H) 5.35 (t, 1H), 5.04 (t, 2H), 4.62 (m, 2H), 2.57 (t, 2H, J=21.6 Hz), 1.9013

2.08 (m, 8H), 1.67 (s, 3H), 1.63 (s, 3H), 1.55 (s, 6H), 1.16 (s, 27H)

C NMR 177.09,

177.01, 143.80, 135.80, 131.55, 124.55, 124.36, 123,74, 123.55, 118.57, 82.40, 63.59,
39.87, 38.91, 27.02 31P NMR 20.02 (d, 1P, J=7.29 Hz), 19.30 (d, 1P, J=6.16 Hz).
Geranylgeranyl tri(pivaloyloxymethyl) methylenediphosphonate (42b)
Geranylgeraniol 2a (93 mg, 0.32 mmols) provided 124 mg of 9b (48%). 1H NMR
5.59-5.69 (m, 6H), 5.33 (t, 1H, J=7.2 Hz), 5.01-5.05 (t, 3H), 4.60 (m, 2H), 2.55 (t, 2H,
J=21.6 Hz), 1.90-2.03 (m, 12H), 1.65 (s, 3H), 1.61 (s, 3H), 1.53 (s, 9H), 1.17 (s, 27H)
13

C NMR 177.08, 177.01, 143.81, 135.83, 135.18, 131.46, 124.41, 124.24, 123.73,

123.55, 118.54, 82.46, 82.13, 63.65, 39.90, 38.91, 27.07, 16.17;

31

P NMR 20.04 (d, 1P,

J=7.29 Hz), 19.31 (d, 1P, J=7.45 Hz)
Geranyl tri(pivaloyloxymethyl) methylenediphosphonate (42c)
Geraniol (28 mg, 0.18 mmols) provided 62 mg of 42c (55%).

1

H NMR 5.61-5.71

(m, 6H), 5.35 (t, 1H, J=7.2 Hz) 5.03 (t, 1H, J=6.8 Hz), 4.60 (m, 2H), 2.57 (t, 2H, J=22
Hz), 1.98-2.06 (m, 4H), 1.67 (s, 3H), 1.64 (s, 3H), 1.56 (s, 3H), 1.19 (s, 27H);

13

C NMR

177.06, 176.99, 143.65, 132.14, 124.03, 123.48, 118.65, 82.21, 63.68, 39.70, 38.91,
26.97, 16.74; 31P NMR 20.00 (d, 1P, J=7.29 Hz), 19.27 (d, 1P, J=8.43 Hz)
Antibody Generation and Characterization
Polyclonal antibody production
Hapten protein conjugates 12a-c were used to immunize rabbits subcutaneously
by emulsifying 1.5 mg of each conjugate with Freund’s complete adjuvant. This was
followed by six secondary boosters of the same dose with incomplete Freund adjuvant
at intervals of 14 days. The rabbits were bled 10 days after each boost. Blood was
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allowed to coagulate overnight in 50 mL centrifuge tubes and sera was collected and
stored at 0 º C.
ELISA Screening
ELISA plates (96-well polystyrene) were coated with 100 up per well of BSA
conjugates or BSA (1 ug/mL) in PBS (pH=7.6) and incubated for 1 hr at 37 º C. The
plates were then washed thoroughly with 10% Tween in PBS buffer (PT) (pH=7.4). 150
up of serum diluted 1:100 in PT buffer containing casein (PCT) was added and diluted
1:3 down the plate, then incubated 1 hr at 37 º C. The plates were washed with PT
buffer and 100 up of secondary antibody (1:10,000) was added to each well. The plates
were incubated 1 hr at 37 º C and again washed. 100 up of p-nitrophenylphosphate was
added to each well (2 pills in 10 ml of Tris buffer ph=9.5). After 20 minutes color began
to develop and absorbance was read at 405 nm.
FTase Protein Substrate Modification
2 µg of recombinant bacterially expressed RDJ2 [200] was incubated with 20 µM
AGPP 5b or FPP 1b or the other analogs and 5 µg FTase in 50 µL of Tris-HCl buffer
(pH=7.4) The reactions were incubated for 30 min at 37 º C, boiled with SDS and PAGE
performed using the protein concentrations indicated on the blots.
Cell Based Antibody Analysis
AGOH Labeling and FTI inhibition of label in HEK-293 cells
Plates were coated with poly-L-Lysine and seeded with HEK-cells in Dulbecco’s
modified Eagle’s medium with 5% fetal bovine serum. Cells were incubated in medium
containing 30 µM lovastatin and 10 µM GGOH for 24 hrs. The media was poured off
then replenished with media without lovastatin and GGOH and were treated with 3 µM
FTI-277 (calbiochem), 20 µM GGTI-2147 (calbiochem) or no inhibitor and incubated at
37° C for 1 hour. DMSO as a vehicle, or 100 µM AGOH 5a was then added and
incubated at 37° C for two hours. Medium was then removed and cells were extracted
into 300 µL PBS containing Protease Inhibitor cocktail set 1 (Calbiochem). The samples
were sonicated and centrifuged for 5 minutes. The supernatant was removed and used
for western blotting.
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AGOH incorporation into unblocked cells
Plates were coated with poly-L-Lysine and seeded with HEK-cells in Dulbecco’s
modified Eagle’s medium with 5% fetal bovine serum. The cells were then treated with
DMSO as a vehicle, or 30 µM AGOH 5a and incubated at 37° C for the indicated time
points. Medium was then removed and cells were extracted into 300 µL PBS containing
Protease Inhibitor cocktail set 1 (Calbiochem). The samples were sonicated and
centrifuged for 5 minutes. The supernatant was removed and used for western blotting.
Western Blot Analysis
Cells were harvested by scraping into 300 µl phosphate buffered saline
containing protease inhibitor cocktail set 1 (calbiochem), followed by sonication on ice.
Protein concentration was determined using a Bradford reagent kit (Pierce). The
proteins from the FTase reaction mixtures or cell lysates were then separated using
12% SDS-polyacrylamide gels followed by transfer to nitrocellulose membranes. The
membranes were incubated in blocking buffer PCT (see ELISA) for one hour at room
temperature, after which the following sequential steps were used: incubation with antiAG 1:1000 to 1:10,000 in PCT for one hour; 3X 15 minute washes with vigorous
shaking in PT buffer (see ELISA); incubation at room temperature one hour with goat
anti-rabbit horseradish peroxidase-conjugated secondary antibody (Zymed) at a dilution
of 1:20,000 in PCT buffer; and four 15 minute washes with PT buffer. The membranes
were then subjected to enhanced chemiluminescence detection by incubation in 20 mL
of detection buffer (Pierce Super Signal) for one minute.
Cell Permeant analog Stability
The time dependent decomposition of 9a and 9b was carried out by analyzing
the disappearance of the tetraesters and the appearance of the parent alcohols 8a and
8b by RP-HPLC analysis. An appropriate amount of either 9a (7 mg, 0.01 mmols) or 9b
(8 mg, 0.01 mmols) was dissolved in 10 µL of acetonitrile and diluted into 990 µL water
or 990 µL serum (DMEM + 10% fetal calf serum) adjusted to pH 7.4. The solutions were
kept at room temperature. At suitable intervals 10 µL aliquots were withdrawn with the
autoinjector and analyzed by RP-HPLC. Each sample was eluted with a gradient of
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water to acetonitrile (9a 70% acetonitrile/water → 100% acetonitrile over 20 min and 9b
80% acetonitrile/water → 100% acetonitrile over 20 min.) Alternatively the analog was
placed in dissolved in D2O and the decomposition was monitored by 31P-NMR.
This work has been published under the following citations.
1. Troutman JM, Chehade KA, Kiegiel K, Andres DA, Spielmann HP. “Synthesis of
acyloxymethyl ester prodrugs of the transferable protein farnesyl transferase substrate
farnesyl methylenediphosphonate.” Bioorg Med Chem Lett. 2004 Oct 4;14(19):4979-82
2. Troutman JM, Roberts MJ, Andres DA, Spielmann HP. “Tools to analyze protein
farnesylation in cells.” Bioconjug Chem. 2005 Sep-Oct;16(5):1209-17
Credits:
1. Post-doctoral researcher Michael J. Roberts was responsible for cell labeling studies.
2. Former graduate student Kareem A. H. Chehade was responsible for measuring the
farnesyl methylene diphosphonate kinetics
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CHAPTER 7 TRANSFERABLE GERANYLGERANYL TRANSFERASE I SUBSTRATE
ANALOUGES
Introduction
The major mechanism by which GGTaseI differentiates between a canonical
FTase target Ca1a2X box and a canonical GGTaseI substrate Ca1a2X sequence is the
composition of the a2-X binding site of the enzyme [49]. In GGTaseI the a2 binding site
is made up of Thr49β, Phe53β, Leu320β, the third and forth GGPP 1 isoprenes and the
target X residue. The X residue binding site is made up of the fourth GGPP isoprene the
a2 residue, Thr49β, His121β, Ala123β, and Phe174β. Interestingly, in the FTase Ca1a2X
binding site the third (terminal) isoprene of FPP 2 interacts directly with only the a2
residue of the target Ca1a2X motif.
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Analogs of FPP with an aniline moiety replacing the third isoprene of FPP have
been extremely useful in probing the endogenous activity of proteins modified by FTase
and in understanding the selectivity of the FTase enzyme. 8-anilinogeranyl diphosphate
(AGPP 3) is transferable by FTase with kinetics nearly identical to those of FPP [159,
161]. FTase reactions with AGPP are also highly selective for canonical FTase
substrates over canonical GGTaseI substrates.(see Chapter 3) Often analogs as
substrates for FTase verses GGTaseI are designed by extending the FPP analog
isoprene chain by one isoprenoid to make GGTaseI substrates analogs [166, 239]. In
this chapter, I will describe how we have utilized this strategy with AGPP 3 and a pNO2
aniline analog of AGPP in an attempt to design new transferable GGTaseI substrate
analogs. We have found that anilinofarnesyl diphosphate (AFPP 4a) and pNO2
anilinofarnesyl diphosphate (NAFPP 4b) analogs can be prepared in a manner
analogous to the method for preparing the AGPP series of analogs. Both of these
analogs are substrates for GGTaseI and a CVIL GGTaseI Ca1a2X peptide, and AFPP
appears to compete very well with the natural substrate of GGTaseI, GGPP. We have
also found that antibodies designed to detect anilinogeranylated proteins are also useful
for the detection of anilinofarnesylated proteins. These results suggest that the AFPP
analogs are substrates and can act as specific probes for the activity of GGTaseI in a
way analogous to AGPP for FTase.
Results
Synthesis of geranylgeranyl diphosphate analogs with substituted aniline moiety
The synthetic route shown in figure 7-2 is analogous to the synthesis of AGPP
with farnesyl acetate 5 as the starting material rather than geranyl acetate. The SeO2
oxidation of farnesyl acetate 5 was significantly less efficient than geranyl acetate
oxidation giving maximum yields of 20%. The yield of the reaction was increased slightly
(30%) using ethereal co-solvents apparently stabilizing the transition state with SeO2.
Altering the hydroxyl protecting group had no effect on the overall yield of the reaction
and no further attempts to optimize the reaction were attempted. Following farnesyl
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acetate oxidation to the α,β-unsaturated aldehyde 6 the aniline moiety was incorporated
by reductive amination followed by saponification to give the alcohols 9a (AFOH) and
9b (NAFOH). The alcohols were then halogenated and converted to diphosphate as
previously described for the AGPP series of FPP analogs giving AFPP 4a and NAFPP
4b.
Affects of altering Analogue Structure on Peptide reactivity
In order to determine if the anilinofarnesyl diphosphate analogs were substrates
for GGTaseI we screened the transfer rate of the analogues with two dansylatedGCaaX peptide substrates utilizing a continuous fluorescence assay. The peptides
corresponded to a canonical GGTaseI substrate peptide (CVIL) and a peptide that is a
substrate for both FTase and GGTaseI (CVIM). We confirmed that GGPP was a
substrate with the CVIM and CVIL peptides (Figure 7-3). We found that AFPP was a
substrate for GGTaseI and reacted with a rate similar to that of GGPP with both the
CVIL and CVIM peptides. However, NAFPP was a substrate only with the CVIL peptide
and no reaction was observed with the CVIM peptide. In addition, AFPP and NAFPP
were not substrates for FTase with an N-dansyl-GCVIM peptide as the isoprenoid
acceptor.
We have previously observed in the FTase reaction that there are three peptide
concentration dependent binding states in the steady-state mechanism of FTase. To
determine if the same was true for GGTaseI we measured initial velocities of a wide
range of CVIL peptide concentrations with each of the analogues. We found that the
third peptide binding state was somewhat apparent in the GGPP reaction. However, we
were unable to reach peptide concentrations sufficient to observe a third peptide
concentration dependent binding state with the AFPP and NAFPP analogues (Figure 74). In addition, we did not observe peptide inhibition with the NAFPP analogue at the
concentrations of peptide analyzed.
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Figure 7-2 synthesis of AFPP and NAFPP
Reagents: (a) SeO2 DCM 2hrs 0º C; (b) aniline 8a-b HOAc, NaBH(OAc)3, DCE, rt; (c)
K2CO3 MeOH/Water; (d) PPh3Cl2, MeCN, rt; 10 minutes ((nBu)4N)3HP2O7, MeCN
overnight.
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Figure 7-3 Analog reactivity with CVIL and CVIM peptides and GGTaseI catalyst
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Reactions were initiated by addition of GGTaseI. Only the compounds shown below
could be transferred to the peptides. No reaction was detected with any of the analogs
with CVLS, CVIM or CAHQ peptides as the isoprenoid acceptor and GGTaseI as the
catalyst. Rates of the reactions are reported in pmols/sec and are based on the
fluorescence enhancement and RP-HPLC analysis of reactions containing 3µM peptide,
12 µM analog and 10 nM GGTaseI. Reactions were run in 96 well plate format. All
reactions were performed in Tris-HCl buffer (pH=7.4) plus detergent and reducing
agent. Note that AFPP is the only analog that also reacts with the CVIM peptide.

Figure 7-4 GGTaseI Steady-State reaction kinetics

GGTaseI Steady-State reaction with a) GGPP b) AFPP c) NAFPP and CVIL. Rates are
reported as rate per unit enzyme. Note the increase in apparent Ki with each analogue.
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In order to determine if the AFPP analogues altered the CVIL peptide reactivity in
the GGTaseI reaction we measured the apparent kcat, Kmpeptide and kcat /Kmpeptide with
the analogs, GGPP and FPP (Table 7-1). We found that the catalytic efficiency of the
CVIL peptide GGTaseI reactions was lowest with FPP and highest with the natural
substrate GGPP. The NAFPP analogue increased the Kmpeptide and kcat with the CVIL
peptide. Interestingly, the catalytic efficiency with NAFPP was five times and three times
lower than the efficiency with GGPP and AFPP respectively. However, the efficiency of
the GGTaseI reaction with NAFPP and the CVIL peptide was four times higher than the
efficiency of GGTaseI with FPP as the donor substrate. Because there was only a small
contribution of a third peptide binding state we also fit the data to the substrate inhibition
equation given in equation 1. We found that the Ki of the CaaX peptide was significantly
higher with AFPP as the substrate therefore peptide inhibition was much more potent
with GGPP as the substrate (Table 7-2).
When the GGTaseI target peptide was replaced with a CVIM peptide we found
that only GGPP and AFPP were reacted efficiently. Both AFPP and GGPP catalytic
efficiency were on the same order as with the CVIL peptide, but the value was reduced
3.6 and 3.2 fold respectively. Surprisingly, no reaction was observed with the NAFPP
analogue, yet even FPP was utilized to some extent by the enzyme. These results
suggest that the NAFPP analogue reduces the ability of GGTaseI to catalyze the
modification of alternative peptide substrates. Interestingly, the reactivity of AFPP with
the different peptide substrates was similar to the reactivity of GGPP only the catalytic
efficiency was slightly reduced. In the case of CVIL as the isoprenoid acceptor the
catalytic efficiency was reduced by an increase in the Kmpeptide while with CVIM both the
kcat and Kmpeptide were increased.
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Table 7-1 GGTaseI reaction kinetics
Steady-state kinetics with the GGTaseI enzyme and substrate analogs.
All reactions were performed in Tris-HCl buffer (pH=7.4) plus detergent and reducing
agent with varying concentrations of the peptide,12 µM analog, and 10 nM GGTaseI.
Note that the transfer kinetics of AFPP are similar to GGPP with CVIL but not CVIM
cmpd

#

peptide

F
GG
AF
NAF
F
GG
AF
NAF

2
1
4a
4b
2
1
4a
4b

CVIL
CVIL
CVIL
CVIL
CVIM
CVIM
CVIM
CVIM

KmCaaX
(µM)
6±1
0.31 ± 0.05
0.65 ± 0.06
30 ± 5
4±2
2.7 ± 0.2
6.4 ± 0.4
NR

kcat
(s-1)
0.034 ± 0.005
0.044 ± 0.002
0.043 ± 0.002
0.64 ± 0.08
<0.001
0.086 ± 0.002
0.127 ± 0.004
NR
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kcat/ KmCaaX
(µM-1• s-1)
0.0053 ± 0.0002
0.091 ± 0.005
0.054 ± 0.002
0.020 ± 0.001
<0.0003
0.025 ± 0.001
0.017 ± 0.001
NR

Table 7-2 Substrate inhibition data fit with AFPP and GGPP
cmpd

#

peptide

GG
AF

1
4a

CVIL
CVIL

KmCaaX
(µM)
2.4 ± 0.9
1.2 ± 0.2

kcat
(s-1)
0.19 ± 0.06
0.066 ± 0.008
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KiCaaX
(µM)
0.5 ± 0.2
5±1

kcat/ KmCaaX
(µM-1• s-1)
0.08 ± 0.04
0.06 ± 0.01

The steady-state kinetic results suggest that the CVIL peptide is much more
readily modified than the CVIM peptide. To test this we mixed the CVIL and CVIM
peptides 1:1 in competition reactions with excess GGPP or AFPP, and analyzed the
resulting products by HPLC. We found that the CVIL to CVIM product ratios were 6:1
and 5:1 with AFPP and GGPP respectively (Figure 7-5). The CVIL to CVIM product ratio
was slightly higher than expected based on the selectivity factor kcat/Kmpeptide and
significantly lower than the expected ratio based on the Kmpeptide alone. These results
were consistent with the model proposed previously for the substrate association
pathway in FTase giving figure 7-6 as the likely kinetic mechanism for GGTaseI.
AFPP competes effectively for CVIL modification
AGPP is competitive with FPP for FTase catalyzed modification of proteins both
in vitro and in cell culture [159, 209]. The relative efficiency of peptide modification by an
alternative isoprenoid substrate over the natural substrate can be determined from the
ratio of products formed in competition experiments between the transferable
analogues, the natural substrate and peptide. We measured products ratios from
competition reactions between transferable AFPP analogues and GGPP for
modification of the Dns-GCVIL peptide by HPLC separation of the products and
integration of the dansyl peak absorbance. Reaction of 1:1 ratios of AFPP and GGPP
with limiting CVIL peptide resulted in a 2:1 ratio of gernaylgeranyl to anilinofarnesyl
modified CVIL. This was an identical ratio to that found for AGPP with FTase and a
CVLS peptide (Fiugre 7-7). Surprisingly, when the peptide target was changed to CVIM,
AFPP was not able to compete with GGPP nearly as well. The product ratio from
reactions containing 1:1 AFPP:GGPP in excess of the CVIM peptide was 8:1
geranylgeranyl to anilinofarnesylated peptide. These results suggested that the identity
of the ability of the analogue to compete with the natural substrate was completely
dependent on the identity of the peptide target. We also found that the NAFPP analogue
was not competitive with GGPP for the modification of either GGTaseI substrate
peptide.
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Figure 7-5 Peptide competition between CVIL and CVIM peptides with a GGTaseI
catalyst
Peptide competition between CVIL and CVIM with GGPP or AFPP as the isoprenoid
donor. Each competition reaction was prepared with a) GGPP or b) AFPP at 6.7 µM and
3 µM CVIL and CVIM peptide. Reactions were stopped using a solution of acetic acid
and isopropanol then analyzed by HPLC. Note that the CVIL outcompetes CVIM with
both GGPP and AFPP as the isoprenoid donor.
A) GGPP + CVIL + CVIM

B) AFPP + CVIL + CVIM
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Figure 7-6 GGTaseI proposed reaction mechanism
Proposed mechanism for the GGTaseI reaction. The mechanism is split into two
pathways path A representing GGPP stimulated product release and path B
representing peptide stimulated product release. E is the GGTaseI enzyme, E-GGPP is
the GGTaseI•GGPP complex, E•GGPP•CaaX is the GGTaseI•GGPP•CaaX peptide
complex, E-Product is the GGTaseI bound product complex, E-Product-GGPP is the
GGTaseI bound to both GGPP and the reaction product, and E-CaaX is the peptide
bound GGTaseI inhibitory complex, E-Product-CaaX is the peptide bound enzyme
product complex
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Figure 7-7 GGPP competition for GGTaseI depends on target peptide.
Fluorescence HPLC chromatograms of competition reactions between AFPP and
GGPP for the modification of a CVIL or CVIM peptide Each competition reaction was
prepared with equimolar GGPP and AFPP at 6.7 µM each and 3 µM CVIL or CVIM
peptide. Reactions were stopped using a solution of acetic acid and isopropanol then
analyzed by HPLC. Note that AFPP competes much more effectively for CVIL than
CVIM.
A) AFPP + GGPP + CVIL

B) AFPP + GGPP + CVIM
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AFPP and NAFPP are recognized by anti-AG and anti-NAG antibodies
AGPP as an unnatural probe for the modification of proteins has been extremely
useful to determine the cellular prenylation status of proteins and for confirming the in
vitro modification of proteins by FTase. In chapter 6, I described the development of
antibodies specific for the anilinogeranyl and pNO2anilinogeranyl modification of
proteins. The antibodies are specific for the aniline isoprenoid of the modified protein. In
order to determine whether the antibodies could detect anilinofarnesylated or
pNO2anilinofarnesylated proteins we prepared proteins modified with the AFPP
analogs. Using a large amount of GGTaseI we were able to obtain bacterially expressed
H-Ras proteins modified in vitro with the AFPP and NAFPP analogs. Western blot
analysis of the reaction mixtures indicated that the analog was incorporated into the
protein and that the antibodies specifically detected the anilinofarnesylated and
pNO2anilinofarnesylated proteins. (Figure 7-8a) Interestingly, the polyclonal anti
anilinogeranyl antibody was unable to detect the anilinofarnesylated protein. However, a
mouse monoclonal antibody raised against the same hapten was able to detect the
modified protein.
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Figure 7-8 NAF and AF detection with anti-AG and anti-NAG antibodies
a) Western blot analysis of anilinofarnesylated and pNO2-anilinofarnesylated Ras
proteins with anti-AG and anti-NAG polyclonal antibodies and anti-AG monoclonal
antibody detection (mAG). Equal protein was loaded into each well but the extent of
modification was not analyzed b) Western blot analysis of H460 and MCF7 cells labeled
with 30 µM AFOH overnight and lysed then run on SDS-PAGE gel. AG-Ras control is
an in vitro AGPP modified Ras protein. Note that the mono-clonal but not the polyclonal
anti-AG antibody can detect the AF modified Ras proteins and that some AF modified
proteins appear to be labeled in the cell lysates.
a)

b)

183

Cell labeling with AFOH
Since the anilinofarnesylated proteins could be detected by the anti-AG
antibodies we were then interested in whether they could be used to label cellular
proteins. To test this we treated cells H460 (lung cancer cell line) and MCF7 (breast
cancer cell line) cells with the AFOH analog or DMSO, lysed the cells and analyzed for
AFOH incorporation into proteins (Figure 7-8b). The anti-AG antibody did not appear to
label a large number of proteins, but AFOH did appear to be incorporated into proteins
with a molecular weight around that of the small molecular weight GTPases. Small
molecular weight GTPases are most commonly geranylgeranylated which is consistent
with these results. Low detection of labeled proteins may have been due to poor
detection by the anti-AG antibody for AF modified proteins, or decreased ability of the
AFOH due be converted to diphosphate and compete with endogenous GGPP.
Discussion
In this chapter we have found that extending the isoprenoid chain of the FTase
transferable analogues AGPP and pNO2-AGPP by one isoprenoid unit gives selective
transferable substrates for the related enzyme GGTaseI. Surprisingly, we found that
peptide substrate inhibition appeared to be significantly less potent for GGTaseI than
has previously been observed with FTase, and with NAFPP as the isoprenoid donor
peptide substrate inhibition was not detected. In addition, the selectivity of the enzyme
for the different GGTaseI substrate peptides appeared to correlate more closely with
kcat/Kmpeptide than was observed previously with FTase. These results suggested that
peptide stimulated release in the GGTaseI mechanism is not nearly as effective as it is
in the FTase reaction mechanism.
AFPP reactivity with CVIL and CVIM peptides were similar to GGPP while the
addition of the pNO2 group to the aniline moiety resulted in a molecule that only reacted
with the CVIL peptide. In addition, AFPP did not compete effectively with GGPP when
the CVIM peptide was the isoprenylation target. The terminal isoprene of GGPP is
known to interact with more of the surface of a peptide substrate than in the FTase
reaction. Therefore, GGTaseI substrate analogues may be particularly sensitive to the
structure of an incoming peptide. Changes in the structure of the isoprenoid result in
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changes in the kinetics of peptide substrates reactivity and may provides an exogenous
mechanism for altering the selectivity of the GGTaseI enzyme.
Experimental
General
All RP-HPLC was performed on an Agilent 1100 HPLC system equipped with a
microplate autosampler, diode array and fluorescence detector. The HPLC analysis was
performed with a vydac C4 column with 0.01% TFA in water (A) and 0.01% TFA CH3CN
(B) as the mobile phase. Peptides were purchased from peptidogenics and each
contained a dansyl group N linked to a glycine linker followed by a C residue then a
variable aaX sequence (VIL or VIM). Spectrofluorometric analyses were performed in a
96-well flat bottom, non-binding surface, black polystyrene plate (Excitation wavelength,
340 nm; emission wavelength 505 nm with a 10 nm cutoff). The plate reader was a
SpectraMax GEMINI XPS fluorescence well-plate reader. Absorbance readings were
determined using a Cary UV/Vis spectrophotometer.
Steady-state peptide kinetics
The kinetic constants Kmpeptide and kcat with GGPP, and the analogs with each
peptide

were

determined

in

triplicate

measurements

using

a

continuous

spectrofluorometric assay adapted for a 96-well plate. The following assay components
were assembled in individual wells of a 96-well plate and incubated at 30° C for 20
minutes: 180 µL of assay buffer (52 mM Tris-HCl, 12 mM MgCl2, 12 µM ZnCl2 pH 7.4),
40 µL of detergent (0.125% n-dodecyl- β-D-maltoside in assay buffer), 40 µL of
reducing agent (50 mM DTT in assay buffer) 20uL of GGPP or analog (200 µM in 25
mM NH4HCO3) and 20 µL of N-dansyl-GCaaX peptide (variable concentration).
Fluorescence was detected using a time based scan at 30° C for 120 minutes. The
velocity of each reaction was determined by converting the rate of increase in
fluorescence intensity units (FLU/s) to µM/s with equation 7-1.
Equation 7-1: vi=(R·P)/(FMAX-FMIN)
Where vi is the velocity of the reaction in µM/s. R is the rate of the reaction in FLU/s. P
is equal to the concentration of modified product in µM (see below). FMAX is the
fluorescence intensity of fully modified product. FMIN is the fluorescence of a reaction
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mixture that contained 20 µL of assay buffer in the place of GGTaseI. Complete
modification of peptides was assumed when fluorescence stabilized for more than 10
minutes and was confirmed by RP-HPLC analysis of the reaction mixture.
Final analysis peptide concentrations were chosen based on preliminary
determination of the Kmpeptide with 0.5, 1, 5 and 10 µM dansyl-GCaaX concentrations
(see below). The final analysis used 8 peptide concentrations which were: 1/6, 1/5, ¼,
½, ¾, 1, 2, and 3 times the estimated Kmpeptide. The reaction was then initiated by the
addition of 20 µL of GGTaseI (final 10

nM). Fluorescence enhancement was

determined as described above.
Complete modification of peptides was assumed when fluorescence stabilized for
more than 10 minutes and was confirmed by RP-HPLC analysis of the reaction mixture.
If the reactions that contained higher concentrations of peptides did not go to
completion the Fmax-Fmin value was extrapolated using a linear plot of the Fmax-Fmin
for each of the lower concentration reactions that did go to completion. Alternatively the
extent of input peptide modified was determined by RP-HPLC analysis of the dansyl
moiety peak absorbance corresponding to the unmodified and modified peptides. The
percent of modified peptide relative to the total input peptide was used to calculate the
concentration of product in the mixture.
The velocities of the reactions were plotted against the concentration of peptide
and were fit to the Michaelis-Menten equation (Equation 7-2) to give the apparent kcat
(appkcat) and Kmpeptide (appKmpeptide) values. Where et was the total enzyme
concentration and [Pep] was the total input peptide. The kcat/Kmpeptide value was derived
from a Lineweaver-Burke plot of the same data points.
Equation 7-2: vi/et=(appkcat*[Pep])/(appKmpeptide+[Pep])
Peptide competition
Competition reactions were prepared with the same components given for the
kcat/Kmpeptide analysis except two peptides were added to the mixture at a single
concentration. Peptides A and B were diluted to 45 µM in Tris-HCl buffer (pH=7.4) and
the concentration checked by reading the Abs of the solution at 340 nm (εdansyl=4250
Abs·M-1·cm-1). 20 µL of peptide A and 20 µL of peptide B were then added to reaction
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mixtures as described above except only 160 µL of assay buffer was added. Separate
reactions were prepared as a standard with GGPP or the analogs and only one peptide
as described above. The reactions were then initiated with the addition of GGTaseI (10
nM final concentration) and analyzed spectrofluorometrically. The reactions were
stopped prior to consumption of more than 50% of either peptide by adding 20 µL of a
stop solution (isopropyl alcohol and acetic acid 8:2). HPLC analysis was then performed
with 100 µL of the reaction mixture loaded onto C18 column and eluted with a linear
gradient of 0-20 min 50% B to 100% B at a flow rate of 1 mL/min. Peaks on the 340 nm
trace chromatogram that corresponded to both the standard reactions and fluorescent
peaks were then integrated. The ratios of products were calculated according to
equation 7-3.
Equation 7-3: (IAmod/ IAtot)/(IBmod /IBtot)
Where IAmod is the integral of the modified peptide A, IAtot is the integral of the
modified peptide A plus the unmodified peptide A, IBmod is the integral of the modified
peptide B and IBtot was the integral of the modified peptide B plus the unmodified peptide
B. Alternatively, the ratios were calculated using the integrals of the standard peptides
fluorescence relative to competition product fluorescence giving less than a 5%
difference in the calculated ratio.
GGPP competition
Competition reactions were prepared with the same components given for the
kcat/Kmpeptide analysis except two isoprenoids were added to the mixture and the peptide
concentration was held constant. GGPP and the analog were diluted to 200 µM in 25
mM NH4HCO3. 20 µL of GGPP and 20 µL of analog were then added to a 260 µL
solution of peptide, DTT and detergent in 52 mM Tris-HCl buffer pH=7.4 (final
concentrations DTT=6.7 mM, DM=0.033%, Peptide=3µM, analog= 13 µM and FPP=13
µM). The concentration of peptide was determined by absorbance of the dansyl group
and isoprenoid diphosphate concentrations were determined using absorbance and the
extinction coefficient of N-Methyl-aniline (9120 Abs·M-1·cm-1) and N-methyl-p-NO2aniline
(18,430 Abs·M-1·cm-1). The reactions were initiated with the addition of FTase and
analyzed spectrofluorometrically (20 nM final GGTaseI concentration). The reactions
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were stopped after 2 hours with a mixture of acetic acid and iPrOH. HPLC analysis was
then performed with 100 µL of the reaction mixture loaded onto C18 column and eluted
with a linear gradient of 0-20 min 50% B to 100% B at a flow rate of 1 mL/min. Peaks on
the 340 nm trace chromatogram that corresponded to standard reaction fluorescent
peaks were then integrated. The ratios of products were calculated using Ianalog/IFPP,
where Ianalog is the integral of the peptide modified with the analog and IFPP is the integral
of the peptide modified with FPP.
GGTaseI Protein Substrate Modification
3 µM recombinant bacterially expressed H-Ras [200] was incubated with 10 µM
AFPP or NAFPP and 1µM FTase in 300 µL of Tris-HCl buffer (pH=7.4) The reactions
were incubated for 30 min at 37 º C, boiled with SDS and PAGE performed using 10 µL
of the reaction mixtures.
AFOH incorporation into unblocked cells
Plates were coated with poly-L-Lysine and seeded with in Dulbecco’s modified
Eagle’s medium with 5% fetal bovine serum. The cells were then treated with DMSO as
a vehicle, or 30 µM AFOH was added and incubated at 37° C overnight. Medium was
then removed and cells were extracted into 500 µL of RIPA buffer containing Protease
Inhibitor cocktail I (calbiochem). The supernatant was removed and used for western
blotting.
Western Blot Analysis
Protein concentration was determined using a Bradford reagent kit (Pierce) with
1:100 dilutions of the cell lysates. The proteins from the GGTaseI reaction mixtures or
cell lysates were then separated using 12% SDS-polyacrylamide gels followed by
transfer to nitrocellulose membranes. The membranes were incubated in blocking buffer
PBS Casein and Tween buffer for one hour at room temperature, after which the
following sequential steps were used: incubation with anti-AG or anti-NAG to 1:10,000
in PCT for one hour; 3 X 15 minute washes with vigorous shaking in PBS Tween buffer;
incubation at room temperature one hour with goat anti-rabbit horseradish peroxidaseconjugated secondary antibody (Zymed) at a dilution of 1:20,000 in PCT buffer; and four
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15 minute washes with PT buffer. The membranes were then subjected to enhanced
chemiluminescence detection by incubation in 20 mL of detection buffer (Pierce Super
Signal) for one minute.
Credits:
Post-doctoral researcher Zhongwen Wang was responsible for the synthesis of AFPP
and NAFPP
Post-doctoral researcher Thangiah Subramanian was responsible for finding that
ethereal solvents improved α,β-unsaturated aldehyde formation
Post-doctoral researcher David Dremmer in the department of pharmacy practice and
science laboratory of Val Adams was responsible for cell treatments with AFOH.

Copyright © Jerry Troutman 2006
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CHAPTER 8 SUMMARY, DISCUSSION AND FUTURE DIRECTIONS
The results presented in this dissertation describe the development of and
biochemical analysis of lipid analogs of isoprenoid diphosphate prenyltransferase
substrates. In chapter 2, I described the synthesis of a small library and a few
exploratory FPP analogs and the finding that FTase accepts a wide variety of ωisoprene substituted analogs as substrates, and that many of these substrates disrupt
the function of oncogenic H-Ras in a whole cell model system. The structural
parameters of the analogs that affected the ability of the analog to transfer to protein
targets did not appear to be the same structural parameters important for the function of
the lipid group on the protein target. The results strongly support the hypothesis that the
relationship of lipid structure of FTase transfer is orthogonal to that of lipid structure on
function. Specifically, the hydrophobicity of the analog did not appear to affect analog
transferability, but was the central property important for the function of the lipid.
The major limitation with using the isoprenoid analogs was the fact that there
were no efficient methods to observe cellular prenylation of proteins with the analogs. It
was possible that the highly charged diphosphate anion of the lipid diphosphate
molecules would prevent cellular uptake of the farnesyl diphosphate analogs. The
Xenopus studies avoided this problem because the analogs were directly injected into
the relatively large oocyte cells. However, such microinjection would not be feasible for
cell culture studies or in vivo studies with the analogs. In chapter 6, I have described the
development of antibodies directed towards the modification of proteins with two of the
unnatural prenyl lipid analogs. Utilizing these antibodies we found that the parent
alcohol of AGPP could traverse a cell membrane and apparently was endogenous
converted to diphosphate and utilized by cellular FTase. AGPP was even competitive
with endogenous pools of FPP for the modification of proteins. In chapter 4 I described
the factors of the analogs affecting FPP competitiveness and found that numerous
transferable analogs were even more competitive that AGPP in vitro. It would be
interesting to see if this was the case in whole cells. It would be possible to test the
competitiveness of a number of the analogs in cells using the reagents developed for
this dissertation since numerous analogs cross-react with the anti-anilinogeranyl
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antibodies. In addition, the antibodies could be very useful for the study of protein
prenylation in multi-cellular organisms and potentially provide a method for studying the
affect of FTIs in such organisms. Collaborators in the laboratory of Professor Daret St.
Clair at the University of Kentucky have treated mice with the anilinogeraniol and
pNO2anilinogeraniol compounds. However, western blot analysis of tissue samples from
these animals have been inconclusive. Importantly, we are also developing methods to
utilize the anti-anilinogeranyl antibodies to isolate prenylated proteins from cell lysates.
The anti-anilinogeranyl antibodies have proved useful for our laboratory as well as a
number of others around the world. Dr. Carol Fierke’s laboratory at the University of
Michigan has made use of them for the purposes of studying the in vitro prenylation of
unusual Ca1a2X containing proteins. The laboratory of Dr. Michael Morgan at Hanover
Medical School in Germany has also made use of these antibodies in studying the
targets of FTIs in hematologic malignancies.
Chapters 3 through 5 are extremely important for understanding the mechanism
of the FTase enzyme and how the kinetic mechanism can be exploited with analogs of
the natural substrate of FTase. In chapter 3, I describe the kinetic mechanism by which
FTase chooses between different Ca1a2X sequence targets. We found that unfarnesylated Ca1a2X peptide binding to the E•product complex had a major affect on the
selectivity of the enzyme for different Ca1a2X substrates. One of the most important
results of this chapter with regards to future studies was the fact that the selectivity of
the enzyme could not be predicted by the classic Michaelis-Menten “selectivity
constant” kcat/Kmpeptide. Instead FTase selectivity was much more dependent on the
Kmpeptide alone. This result gives a key parameter of the steady-state FTase reaction
that is central to predicting the Ca1a2X selectivity of the enzyme with different isoprenoid
donors. In addition, I described the ability of the analog to alter the Ca1a2X selectivity of
the FTase enzyme. Later in chapter 5, I described how we could take advantage of the
lipid interaction between the isoprenoid and peptide target of the FTase reaction to
create Ca1a2X selective analogs that converted FTase from a relatively promiscuous
enzyme to one with much more limited target selectivity. The next logical extension of
this work would be to determine if these factors were equally important in a whole cell
system. Unfortunately, the antibodies development thus far cannot detect the
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modification of proteins with the selective analogs. However, the methods used for
developing the anti-anilinogeranyl antibodies could easily be adapted to other lipid
modifications.
Taken together the results I have described in this dissertation indicate that it will
be possible to develop selective, FPP or GGPP competitive, prenyl function inhibitors of
proteins. Such prenyl function inhibitors would be a major step forward for the
development of new therapeutics for diseases ranging from cancer to hepatitis delta
infections. Selectivity would allow specific targeting of only certain proteins for inhibition
of function and likely greatly reduce toxicity associated with the use of a FTI. Selectivity
would be especially important for diseases like hepatitis delta infection. The large
antigen of the hepatitis delta protein that must be farnesylated for the virus to function
has a highly unusual C-terminal Ca1a2X sequence, CRPQ. Analogs designed to only
target that particular sequence would likely not affect the prenylation of any proteins
other than the hepatitis delta protein. In conclusion, there is still a great deal of work that
needs to be done to reach the development of Ca1a2X protein selective prenyl function
inhibitors. The work in this dissertation however lays significant ground work for
understanding the properties important for such an inhibitor and the properties that are
important for Ca1a2X selectivity. This work also describes the development of an
important novel reagent that could be used to study prenylation in cells and possibly
large organisms.

Copyright © Jerry Troutman 2006
192

REFERENCES
1.
2.
3.
4.
5.
6.
7.

8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.

Voet, D. and J.G. Voet, Biochemistry. 2nd ed. 1995: John Wiley& Sons, Inc.
Magee, T. and C. Marshall, New insights into the interaction of Ras with the
plasma membrane. Cell, 1999. 98(1): p. 9-12.
Ikezawa, H., Glycosylphosphatidylinositol (GPI)-anchored proteins. Biol Pharm
Bull, 2002. 25(4): p. 409-17.
Bhatnagar, R.S., et al., The structure of myristoyl-CoA:protein Nmyristoyltransferase. Biochim Biophys Acta, 1999. 1441(2-3): p. 162-72.
Resh, M.D., Membrane targeting of lipid modified signal transduction proteins.
Subcell Biochem, 2004. 37: p. 217-32.
McTaggart, S.J., Isoprenylated proteins. Cell Mol Life Sci, 2006. 63(3): p. 255-67.
Blanco-Colio, L.M., et al., 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase
inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth
muscle cells by downregulation of Bcl-2 expression and Rho A prenylation.
Atherosclerosis, 2002. 161(1): p. 17-26.
Houten, S.M., et al., Regulation of isoprenoid/cholesterol biosynthesis in cells
from mevalonate kinase-deficient patients. J Biol Chem, 2003. 278(8): p. 573643.
O'Donnell, M.P., et al., The mevalonate pathway: importance in mesangial cell
biology and glomerular disease. Miner Electrolyte Metab, 1993. 19(3): p. 173-9.
Stanley Fernandez, S.M., B.A. Kellogg, and C.D. Poulter, Farnesyl diphosphate
synthase. Altering the catalytic site to select for geranyl diphosphate activity.
Biochemistry, 2000. 39(50): p. 15316-21.
Kellogg, B.A. and C.D. Poulter, Chain elongation in the isoprenoid biosynthetic
pathway. Curr Opin Chem Biol, 1997. 1(4): p. 570-8.
Tarshis, L.C., et al., Regulation of product chain length by isoprenyl diphosphate
synthases. Proc Natl Acad Sci U S A, 1996. 93(26): p. 15018-23.
Basso, A.D., P. Kirschmeier, and W.R. Bishop, Lipid posttranslational
modifications. Farnesyl transferase inhibitors. J Lipid Res, 2006. 47(1): p. 15-31.
O'Regan, R.M. and F.R. Khuri, Farnesyl transferase inhibitors: the next targeted
therapies for breast cancer? Endocr Relat Cancer, 2004. 11(2): p. 191-205.
Doll, R.J., P. Kirschmeier, and W.R. Bishop, Farnesyltransferase inhibitors as
anticancer agents: critical crossroads. Curr Opin Drug Discov Devel, 2004. 7(4):
p. 478-86.
Sebti, S.M., Blocked pathways: FTIs shut down oncogene signals. Oncologist,
2003. 8 Suppl 3: p. 30-8.
Santucci, R., et al., Farnesyltransferase inhibitors and their role in the treatment
of multiple myeloma. Cancer Control, 2003. 10(5): p. 384-7.
de Bono, J.S., A.W. Tolcher, and E.K. Rowinsky, Farnesyltransferase inhibitors
and their potential in the treatment of breast carcinoma. Semin Oncol, 2003. 30(5
Suppl 16): p. 79-92.
Adjei, A.A., Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer
Inst, 2001. 93(14): p. 1062-74.

193

20.
21.
22.

23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.

Brassard, D.L., et al., Inhibitors of farnesyl protein transferase and MEK1,2
induce apoptosis in fibroblasts transformed with farnesylated but not
geranylgeranylated H-Ras. Exp Cell Res, 2002. 273(2): p. 138-46.
Cuda, G., et al., Protection of human endothelial cells from oxidative stress: role
of Ras-ERK1/2 signaling. Circulation, 2002. 105(8): p. 968-74.
Hochholdinger, F., et al., Novel membrane-targeted ERK1 and ERK2 chimeras
which act as dominant negative, isotype-specific mitogen-activated protein
kinase inhibitors of Ras-Raf-mediated transcriptional activation of c-fos in NIH
3T3 cells. Mol Cell Biol, 1999. 19(12): p. 8052-65.
Khosravi-Far, R., et al., Activation of Rac1, RhoA, and mitogen-activated protein
kinases is required for Ras transformation. Mol Cell Biol, 1995. 15(11): p. 644353.
Carloni, V., et al., Tyrosine phosphorylation of focal adhesion kinase by PDGF is
dependent on ras in human hepatic stellate cells. Hepatology, 2000. 31(1): p.
131-40.
Reuther, G.W., et al., Analysis of function and regulation of proteins that mediate
signal transduction by use of lipid-modified plasma membrane-targeting
sequences. Methods Enzymol, 2000. 327: p. 331-50.
Gschwind, A., O.M. Fischer, and A. Ullrich, The discovery of receptor tyrosine
kinases: targets for cancer therapy. Nat Rev Cancer, 2004. 4(5): p. 361-70.
Schlessinger, J., Cell signaling by receptor tyrosine kinases. Cell, 2000. 103(2):
p. 211-25.
Coxon, F.P. and M.J. Rogers, The role of prenylated small GTP-binding proteins
in the regulation of osteoclast function. Calcif Tissue Int, 2003. 72(1): p. 80-4.
Scheffzek, K., et al., The Ras-RasGAP complex: structural basis for GTPase
activation and its loss in oncogenic Ras mutants. Science, 1997. 277(5324): p.
333-8.
Wittinghofer, A., K. Scheffzek, and M.R. Ahmadian, The interaction of Ras with
GTPase-activating proteins. FEBS Lett, 1997. 410(1): p. 63-7.
Scheffzek, K., et al., Crystal structure of the GTPase-activating domain of human
p120GAP and implications for the interaction with Ras. Nature, 1996. 384(6609):
p. 591-6.
Karbowniczek, M., et al., Regulation of B-Raf kinase activity by tuberin and Rheb
is mammalian target of rapamycin (mTOR)-independent. J Biol Chem, 2004.
279(29): p. 29930-7.
Hu, C.D., et al., Cysteine-rich region of Raf-1 interacts with activator domain of
post-translationally modified Ha-Ras. J Biol Chem, 1995. 270(51): p. 30274-7.
Wang, Y., et al., The RAS effector RIN1 directly competes with RAF and is
regulated by 14-3-3 proteins. Molecular and Cellular Biology, 2002. 22(3): p. 916926.
Bondeva, T., et al., Structural Determinants of Ras-Raf Interaction Analyzed in
Live Cells. Molecular Biology of the Cell, 2002. 13: p. 2323-2333.
Hekman, M., et al., Associations of B- and C-Raf with cholesterol,
phosphatidylserine, and lipid second messengers: preferential binding of Raf to
artificial lipid rafts. J Biol Chem, 2002. 277(27): p. 24090-102.

194

37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.

Casey, P.J., Protein lipidation in cell signaling. Science, 1995. 268(5208): p. 2215.
Marshall, C.J., Protein prenylation: a mediator of protein-protein interactions.
Science, 1993. 259(5103): p. 1865-6.
Thapar, R., J.G. Williams, and S.L. Campbell, NMR characterization of full-length
farnesylated and non-farnesylated H-Ras and its implications for Raf activation. J
Mol Biol, 2004. 343(5): p. 1391-408.
Cox, A.D. and C.J. Der, Protein prenylation: more than just glue? Curr Opin Cell
Biol, 1992. 4(6): p. 1008-16.
Epand, R.M., Biophysical studies of lipopeptide-membrane interactions.
Biopolymers, 1997. 43(1): p. 15-24.
Scheffzek, K., et al., The Rac–RhoGDI complex and the structural basis for the
regulation of Rho proteins by RhoGDI. Nat. Struc. Biol., 2000. 7(2): p. 122-126.
Hackenberger, C.P., et al., Semisynthesis of a glycosylated Im7 analogue for
protein folding studies. J Am Chem Soc, 2005. 127(37): p. 12882-9.
Ichiba, T., et al., Activation of C3G guanine nucleotide exchange factor for Rap1
by phosphorylation of tyrosine 504. J Biol Chem, 1999. 274(20): p. 14376-81.
Casey, P.J., Biochemistry of protein prenylation. J Lipid Res, 1992. 33(12): p.
1731-40.
Casey, P.J., et al., Prenylation and G protein signaling. Recent Prog Horm Res,
1994. 49: p. 215-38.
Casey, P.J. and M.C. Seabra, Protein prenyltransferases. J Biol Chem, 1996.
271(10): p. 5289-92.
Fu, H.W. and P.J. Casey, Enzymology and biology of CaaX protein prenylation.
Recent Prog Horm Res, 1999. 54: p. 315-42; discussion 342-3.
Reid, T.S., et al., Crystallographic analysis of CaaX prenyltransferases
complexed with substrates defines rules of protein substrate selectivity. J Mol
Biol, 2004. 343(2): p. 417-33.
Moores, S.L., et al., Sequence dependence of protein isoprenylation. J Biol
Chem, 1991. 266(22): p. 14603-10.
Armstrong, S.A., et al., CAAX geranylgeranyl transferase transfers farnesyl as
efficiently as geranylgeranyl to RhoB. J Biol Chem, 1995. 270(14): p. 7864-8.
Boutin, J.A., et al., Investigation of S-farnesyl transferase substrate specificity
with combinatorial tetrapeptide libraries. Cell Signal, 1999. 11(1): p. 59-69.
James, G.L., J.L. Goldstein, and M.S. Brown, Polylysine and CVIM sequences of
K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine
peptidomimetic in vitro. J Biol Chem, 1995. 270(11): p. 6221-6.
Huang, C.-c., K.E. Hightower, and C.A. Fierke, Mechanistic Studies of Rat
Protein Farnesyltransferase Indicate an Associative Transition State.
Biochemistry, 2000. 39: p. 2593-2602.
Pompliano, D.L., et al., Steady-state kinetic mechanism of Ras farnesyl:protein
transferase. Biochemistry, 1992. 31(15): p. 3800-7.
Maurer-Stroh, S. and F. Eisenhaber, Refinement and prediction of protein
prenylation motifs. Genome Biol, 2005. 6(6): p. R55.

195

57.
58.
59.
60.
61.
62.
63.
64.

65.
66.
67.
68.
69.
70.
71.
72.
73.

Michaelson, D., et al., Postprenylation CAAX Processing Is Required for Proper
Localization of Ras but Not Rho GTPases. Mol Biol Cell, 2005. 16(4): p. 16061616.
Bergo, M.O., et al., Absence of the CAAX endoprotease Rce1: effects on cell
growth and transformation. Mol Cell Biol, 2002. 22(1): p. 171-81.
Kramer, K., et al., Isoprenylcysteine carboxyl methyltransferase activity
modulates endothelial cell apoptosis. Mol Biol Cell, 2003. 14(3): p. 848-57.
Winter-Vann, A.M., et al., Targeting Ras signaling through inhibition of carboxyl
methylation: an unexpected property of methotrexate. Proc Natl Acad Sci U S A,
2003. 100(11): p. 6529-34.
Hollander, I., E. Frommer, and R. Mallon, Human ras-converting enzyme
(hRCE1) endoproteolytic activity on K-Ras-derived peptides. Anal. Biochem.,
2000. 286: p. 129-137.
Dolence, J.M., et al., Studies with Recombinant Saccharomyces cereVisiae
CaaX Prenyl Protease Rce1p†. Biochemistry, 2000. 39: p. 4096-4104.
Maske, C.P., et al., A carboxyl-terminal interaction of lamin B1 is dependent on
the CAAX endoprotease Rce1 and carboxymethylation. J Cell Biol, 2003. 162(7):
p. 1223-32.
Schmidt, W.K., et al., Endoplasmic reticulum membrane localization of Rce1p
and Ste24p, yeast proteases involved in carboxyl-terminal CAAX protein
processing and amino-terminal a-factor cleavage. Proc Natl Acad Sci U S A,
1998. 95(19): p. 11175-80.
Bergo, M.O., et al., Inactivation of Icmt inhibits transformation by oncogenic KRas and B-Raf. J Clin Invest, 2004. 113(4): p. 539-50.
Romano, J.D. and S. Michaelis, Topological and mutational analysis of
Saccharomyces cerevisiae Ste14p, founding member of the isoprenylcysteine
carboxyl methyltransferase family. Mol Biol Cell, 2001. 12(7): p. 1957-71.
Linder, M.E. and R.J. Deschenes, New Insights into the Mechanisms of Protein
Palmitoylation. Biochemistry, 2003. 42(15): p. 4311-4320.
Fujiyama, A., et al., S-farnesylation and methyl esterification of C-terminal
domain of yeast RAS2 protein prior to fatty acid acylation. J Biol Chem, 1991.
266(27): p. 17926-31.
Melkonian, K.A., et al., Role of lipid modifications in targeting proteins to
detergent-resistant membrane rafts. Many raft proteins are acylated, while few
are prenylated. J Biol Chem, 1999. 274(6): p. 3910-7.
Resh, M.D., Regulation of cellular signalling by fatty acid acylation and
prenylation of signal transduction proteins. Cell Signal, 1996. 8(6): p. 403-12.
Dolence, J.M., et al., Yeast protein farnesyltransferase: steady-state kinetic
studies of substrate binding. Biochemistry, 1995. 34(51): p. 16687-94.
Furfine, E.S., et al., Protein farnesyltransferase: kinetics of farnesyl
pyrophosphate binding and product release. Biochemistry, 1995. 34(20): p. 685762.
Zhang, F.L. and P.J. Casey, Influence of metal ions on substrate binding and
catalytic activity of mammalian protein geranylgeranyltransferase type-I. Biochem
J, 1996. 320 ( Pt 3): p. 925-32.

196

74.
75.
76.
77.

78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.

Tschantz, W.R., E.S. Furfine, and P.J. Casey, Substrate Binding Is Required for
Release of Product from Mammalian Protein Farnesyltransferase. J Biol Chem,
1997. 272(15): p. 9989-9993.
Fu, H.W., L.S. Beese, and P.J. Casey, Kinetic analysis of zinc ligand mutants of
mammalian protein farnesyltransferase. Biochemistry, 1998. 37(13): p. 4465-72.
Huang, C., K.E. Hightower, and C.A. Fierke, Mechanistic studies of rat protein
farnesyltransferase indicate an associative transition state. Biochemistry, 2000.
39(10): p. 2593-602.
Sebti, S.M. and A.D. Hamilton, Farnesyltransferase and
geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic
and bench to bedside issues. Expert Opin Investig Drugs, 2000. 9(12): p. 276782.
Hightower, K.E., et al., Lysine(164)alpha of protein farnesyltransferase is
important for both CaaX substrate binding and catalysis. Biochem J, 2001.
360(Pt 3): p. 625-31.
Long, S.B., et al., The crystal structure of human protein farnesyltransferase
reveals the basis for inhibition by CaaX tetrapeptides and their mimetics. Proc
Natl Acad Sci U S A, 2001. 98(23): p. 12948-53.
Long, S.B., P.J. Casey, and L.S. Beese, Reaction path of protein
farnesyltransferase at atomic resolution. Nature, 2002. 419(6907): p. 645-50.
Tobin, D.A., et al., Structural characterization of the zinc site in protein
farnesyltransferase. J Am Chem Soc, 2003. 125(33): p. 9962-9.
Sousa, S.F., P.A. Fernandes, and M.J. Ramos, Unraveling the mechanism of the
farnesyltransferase enzyme. J Biol Inorg Chem, 2005. 10(1): p. 3-10.
Park, H.W., et al., Crystal structure of protein farnesyltransferase at 2.25
angstrom resolution. Science, 1997. 275(5307): p. 1800-4.
Dunten, P., et al., Protein Farnesyltransferase: Structure and Implications for
Substrate Binding. Biochemistry, 1998. 37(22): p. 7907-7912.
Long, S.B., P.J. Casey, and L.S. Beese, Cocrystal Structure of Protein
Farnesyltransferase Complexed with a Farnesyl Diphosphate Substrate.
Biochemistry, 1998. 37: p. 9612-9618.
Strickland, C.L., et al., Crystal Structure of Farnesyl Protein Transferase
Complexed with a CaaX Peptide and Farnesyl Diphosphate Analogue.
Biochemistry, 1998. 37: p. 16601-16611.
Taylor, J.S., et al., Structure of mammalian protein geranylgeranyltransferase
type-I. Embo J, 2003. 22(22): p. 5963-74.
Seabra, M.C., et al., Protein farnesyltransferase and geranylgeranyltransferase
share a common alpha subunit. Cell, 1991. 65(3): p. 429-34.
Huang, C.C., P.J. Casey, and C.A. Fierke, Evidence for a catalytic role of zinc in
protein farnesyltransferase. Spectroscopy of Co2+-farnesyltransferase indicates
metal coordination of the substrate thiolate. J Biol Chem, 1997. 272(1): p. 20-3.
Hightower, K.E., et al., H-Ras peptide and protein substrates bind protein
farnesyltransferase as an ionized thiolate. Biochemistry, 1998. 37(44): p. 1555562.

197

91.
92.

93.
94.
95.
96.
97.
98.
99.
100.

101.
102.

103.

104.
105.
106.

Rozema, D.B. and C.D. Poulter, Yeast protein farnesyltransferase. pKas of
peptide substrates bound as zinc thiolates. Biochemistry, 1999. 38(40): p. 1313846.
Woo, J.T., et al., Inhibitory effects of mevastatin and a geranylgeranyl transferase
I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor
activator of NFkappaB ligand (RANKL) or tumor necrosis factor-alpha (TNFalpha). Biochem Pharmacol, 2005. 69(1): p. 87-95.
Shi, Y., et al., Farnesyltransferase inhibitor effects on prostate tumor microenvironment and radiation survival. Prostate, 2005. 62(1): p. 69-82.
Gotlib, J., Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.
Curr Hematol Rep, 2005. 4(1): p. 77-84.
Cornelissen, B., et al., Synthesis, biodistribution and effects of
farnesyltransferase inhibitor therapy on tumour uptake in mice of 99mTc labelled
epidermal growth factor. Nucl Med Commun, 2005. 26(2): p. 147-53.
Cestac, P., et al., Prenylation inhibitors stimulate both estrogen receptor alpha
transcriptional activity through AF-1 and AF-2 and estrogen receptor beta
transcriptional activity. Breast Cancer Res, 2005. 7(1): p. R60-70.
O'Meara S, J. and B.T. Kinsella, The effect of the farnesyl protein transferase
inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor.
Biochem J, 2004.
Marzo, I., et al., Farnesyltransferase inhibitor BMS-214662 induces apoptosis in
B-cell chronic lymphocytic leukemia cells. Leukemia, 2004. 18(10): p. 1599-604.
Karp, J.E., et al., Current status of clinical trials of farnesyltransferase inhibitors.
Curr Opin Oncol, 2001. 13(6): p. 470-6.
Alsina, M., et al., Farnesyltransferase inhibitor tipifarnib is well tolerated, induces
stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival
pathways in patients with advanced multiple myeloma. Blood, 2004. 103(9): p.
3271-7.
Head, J. and S.R. Johnston, New targets for therapy in breast cancer:
farnesyltransferase inhibitors. Breast Cancer Res, 2004. 6(6): p. 262-8.
Reid, T.S. and L.S. Beese, Crystal structures of the anticancer clinical candidates
R115777 (Tipifarnib) and BMS-214662 complexed with protein
farnesyltransferase suggest a mechanism of FTI selectivity. Biochemistry, 2004.
43(22): p. 6877-84.
Reid, T.S., S.B. Long, and L.S. Beese, Crystallographic analysis reveals that
anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and
geranylgeranyltransferase-I by different binding modes. Biochemistry, 2004.
43(28): p. 9000-8.
deSolms, S.J., et al., Dual protein farnesyltransferase-geranylgeranyltransferaseI inhibitors as potential cancer chemotherapeutic agents. J Med Chem, 2003.
46(14): p. 2973-84.
Bell, I.M., et al., 3-Aminopyrrolidinone Farnesyltransferase Inhibitors: Design of
Macrocyclic Compounds with Improved Pharmacokinetics and Excellent Cell
Potency. J. Med. Chem., 2002. 45: p. 2388-2409.
Gianni, L., The future of targeted therapy: combining novel agents. Oncology,
2002. 63 Suppl 1: p. 47-56.
198

107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.

Fiordalisi, J.J., et al., High affinity for farnesyltransferase and alternative
prenylation contribute individually to K-Ras4B resistance to farnesyltransferase
inhibitors. J Biol Chem, 2003. 278(43): p. 41718-27.
Kloog, Y. and A.D. Cox, Prenyl-binding domains: potential targets for Ras
inhibitors and anti-cancer drugs. Semin Cancer Biol, 2004. 14(4): p. 253-61.
Sepp-Lorenzino, L., et al., A peptidomimetic inhibitor of farnesyl:protein
transferase blocks the anchorage-dependent and -independent growth of human
tumor cell lines. Cancer Res, 1995. 55(22): p. 5302-9.
Cox, A.D. and C.J. Der, Farnesyltransferase inhibitors and cancer treatment:
targeting simply Ras? Biochim Biophys Acta, 1997. 1333(1): p. F51-71.
Sebti, S.M. and C.J. Der, Opinion: Searching for the elusive targets of
farnesyltransferase inhibitors. Nat Rev Cancer, 2003. 3(12): p. 945-51.
Otto, J.C. and P.J. Casey, The Hepatitis Delta Virus Large Antigen Is
Farnesylated Both in Vitro and in Animal Cells. J. Biological Chem., 1996. 271(9):
p. 4569-4572.
Lin, H.P., et al., Localization of isoprenylated antigen of hepatitis delta virus by
anti-farnesyl antibodies. J Gen Virol, 1999. 80 ( Pt 1): p. 91-6.
Sato, S., C. Cornillez-Ty, and D.W. Lazinski, By inhibiting replication, the large
hepatitis delta antigen can indirectly regulate amber/W editing and its own
expression. J Virol, 2004. 78(15): p. 8120-34.
Buckner, F.S., et al., Cloning, heterologous expression, and distinct substrate
specificity of protein farnesyltransferase from Trypanosoma brucei. J Biol Chem,
2000. 275(29): p. 21870-21876.
Vogtherr, M., et al., Antimalarial Drug Quinacrine Binds to C-Terminal Helix of
Cellular Prion Protein. J. Med. Chem., 2003. 46: p. 3563-3564.
Chakrabarti, D., et al., Protein farnesyltransferase and protein prenylation in
Plasmodium falciparum. J Biol Chem, 2002. 277(44): p. 42066-73.
Moura, I.C., et al., Limonene arrests parasite development and inhibits
isoprenylation of proteins in Plasmodium falciparum. Antimicrob Agents
Chemother, 2001. 45(9): p. 2553-8.
Bordier, B.B., et al., In vivo antiviral efficacy of prenylation inhibitors against
hepatitis delta virus. J Clin Invest, 2003. 112(3): p. 407-14.
Bordier, B.B. and J.S. Glenn, Testing antivirals against hepatitis delta virus:
farnesyl transferase inhibitors. Methods Mol Med, 2004. 96: p. 539-53.
O'Malley, B. and D.W. Lazinski, Roles of carboxyl-terminal and farnesylated
residues in the functions of the large hepatitis delta antigen. J Virol, 2005. 79(2):
p. 1142-53.
Winter-Vann, A.M. and P.J. Casey, Post-prenylation-processing enzymes as new
targets in oncogenesis. Nat Rev Cancer, 2005. 5(5): p. 405-12.
Winter-Vann, A.M., et al., A small-molecule inhibitor of isoprenylcysteine carboxyl
methyltransferase with antitumor activity in cancer cells. Proc Natl Acad Sci U S
A, 2005. 102(12): p. 4336-41.
Schlitzer, M., A. Winter-Vann, and P.J. Casey, Non-peptidic, non-prenylic
inhibitors of the prenyl protein-specific protease Rce1. Bioorg Med Chem Lett,
2001. 11(3): p. 425-7.

199

125.
126.
127.
128.
129.
130.
131.

132.
133.
134.
135.
136.
137.
138.
139.
140.
141.

Chen, Y., Y.T. Ma, and R.R. Rando, Solubilization, partial purification, and affinity
labeling of the membrane-bound isoprenylated protein endoprotease.
Biochemistry, 1996. 35(10): p. 3227-37.
Jang, G.F. and M.H. Gelb, Substrate specificity of mammalian prenyl proteinspecific endoprotease activity. Biochemistry, 1998. 37(13): p. 4473-81.
Ma, Y.T., B.A. Gilbert, and R.R. Rando, Farnesylcysteine analogs to probe role
of prenylated protein methyltransferase. Methods Enzymol, 1995. 250: p. 226-34.
Ma, Y.T., B.A. Gilbert, and R.R. Rando, Inhibitors of the isoprenylated protein
endoprotease. Biochemistry, 1993. 32(9): p. 2386-93.
Wang, H., et al., Inhibition of growth and p21ras methylation in vascular
endothelial cells by homocysteine but not cysteine. J Biol Chem, 1997. 272(40):
p. 25380-5.
Hoffman, D.R., W.E. Cornatzer, and J.A. Duerre, Relationship between tissue
levels of S-adenosylmethionine, S-adenylhomocysteine, and transmethylation
reactions. Can J Biochem, 1979. 57(1): p. 56-65.
Coward, J.K., D.L. Bussolotti, and C.D. Chang, Analogs of Sadenosylhomocysteine as potential inhibitors of biological transmethylation.
Inhibition of several methylases by S-tubercidinylhomocysteine. J Med Chem,
1974. 17(12): p. 1286-9.
Liau, M.C., C.F. Chang, and F.F. Becker, Alteration of S-adenosylmethionine
synthetases during chemical hepatocarcinogenesis and in resulting carcinomas.
Cancer Res, 1979. 39(6 Pt 1): p. 2113-9.
Liau, M.C., et al., Correlation of isozyme patterns of S-adenosylmethionine
synthetase with fetal stages and pathological states of the liver. Cancer Res,
1979. 39(1): p. 162-9.
Liau, M.C., C.F. Chang, and B.C. Giovanella, Demonstration of an altered Sadenosylmethionine synthetase in human malignant tumors xenografted into
athymic nude mice. J Natl Cancer Inst, 1980. 64(5): p. 1071-5.
Shi, Y.Q. and R.R. Rando, Kinetic mechanism of isoprenylated protein
methyltransferase. J Biol Chem, 1992. 267(14): p. 9547-51.
Lamango, N.S., et al., Inhibition mechanism of S-adenosylmethionine-induced
movement deficits by prenylcysteine analogs. Pharmacol Biochem Behav, 2003.
76(3-4): p. 433-42.
Volker, C., et al., Effects of farnesylcysteine analogs on protein carboxyl
methylation and signal transduction. J Biol Chem, 1991. 266(32): p. 21515-22.
Lamango, N.S. and C.G. Charlton, Farnesyl-L-cysteine analogs block SAMinduced Parkinson's disease-like symptoms in rats. Pharmacol Biochem Behav,
2000. 66(4): p. 841-9.
Henriksen, B.S., et al., Synthesis of desthio prenylcysteine analogs: sulfur is
important for biological activity. Bioorg Med Chem Lett, 2005. 15(22): p. 5080-3.
Anderson, J.L., et al., The isoprenoid substrate specificity of isoprenylcysteine
carboxylmethyltransferase: development of novel inhibitors. J Biol Chem, 2005.
280(33): p. 29454-61.
Gibbs, B.S., et al., Novel Farnesol and Geranylgeraniol Analogues: A Potential
New Class of Anticancer Agents Directed against Protein Prenylation. J. Med.
Chem., 1999. 42: p. 3800-3808.
200

142.
143.
144.
145.
146.
147.
148.
149.

150.
151.
152.
153.
154.
155.
156.
157.

Dudler, T. and M.H. Gelb, Probing the role of H-Ras lipidation for signaling
functions in Xenopus laevis oocytes. Methods Mol Biol, 1999. 116: p. 161-76.
Dudler, T. and M.H. Gelb, Palmitoylation of Ha-Ras facilitates membrane binding,
activation of downstream effectors, and meiotic maturation in Xenopus oocytes. J
Biol Chem, 1996. 271(19): p. 11541-7.
Pomerance, M., et al., Stimulation of mitogen-activated protein kinase by
oncogenic Ras p21 in Xenopus oocytes. Requirement for Ras p21-GTPaseactivating protein interaction. J Biol Chem, 1992. 267(23): p. 16155-60.
Hattori, S., et al., Activation of mitogen-activated protein kinase and its activator
by ras in intact cells and in a cell-free system. J Biol Chem, 1992. 267(28): p.
20346-51.
Kim, R., J. Rine, and S.H. Kim, Prenylation of mammalian Ras protein in
Xenopus oocytes. Mol Cell Biol, 1990. 10(11): p. 5945-9.
Gibbs, J.B., et al., Xenopus oocyte germinal-vesicle breakdown induced by
[Val12]Ras is inhibited by a cytosol-localized Ras mutant. Proc Natl Acad Sci U S
A, 1989. 86(17): p. 6630-4.
Gaon, I., et al., Photoactive Analogs of Farnesyl Pyrophosphate Containing
Benzoylbenzoate Esters: Synthesis and Application to Photoaffinity Labeling of
Yeast Protein Farnesyltransferase. J. Org. Chem., 1996. 61: p. 7738-7745.
Turek-Etienne, T.C., C.L. Strickland, and M.D. Distefano, Biochemical and
Structural Studies with Prenyl Diphosphate Analogues Provide Insights into
Isoprenoid Recognition by Protein Farnesyl Transferase. Biochemistry, 2003. 42:
p. 3716-3724.
Edelstein, R.L. and M.D. Distefano, Photoaffinity labeling of yeast farnesyl
protein transferase and enzymatic synthesis of a Ras protein incorporating a
photoactive isoprenoid. Biochem Biophys Res Commun, 1997. 235(2): p. 377-82.
Kale, T.A. and M.D. Distefano, Diazotrifluoropropionamido-containing
prenylcysteines: syntheses and applications for studying isoprenoid-protein
interactions. Org Lett, 2003. 5(5): p. 609-12.
Rose, M.W., et al., Evaluation of geranylazide and farnesylazide diphosphate for
incorporation of prenylazides into a CAAX box-containing peptide using protein
farnesyltransferase. J Pept Res, 2005. 65(6): p. 529-37.
Kale, T.A., et al., Use of synthetic isoprenoid analogues for understanding protein
prenyltransferase mechanism and structure. Curr Top Med Chem, 2003. 3(10): p.
1043-74.
Reigard, S.A., et al., Interplay of isoprenoid and peptide substrate specificity in
protein farnesyltransferase. Biochemistry, 2005. 44(33): p. 11214-23.
Henriksen, B.S., et al., Computational and conformational evaluation of FTase
alternative substrates: insight into a novel enzyme binding pocket. J Chem Inf
Model, 2005. 45(4): p. 1047-52.
Zhou, C., Y. Shao, and R.A. Gibbs, Aromatic Farnesyl Diphosphate Analogues:
Vinyl Triflate-Mediated Synthesis and Preliminary Enzymatic Evaluation. Biorg.
and Med. Chem. Lett., 2002. 12: p. 1417-1420.
Rawat, D.S. and R.A. Gibbs, Synthesis of 7-Substituted Farnesyl Diphosphate
Analogues. Org. Lett., 2002. 4(18): p. 3027-3030.

201

158.
159.
160.
161.
162.
163.
164.
165.
166.
167.

168.
169.
170.
171.
172.
173.

Zahn, T.J., et al., Synthesis and evaluation of GGPP geometric isomers:
divergent substrate specificities of FTase and GGTase I. Bioorg Med Chem Lett,
2001. 11(12): p. 1605-8.
Chehade, K.A., et al., Design and synthesis of a transferable farnesyl
pyrophosphate analogue to Ras by protein farnesyltransferase. J Org Chem,
2000. 65(10): p. 3027-33.
Micali, E., et al., Protein farnesyltransferase isoprenoid substrate discrimination is
dependent on isoprene double bonds and branched methyl groups.
Biochemistry, 2001. 40(41): p. 12254-65.
Chehade, K.A., et al., Photoaffinity analogues of farnesyl pyrophosphate
transferable by protein farnesyl transferase. J Am Chem Soc, 2002. 124(28): p.
8206-19.
Troutman, J.M., et al., Synthesis of acyloxymethyl ester prodrugs of the
transferable protein farnesyl transferase substrate farnesyl
methylenediphosphonate. Bioorg Med Chem Lett, 2004. 14(19): p. 4979-82.
Subramanian, T., et al., Directed library of anilinogeranyl analogues of farnesyl
diphosphate via mixed solid- and solution-phase synthesis. Org Lett, 2005. 7(11):
p. 2109-12.
Stremler, K.E. and C.D. Poulter, Methane- and Difluoromethanediphosphonate
Analogues of Geranyl Diphosphate: Hydrolysis-Inert Alternate Substrates. JACS,
1987. 109: p. 5542-5544.
Kim, M., et al., Synthesis and activity of fluorescent isoprenoid pyrophosphate
analogues. J Org Chem, 2004. 69(24): p. 8186-93.
Dursina, B., et al., Identification and specificity profiling of protein
prenyltransferase inhibitors using new fluorescent phosphoisoprenoids. J Am
Chem Soc, 2006. 128(9): p. 2822-35.
Bukhtiyarov, Y.E., C.A. Omer, and C.M. Allen, Photoreactive Analogs of Prenyl
Diphosphates as Inhibitors and Probes of Human Protein Farnesyltransferase
and Geranylgeranyltransferase Type-I. Journal of Biological Chemistry, 1995.
270(32): p. 19035-19040.
Kho, Y., et al., A tagging-via-substrate technology for detection and proteomics of
farnesylated proteins. Proc Natl Acad Sci U S A, 2004. 101(34): p. 12479-84.
Cox, A.D. and C.J. Der, The ras/cholesterol connection: implications for ras
oncogenicity. Crit Rev Oncog, 1992. 3(4): p. 365-400.
Crick, D.C., D.A. Andres, and C.J. Waechter, Farnesol is utilized for protein
isoprenylation and the biosynthesis of cholesterol in mammalian cells. Biochem
Biophys Res Commun, 1995. 211(2): p. 590-9.
Adjei, A.A., An overview of farnesyltransferase inhibitors and their role in lung
cancer therapy. Lung Cancer, 2003. 41 Suppl 1: p. S55-62.
Rowinsky, E.K., J.J. Windle, and D.D. Von Hoff, Ras protein farnesyltransferase:
A strategic target for anticancer therapeutic development. J Clin Oncol, 1999.
17(11): p. 3631-52.
Zhu, K., A.D. Hamilton, and S.M. Sebti, Farnesyltransferase inhibitors as
anticancer agents: current status. Curr Opin Investig Drugs, 2003. 4(12): p. 142835.

202

174.
175.
176.
177.

178.
179.
180.
181.
182.
183.
184.
185.
186.
187.

188.
189.

Zhang, F.L. and P.J. Casey, Protein prenylation: molecular mechanisms and
functional consequences. Annu Rev Biochem, 1996. 65: p. 241-69.
Vergnes, L., et al., Lamin B1 is required for mouse development and nuclear
integrity. Proc Natl Acad Sci U S A, 2004. 101(28): p. 10428-33.
Roskoski, R., Jr., Protein prenylation: a pivotal posttranslational process.
Biochem Biophys Res Commun, 2003. 303(1): p. 1-7.
Caplin, B.E., Y. Ohya, and M.S. Marshall, Amino acid residues that define both
the isoprenoid and CAAX preferences of the Saccharomyces cerevisiae protein
farnesyltransferase. Creating the perfect farnesyltransferase. J Biol Chem, 1998.
273(16): p. 9472-9.
Ramamurthy, V., et al., AIPL1, a protein implicated in Leber's congenital
amaurosis, interacts with and aids in processing of farnesylated proteins. Proc
Natl Acad Sci U S A, 2003. 100(22): p. 12630-5.
Chen, X., et al., Inhibition of farnesyl protein transferase and P21ras memebrane
association by d-limonene in human pancreas tumor cells in vitro. Chin Med Sci
J, 1999. 14(3): p. 138-44.
Otto, J.C., et al., Cloning and characterization of a mammalian prenyl proteinspecific protease. J Biol Chem, 1999. 274(13): p. 8379-82.
Dudler, T. and M.H. Gelb, Replacement of the H-Ras Farnesyl Group by Lipid
Analogues: Implications for Downstream Processing and Effector Activation in
Xenopus Oocytes. Biochemistry, 1997. 36: p. 12434-12441.
McGeady, P., et al., The farnesyl group of H-Ras facilitates the activation of a
soluble upstream activator of mitogen-activated protein kinase. J Biol Chem,
1995. 270(44): p. 26347-51.
Zhao, J., H.F. Kung, and V. Manne, Farnesylation of p21 Ras proteins in
Xenopus oocytes. Cell Mol Biol Res, 1994. 40(4): p. 313-21.
Turek, T.C., et al., Synthesis of farnesyl diphosphate analogues containing etherlinked photoactive benzophenones and their application in studies of protein
prenyltransferases. J Org Chem, 2001. 66(10): p. 3253-64.
Eummer, J.T., et al., Novel Limonene Phosphate and Farnesyl Diphosphate
Analogues: Design, Synthesis, and Evaluation as Potential Protein-Farnesyl
Transferase Inhibitors. Biorg. and Med. Chem., 1999. 7: p. 241-250.
Maltais, R., M.R. Tremblay, and D. Poirier, Solid-phase synthesis of
hydroxysteroid derivatives using the diethylsilyloxy linker. J Comb Chem, 2000.
2(6): p. 604-14.
Maltais, R., V. Luu-The, and D. Poirier, Parallel solid-phase synthesis of 3betapeptido-3alpha-hydroxy-5alpha-androstan-17-one derivatives for inhibition of
type 3 17beta-hydroxysteroid dehydrogenase. Bioorg Med Chem, 2001. 9(12): p.
3101-11.
Maltais, R., V. Luu-The, and D. Poirier, Synthesis and optimization of a new
family of type 3 17 beta-hydroxysteroid dehydrogenase inhibitors by parallel
liquid-phase chemistry. J Med Chem, 2002. 45(3): p. 640-53.
Haque, T.S., et al., Parallel synthesis of potent, pyrazole-based inhibitors of
Helicobacter pylori dihydroorotate dehydrogenase. J Med Chem, 2002. 45(21): p.
4669-78.

203

190.
191.
192.
193.
194.
195.
196.
197.
198.
199.
200.
201.
202.
203.
204.
205.

Lepre, C.A., et al., Applications of SHAPES screening in drug discovery. Comb
Chem High Throughput Screen, 2002. 5(8): p. 583-90.
Ma, S., D. Duan, and Y. Wang, Palladium(0)-catalyzed coupling-cyclization
reaction of polymer-supported aryl iodides with 1,2-allenyl carboxylic acids. Solidphase parallel synthesis of butenolides. J Comb Chem, 2002. 4(3): p. 239-47.
Mu, Y., et al., Cuprate-Mediated Synthesis and Biological Evaluation of
Cyclopropyl- and tert-Butylfarnesyl Diphosphate Analogs. J. Org. Chem., 1996.
61: p. 8010-8015.
Davisson, V.J., et al., Phosphorylation of Isoprenoid Alcohols. J. Org. Chem.,
1986. 51: p. 4768-4779.
Pompliano, D.L., R.P. Gomez, and N.J. Anthony, Intramolecular Fluorescence
Enhancement - a Continuous Assay of Ras Farnesyl - Protein Transferase.
Journal of the American Chemical Society, 1992. 114(20): p. 7945-7946.
Niemi, R., et al., Bisphosphonate prodrugs: synthesis and in vitro evaluation of
alkyl and acyloxymethyl esters of etidronic acid as bioreversible prodrugs of
etidronate. Eur J Pharm Sci, 2000. 11(2): p. 173-80.
Carnero, A., B. Jimenez, and J.C. Lacal, Progesterone but not ras requires MPF
for in vivo activation of MAPK and S6 KII: MAPK is an essential conexion point of
both signaling pathways. J Cell Biochem, 1994. 55(4): p. 465-76.
Lambert, W.J., Modeling Oil-Water Partitioning and Membrane Permeation Using
Reversed-Phase Chromatography. Journal of Chromatography A, 1993. 656(12): p. 469-484.
Niemi, R., et al., Bisphosphonate prodrugs: synthesis and in vitro evaluation of
novel acyloxyalkyl esters of clodronic acid. J Med Chem, 1999. 42(24): p. 50538.
Ahlmark, M., et al., Bisphosphonate prodrugs: synthesis and in vitro evaluation of
novel clodronic acid dianhydrides as bioreversible prodrugs of clodronate. J Med
Chem, 1999. 42(8): p. 1473-6.
Andres, D.A., et al., Expression cloning of a novel farnesylated protein, RDJ2,
encoding a DnaJ protein homologue. Arch Biochem Biophys, 1997. 346(1): p.
113-24.
Pompliano, D.L., et al., Isoprenoid diphosphate utilization by recombinant human
farnesyl:protein transferase: interactive binding between substrates and a
preferred kinetic pathway. Biochemistry, 1993. 32(32): p. 8341-7.
Ferscht, A.R., Structure and Mechanism in Protein Science: A Guide to Enzyme
Catalysis and Protein Folding. 1999, New York: W. H. Freeman.
Hartman, H.L., K.A. Hicks, and C.A. Fierke, Peptide specificity of protein
prenyltransferases is determined mainly by reactivity rather than binding affinity.
Biochemistry, 2005. 44(46): p. 15314-24.
Hightower, K.E., et al., H-Ras Peptide and Protein Substrates Bind Protein
Farnesyltransferase as an Ionized Thiolate. Biochemistry, 1998. 37: p. 1555515562.
Long, S.B., P.J. Casey, and L.S. Beese, The basis for K-Ras4B binding
specificity to protein farnesyltransferase revealed by 2 A resolution ternary
complex structures. Structure Fold Des, 2000. 8(2): p. 209-22.

204

206.
207.
208.
209.
210.
211.
212.
213.
214.
215.

216.
217.
218.

219.
220.
221.
222.
223.

Schaber, M.D., et al., Polyisoprenylation of Ras in vitro by a farnesyl-protein
transferase. J Biol Chem, 1990. 265(25): p. 14701-4.
Hussein, D. and S.S. Taylor, Farnesylation of Cenp-F is required for G2/M
progression and degradation after mitosis. J. Cell Science, 2002. 115(17): p.
3403-3414.
Kinsella, B.T., R.A. Erdman, and W.A. Maltese, Carboxyl-terminal isoprenylation
of ras-related GTP-binding proteins encoded by rac1, rac2, and ralA. J Biol
Chem, 1991. 266(15): p. 9786-94.
Troutman, J.M., et al., Tools to analyze protein farnesylation in cells. Bioconjug
Chem, 2005. 16(5): p. 1209-17.
Bos, J.L., ras oncogenes in human cancer: a review. Cancer Res, 1989. 49(17):
p. 4682-9.
Adnane, J., et al., Suppression of rho B expression in invasive carcinoma from
head and neck cancer patients. Clin Cancer Res, 2002. 8(7): p. 2225-32.
Gibbs, J.B., A. Oliff, and N.E. Kohl, Farnesyltransferase inhibitors: Ras research
yields a potential cancer therapeutic. Cell, 1994. 77(2): p. 175-8.
Karp, J.E. and J.E. Lancet, Farnesyltransferase inhibitors (FTIs) in myeloid
malignancies. Ann Hematol, 2004. 83 Suppl 1: p. S87-8.
Hicks, K.A., H.L. Hartman, and C.A. Fierke, Upstream polybasic region in
peptides enhances dual specificity for prenylation by both farnesyltransferase
and geranylgeranyltransferase type I. Biochemistry, 2005. 44(46): p. 15325-33.
Turek-Etienne, T.C., C.L. Strickland, and M.D. Distefano, Biochemical and
structural studies with prenyl diphosphate analogues provide insights into
isoprenoid recognition by protein farnesyl transferase. Biochemistry, 2003.
42(13): p. 3716-24.
Maltese, W.A., Posttranslational modification of proteins by isoprenoids in
mammalian cells. Faseb J, 1990. 4(15): p. 3319-28.
Andres, D.A., et al., Rapid identification of cysteine-linked isoprenyl groups by
metabolic labeling with [3H]farnesol and [3H]geranylgeraniol. Methods Mol Biol,
1999. 116: p. 107-23.
Gronborg, M., et al., A mass spectrometry-based proteomic approach for
identification of serine/threonine-phosphorylated proteins by enrichment with
phospho-specific antibodies: identification of a novel protein, Frigg, as a protein
kinase A substrate. Mol Cell Proteomics, 2002. 1(7): p. 517-27.
Liu, X.H., et al., Antigenic prenylated peptide conjugates and polyclonal
antibodies to detect protein prenylation. Bioconjug Chem, 2004. 15(2): p. 270-7.
Baron, R., et al., RhoB prenylation is driven by the three carboxyl-terminal amino
acids of the protein: evidenced in vivo by an anti-farnesyl cysteine antibody. Proc
Natl Acad Sci U S A, 2000. 97(21): p. 11626-31.
Holstein, S.A., et al., Isoprenoid Pyrophosphate Analogues Regulate Expression
of Ras-Related Proteins. Biochemistry, 2003. 42: p. 4384-4391.
Berndt, P., G.B. Fields, and M. Tirrell, Synthetic lipidation of peptides and amino
acids: monolayer structure and properties. J Am Chem Soc, 1995. 117: p. 95159522.
Yang, G., et al., Anti-cocaine catalytic antibodies: a synthetic approach to
improved antibody diversity. J Am Chem Soc, 1996. 118: p. 5881-5890.
205

224.
225.
226.
227.
228.
229.
230.
231.

232.
233.
234.
235.
236.
237.
238.
239.

Habeeb, A.F.S.A., Determination of free amino groups in protien by
trinitrobenzene sulfonic acid. Anal. Biochem., 1966. 14: p. 328.
Crick, D.C., D.A. Andres, and C.J. Waechter, Novel salvage pathway utilizing
farnesol and geranylgeraniol for protein isoprenylation. Biochem Biophys Res
Commun, 1997. 237(3): p. 483-7.
Thai, L., et al., Farnesol is utilized for isoprenoid biosynthesis in plant cells via
farnesyl pyrophosphate formed by successive monophosphorylation reactions.
PNAS, 1999. 96(23): p. 13080-13085.
McGuire, T.F. and S.M. Sebti, Geranylgeraniol potentiates lovastatin inhibition of
oncogenic H-Ras processing and signaling while preventing cytotoxicity.
Oncogene, 1997. 14(3): p. 305-12.
Lesh, R.E., et al., Inhibition of geranylgeranylation blocks agonist-induced actin
reorganization in human airway smooth muscle cells. Am J Physiol Lung Cell Mol
Physiol, 2001. 281(4): p. L824-31.
Rowell, C.A., et al., Direct demonstration of geranylgeranylation and
farnesylation of Ki-Ras in vivo. J Biol Chem, 1997. 272(22): p. 14093-7.
Whyte, D.B., et al., K- and N-Ras are geranylgeranylated in cells treated with
farnesyl protein transferase inhibitors. J Biol Chem, 1997. 272(22): p. 14459-64.
Danesi, R., C.A. McLellan, and C.E. Myers, Specific Labeling of Isoprenylated
Proteins: Application To Study Inhibitors of the Post-Translational Farnesylation
and Geranylgeranlylation. Biochem. Biophys. Res. Comm., 1995. 206(2): p. 637643.
Crick, D.C., et al., Geranylgeraniol overcomes the block of cell proliferation by
lovastatin in C6 glioma cells. J Neurochem, 1998. 70(6): p. 2397-405.
Serafinowska, H.T., et al., Synthesis and in vivo evaluation of prodrugs of 9-[2(phosphonomethoxy)ethoxy]adenine. J Med Chem, 1995. 38(8): p. 1372-9.
Shaw, J.P., et al., Metabolism and pharmacokinetics of novel oral prodrugs of 9[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm Res, 1997.
14(12): p. 1824-9.
Dickson, J.K., Jr., et al., Orally active squalene synthase inhibitors:
bis((acyloxy)alkyl) prodrugs of the alpha-phosphonosulfonic acid moiety. J Med
Chem, 1996. 39(3): p. 661-4.
Kim, K.W., et al., Inactivation of farnesyltransferase and
geranylgeranyltransferase I by caspase-3: cleavage of the common alpha
subunit during apoptosis. Oncogene, 2001. 20(3): p. 358-66.
Vepsalainen, J.J., Bisphosphonate prodrugs: a new synthetic strategy to
tetraacyloxymethyl esters of methylenebisphosphonates. Tetrahedron Lett.,
1999. 40: p. 8491-8493.
Yuan, L.C., T.C. Dahl, and R. Oliyai, Degradation kinetics of
oxycarbonyloxymethyl prodrugs of phosphonates in solution. Pharm Res, 2001.
18(2): p. 234-7.
George J. Quellhorst, J., C.M. Allen, and M. Wessling-Resnick, Modification of
Rab5 with a photoactivatable analog of geranylgeranyl diphosphate. J Biol
Chem, 2001. 276(44): p. 40727-40733.

206

VITA
Jerry M. Troutman
Born August 21st, 1976, Concord, North Carolina
Education
B.S. in Chemistry, Biochemistry and Philosophy, East Carolina University, Greenville,
NC, 5/2000
Professional Positions Held
Graduate Research Assistant, University of Kentucky, 8/2000-present
Laboratory Technician II, Southern Testing and Research, Wilson, NC 8/98-5/99
Scholastic Honors and Awards
Graduate:
Kentucky Research Challenge Trust Fellowship
Undergraduate:
UBE Outstanding Senior Scholarship
Professional Publications
Troutman JM, Roberts MJ, Andres DA, Spielmann HP. “Tools to analyze protein
farnesylation in cells.” Bioconjug Chem. 2005 Sep-Oct;16(5):1209-17
Subramanian T, Wang Z, Troutman JM, Andres DA, Spielmann HP. “Directed library of
anilinogeranyl analogues of farnesyl diphosphate via mixed solid- and solution-phase
synthesis.” Org Lett. 2005 May 26;7(11):2109-12
Troutman JM, Chehade KA, Kiegiel K, Andres DA, Spielmann HP. “Synthesis of
acyloxymethyl ester prodrugs of the transferable protein farnesyl transferase substrate
farnesyl methylenediphosphonate.” Bioorg Med Chem Lett. 2004 Oct 4;14(19):4979-82
Kelly MA, Chellgren BW, Rucker AL, Troutman JM, Fried MG, Miller AF, Creamer TP.
“Host-guest study of left-handed polyproline II helix formation.”
Biochemistry. 2001 Dec 4;40(48):14376-83

Jerry M. Troutman

207

